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Chapter 1, Introduction
Part of this work is currently in press:
Leukemia advance online publication, 23 September 2010;doi:10.1038/leu.2010.195
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Introduction
The transport of resources in higher, m ulticelular organisms requires a complex 
network of vessels that allows the transport medium to reach all distant places of 
the body. The oxygen binding protein hemoglobin is the first known oxygen carrier in 
evolution1. In smaller organisms hemoglobin-like proteins are freely circulating in bodily 
fluids. In larger animals, where transport of resources is more complicated, cells are used 
to transport the oxygen containing hemoglobins from the respiratory organs to distant 
places of the body. All vertebrates, except cold-water ice fish, transport oxygen via hemo­
globin in red blood cells2. In humans, the lifespan of the red blood cell (erythrocyte) is 
around 120 days. In order to maintain a sufficient number of erythrocytes an average 
human male requires a daily production of 200 billion erythrocytes3. Apart from erythro­
cytes, the blood of higher organisms contains cells that are involved in the hosts defense 
against pathogens (e.g. fungi, bacteria, viruses) or pathogenic processes (cancer) and 
cells that are required for repair of damaged blood vessels. Altogether the human body 
requires a production of close to 1 trillion (1 x 1012) new blood cells every day. This process 
of blood cell production is called hematopoiesis.
Hematopoiesis
All mature blood cells arise from a small population of cells termed hemato­
poietic stem cells (HSCs)4. These cells are characterized by an unrestricted self-renewal 
capacity.
A small pool of HSCs is capable of providing a life-long production of functional 
blood cells. The self-renewal potential of these cells is illustrated by experiments showing 
that a single HSC is capable of regenerating an almost complete hematopoietic system 
in animals that are subjected to radiation that caused lethal failure of the hematopoietic 
system5. This regenerative capacity is exploited in the treatment of various diseases 
where the patient's own stem cells are either destroyed in the treatment of malignant 
disease or carry a mutation that prevents normal hematopoiesis (table 1).
In adult humans, hematopoiesis takes place in the bone marrow where the HSC 
resides in a microenvironment that serves both a supportive and protective function6;7. 
Here, by a tightly controlled process of proliferation and differentiation the stem cell 
gives rise to mature functional blood cells. Hematopoietic cells are divided into a myeloid 
and lymphoid compartment (figure 1). In the classical tree-shaped model, the HSC 
gives rise to the common myeloid progenitor (CMP) and common lymphoid progenitor
(CLP). The CLP differentiates into the 
mature lymphocytes: the B- and T-cells 
and Natural Killer (NK) cells . The CMP 
further differentiates into the megakaryo- 
cytic/erythrocytic progenitor (MEP) and 
the granulocyte/macrophage progenitor 
(GMP), each giving rise to a distinct set of 
functional blood cells. Although for clarity 
reasons the tree-shaped model displayed 
in figure 1  is used in this thesis, many 
recent reports have shown a large plas­
ticity in cell fate of progenitor cells during 
hematopoietic differentiation (reviewed by 
Ceredig et al.8). The tree-shaped model of 
hematopoiesis is based on, and supported 
by in vitro experiments where progenitor 
cells are forced to differentiate into mature 
cells by exposing the cells to a variety of 
differentiation inducing cytokines. Recent 
studies however showed that the lineage 
restriction of progenitors in these in vitro 
studies is merely a result of the applied 
cytokines. The plasticity of hemato­
poietic progenitors is demonstrated by the 
capacity of lymphoid progenitor cells to 
generate myeloid cells9;10.
Leukemia
The constant requirement of new 
mature blood cells demands a highly effi­
cient and flawless process of hemato­
poiesis. A deficiency of functional cells as a 
result of deregulation of this process may 
lead to clinical symptoms. This defective
Diseases Treated with Hematopoietic 
Stem Cell Transplantation
Autologous transplantation 
Malignancies 
Multiple myeloma 
Non-Hodgkin's lymphoma 
Hodgkin's disease 
Acute myeloid leukemia 
Neuroblastoma 
Ovarian cancer 
Germ-cell tumors 
Other diseases 
Autoimmune disorders 
Amyloidosis
Allogeneic transplantation
Malignancies
Acute myeloid leukemia
Acute lymphoblastic leukemia
Chronic myeloid leukemia
Myelodysplastic syndromes
Myeloproliferative disorders
Non-Hodgkin's lymphoma
Hodgkin's disease
Chronic lymphocytic leukemia
Multiple myeloma
Juvenile chronic myeloid leukemia
Other diseases
Aplastic anemia
Paroxysmal nocturnal hemoglobinuria 
Fanconi's anemia 
Blackfan-Diamond anemia 
Thalassemia major 
Sickle cell anemia
Severe combined immunodeficiency 
Wiskott-Aldrich syndrome 
Inborn errors of metabolism
Table 1: Examples of d iseases treated 
with hematopoietic stem-cell transplan­
tation (adapted from Copelan217)
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hematopoiesis may be caused by inherited or acquired mutations in the DNA of the HSC 
or cells that provide essential stimuli. Next to a deficiency of mature, functional cells, 
these mutations can cause a population of immature cells to accumulate in the bone 
marrow and due to space restrictions eventually in the blood. Typically, the presence of 
more than 2 0 %  immature progenitor cells (blasts) in the bone marrow is called acute 
leukemia. As these immature cells disrupt the microenvironment and compete for 
the available space in the bone marrow with non-malignant HSCs and progenitor cells,
0
- v-VA
Dendritic cell
M acrophage
Erythrocyte M egakaryocyte
Figure 1: schem atic overview of hematopoiesis. Blood cell development is a tightly controlled 
process of proliferation and differentiation that allows the formation of mature functional blood cells. The 
10 hematopoietic stem cell can either self renew or differentiate into more mature progenitor cells. These
--------  progenitor cells also have (limited) self renewal capacity and may further differentiate into mature cells.
HSC = hematopoietic stem cell, NK = natural killer cell, CLP = common lymphoid progenitor, CMP = 
common myeloid progenitor, MEP = megakaryocyte-erythroid progenitor, DC = dendritic cell, GMP = 
granulocyte-macrophage progenitor, Th = T helper cell and iTreg = inducible regulatory T cell.
normal hematopoiesis is suppressed. This results in a deficiency of normal, mature blood 
cells and will lead to the symptoms such as fatigue, infections and/or bleeding disorders.
Typically, leukemia is associated with accumulation of immature cells that show 
arrested differentiation, growth factor independent proliferation and a decreased suscep­
tibility to apoptotic stimuli. Several types of leukemia can be distinguished based on the 
type of cell that is affected and the developmental stage where differentiation is blocked. 
Based on these characteristics, leukemia is divided into chronic and acute lymphoid (CLL 
and ALL) and chronic and acute myeloid leukemia (CML and AML). A further subdivision 
can be made according to morphological characteristics (as in the French-American- 
British classification of AML)11;12 or including genetic and molecular markers (Table 2) that 
are causative or significant for survival and treatment strategy13;14. In the past decades 
the treatment strategies of leukemic patients have been improved impressively. The 
development of new chemotherapeutic agents and the application of combinations of 
drugs has significantly increased the patient's chances of survival. Drug administration 
protocols however have been stretched to the limits of the small therapeutic window 
that divides beneficial from toxic effects. To further improve treatment strategies newly 
designed drugs are necessary. The identification of mutations that cause leukemia has 
been of great help to our understanding of both normal hematopoiesis and the patho­
logical processes that cause leukemia. Furthermore, the identification of the biochemical 
mechanisms underlying the leukemic transformation may provide a substrate for 
targeted therapy. These new drugs may dramatically increase the specificity of treatment 
and thereby strongly reduce the treatment related morbidity and mortality (for example: 
the treatment of CML with specific tyrosine kinase inhibitors, such as Imatinib15;16).
Regulation of hematopoiesis
The identification of DNA mutations that cause defective hemato- 
poiesis, together with loss-of-function and over-expression studies has provided 
great insight in the molecular mechanisms that drive and control hematopoiesis. 
As will be discussed in more detail below, proliferation of the HSC and progenitor 
cells is controlled by extracellular stimuli (extrinsic factors) coming from soluble 
factors (growth factors, cytokines) or cell-cell interactions that control expression 
or activation of cellular proteins (intrinsic factors). The lineage-fate decisions of the 
progenitor cells are also controlled by the combination of extrinsic and intrinsic factors.
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Recurrent mutations in myeloid leukemia
Genes Type o f mutation
Biochemical /  Biological 
function
Incidence
Prognostic
value
Chronic Myeloid Leukemia
BCR-ABL Gene fusion Signal transduction >95%
p53 Mutations / Deletions Tumor suppressor
>20%
(in blast crisis)
poor
Acute Myeloid Leukemia
AML1-ETO Gene fusion Transcription factor 10% good
ASXL1 Mutations Epigenetic regulation 25% poor
BAALC Overexpression Unknown 25-30% poor
BCR-ABL Gene fusion Signal transduction 1-2% poor
CBFß-MYH11 Gene fusion Transcription factor 10% good
Cbl Mutations Ubiquitination 10%
C/EBPa Mutations Transcription factor 5% good
c-KIT Mutations Signal transduction 1-5%
DEK-CAN Gene fusion Cell cycle regulation 1-2% poor
ERG Overexpression Transcription factor poor
EVI-1 Over expression Transcription factor poor
FLT3 Mutations Signal transduction 20-25% poor
IDH1 Mutations NADPH production 16%
MLL Duplication Epigenetic regulation 5% poor
MLL
Gene fusion (multiple 
partners)
Epigenetic regulation 10% poor
MN1 overexpression Transcription factor poor
NPM1 Mutations Ribosome function 35% good
N-RAS Mutations Signal transduction 5-10% poor
PML-RAR Gene fusion Transcription factor 5-10% good
p53 Mutations / Deletions Tumor suppressor 1-5%
Pu.1 Mutations Transcription factor 1-5%
TET2 Mutations / Deletions
Putative epigenetic 
regulator
10-15%
WT-1 Mutations Transcription factor 10% poor
12
Table 2: Examples of recurrent mutations found in myeloid leukemia (adapted from Jansen et al. 218)
The first step that drives hematopoiesis is the secretion of hematopoietic growth 
factors and cytokines. These cytokines are produced by cells of hematopoietic origin 
(for example: activated T-cells secrete GM -CSF17) but cells of non-hematopoietic origin 
(including fibroblasts, liver, kidney and stroma cells) contribute strongly, as is underlined 
by the importance of the bone marrow stroma micro-environment6;7. For example, the 
cytokines GM-CSF, G -CSF and M -CSF together contribute to control the production of 
monocytes and granulocytes18 while erythropoietin and thrombopoietin are crucial stimu­
lators of red blood cell and thrombocyte formation respectively19;20.
The next step is the activation of receptors through binding of growth factors or 
cytokines. This triggers a series of intracellular events that eventually results in altered 
expression of genes that control proliferation or differentiation (for example: the NF-kB 
signal transduction route, see below). The intracellular events may include the formation 
of protein complexes, activation of enzymatic activity or translocation, typically the result 
of differential post-translational modification (for example: phosphorylation or meth- 
ylation). Mutations have been identified in patients with leukemia that interfere with 
normal receptor signaling (Table 2), (for example: BCR-ABL21 and FLT322).
Usually, the end-point of receptor induced signal transduction is regulation 
of transcription of a specific set of genes. The signal transduction cascade leads to acti­
vation of transcription factors or provides activated cofactors that are required for proper 
transcriptional regulation. A number of transcriptional regulators have been identified 
that are crucial for hematopoiesis. While loss of a single transcription factor may result 
in a complete block of lineage differentiation, normal hematopoiesis requires a tightly 
balanced activity of multiple transcription factors that together promote the differen­
tiation towards one type while restricting the formation of another lineage (as is now 
modeled for T-cell and neutrophil development)2^ 24. CCAAT/enhancer binding proteins 
(C/EBP) a,b,e, and Pu.1 for the myeloid lineage and RUNX1, EBF, Pax5, and GATA1 for 
lymphoid development are only few, but extensively studied examples of lineage specific 
transcription factors that are essential for development of the complete hematopoietic 
cell repertoire8. Importantly, many of these transcription factors do not direct differen­
tiation towards a single lineage but in contrast, multiple cell fates are regulated by the 
same sets of transcription factors. This especially holds true for Growth factor indepen­
dence 1 (Gfii) and G fiib , two closely related transcription factors that have now been 
implicated in the development of almost every cell lineage in hematopoiesis.
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Growth factor independence 1
Growth Factor Independence 1  (Gfii) was originally identified as the target gene 
of a Moloney murine leukemia virus (MoMLV) insertion locus in an in vitro screen for 
factors that drive progression of a leukemia T  cell line to Interleukin (IL)-2-independent 
growth. Following its discovery, a paralogue, Gfiib , was identified. As a result of extensive
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Figure 2. Gfi1 and Gfi1b are transcriptional regulators. Schematic overview of human Gfii and 
Gfiib. Numbers denote amino acid positions. The location of the reported mutations in Gfii (N382S 
and K403R)6667 are indicated with asterisks. A recent mutational screen studying a large cohort of SCN 
cases identified potential new Gfii mutations (P107A, L400F and R412X)67. Additional studies are 
required to determine whether these are real mutations contributing to SCN or whether they represent 
rare polymorphisms. The SNAG and Zinc finger domains are indicated. Gfii and G fiib  proteins show 
90% and 89% identity between the SNAG and Zinc finger domains, respectively. The similarity between 
the intermediate domains is 39%. The minimally required Gfii domain for the interaction with interacting 
partners is indicated with horizontal arrows. Blue and red shaded areas represent chromatin modifying 
enzymes and transcription factors, respectively. All G fii and G fiib  transcription factor interactions occur 
through the Zinc fingers. Non-shaded areas represent other proteins. G fiib  interacts with many Gfii 
binding partners. G fiib  also interacts with the histone methyltransferase SUV39Hi and GATAi. G fiib  is 
also part of a complex that contains several other transcription factors 4i;52;57.
research, it is now known that G fii and G fiib  are transcription factors that play a crucial 
role in hematopoiesis. Mouse studies have shown that G fii is implicated in the devel­
opment and function of hematopoietic stem cells, B and T cells, dendritic cells, granu­
locytes and macrophages, whereas G fiib  is essential for megakaryocytic and erythroid 
development.
Molecular function of Gfi1 and Gfi1b
Structure and expression regulation of Gfii and G fiib  proteins
The human G fii and G fiib  genes encode for 422 and 330 amino acid transcription 
factors, respectively. At the N-terminus they contain a small conserved SNAG (Snail/ 
G fii) domain that is also present in other transcriptional repressors (Figure 2) 25-28. The 
SNAG domain serves as an interaction domain to recruit proteins that modify histones29. 
At the C-terminus both proteins contain six C 2H2 type Zinc fingers of which Zinc fingers 
3-5 are essential for DNA binding26;30;3i. Between the SNAG and Zinc finger domains 
resides an intermediate domain that binds proteins implicated in transcriptional regu­
lation but also proteins that control protein modifications and RNA splicing (Figure 2). 
Both the SNAG and Zinc finger domains are more than 8 9 %  identical between G fii and 
G fiib , whereas the intermediate region shows low similarity (39%) at the protein level. 
Despite these differences, the insertion of G fiib  coding sequences in the G fii gene locus 
almost completely rescued the hematopoietic phenotypes observed in G fii null mice32. 
This strongly suggests that the proteins exert similar molecular functions. However, a 
non-hematopoietic phenotype, loss of hearing, caused by G fii deficiency was not rescued 
by inserting G fiib  in the G fii gene locus indicating that in certain tissues these proteins 
function in a different way32. Besides in inner ear development, G fii plays also a role in 
gut33 and lung34-36 development. Currently, it is unknown whether G fiib  also plays a role 
in the development of non-hematopoietic tissues. Nevertheless, despite their similar 
molecular function in hematopoiesis, loss of either G fii or G fiib  results in very different, 
non-overlapping hematopoietic phenotypes. This may in part be caused by the tissue 
specific expression of these genes.
Because G fii and G fiib  are so important for normal hematopoietic devel­
opment it is important to determine how expression of these genes is regulated. The 
signaling pathways and transcription factors that regulate G fii and G fiib  gene expression 
are just emerging (Table 3). In many hematopoietic subsets, the expression of the G fii 
and G fiib  genes can be auto-regulated by the G fii and G fiib  proteins themselves37-39.
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L ineage P resu m ed  F u n c tio n * F acto rs  that R e levan t ta rg et R efe rences
reg u la te  gene  
exp ress ion
genes
H em ato p o ie tic  
stem  cells
Restricts stem cell 
proliferation
p53, H O X A IO p21* 42-44;100
M yelo id  L ineag e
M yelo id
prog en itors
Inhibits proliferation 
Required for 
differentiation
G -C S F, 
EG R /N A B-2, 
PLZF, IKAROS
HoxA9*, PBX1*, 
MEIS1*
CSF1*, CSF1R*, 
MiR21*, 
MÌR196B*, 
ELA2*, MMP8*, 
C/EBPe, Pu.1*, 
Id2*
20;32;50;54;
55;
56;101;102
M on ocytes Repression of
granulocyte-specific
genes
T r ia d i“ ELA2*, C/EBPa* 103
N eu tro ph ils Required for peripheral 
mobilization0
G -C S F CXCR4* 104;105
M acrop hages Repression of cytokine 
expression
LPS, Gram  
negative bacteria
TNFa, IL-1P, IL- 
10, Pu.1*
10;11;20
M yelo id  den d ritic  
cells
Required for formation, 
activation and Ag 
presentation
G M -C S F , LPS SOCS3, PIAS3D, 
STAT3, IL-12
63
E ryth ro cytes Required for definitive 
erythropoiesis
EPO , G ATA1, 
G ATA2, G fii 
H M G B 2, O cti
Bcl-XL*,
TGFpIIIR*,
C-myc
15;21;91-
93;106
M egakaryocytes Required for 
m egakaryopoiesis
91;92;106;10
7
Lym pho id
L ineage
Lym pho id
pro g en ito r
subsets
Required for proliferation, 
differentiation and 
survivalE
IKAROS 
cKit, IL-7R, 
TRAF5
20;47;48;64;
65
C D 4 + /C D 8 +  T  
cells
Controls C D 4 /C D 8  
lineage decisionF
Id1, Id2 47;48;64
N aive C D 8+  T  
cells
Required for proliferation 
Required for proper T cell 
response
IL-7
T cell activation
p21G, IL-7Ra 
CD45h, ZAP70-P
H
38;72;81
C D 4+  h e lp er T  
cells
Inhibits IFNy production in 
Th1
Required for Th2  
proliferation and survival
Inhibits Th17 and iTreg 
differentiation
T cell receptor 
signaling, IL-2, 
IL-4, S TA T6, 
TG Fp
Bcl-XL, p27, 
STAT5, GATA3
IL-17a*, IL-17f*
66;67;70;75
C D 8+  cyto to x ic  T  
cells
Controls m emory T cell 
developm ent
IL-7 IL-7Ra* 73;74
B -cells Required for B-cell 
developm ent 
Inhibits Ig secretion
B cell receptor 
signaling, LPS
PIAS3, STAT5, 
IL-7Ra*, TGFp, 
Pu.1*
Id2*
20;56;86;89;
90
Lym pho id  
dend ritic  cells
Required for developm ent 63
Table 3. Gf¡1 and G filb  play important roles in many aspects of hematopoiesis. Shown here are the 
different stages of hematopoiesis that are controlled by Gfi1/Gfi1b with relevant targets that are impli­
cated. Genes that are directly controlled by Gfil or G filb  are marked with an asterisk. A: indicated are 
functions for Gfil except for erythrocytes and megakaryocytes where G filb  is implicated (see text); B: 
Triadl does not regulate Gfil gene expression but inhibits proteasomal degradation of Gfil protein in 
myeloid cells; C: Gfil expression is induced by G-CSF. Gfil directly represses CXCR4. CXCR4 down- 
modulation by G-CSF is required for release of neutrophils in the bone marrow. Formal proof that Gfil 
is absolutely required for release of neutrophils into the peripheral blood is lacking; D: The activity of 
PIAS3 is controlled by Gfil through a protein-protein interaction; E: Gfil inhibits apoptosis of cKit+ 
progenitor subsets and is required differentiation of very early uncommitted CD4-/CD8-/c-Kit+ T cell 
progenitors. Lack of Gfil is associated with the formation of a Lin-CD44hiCD25int subset. Gfil inhibits 
CD4-/CD8- towards CD4+/CD8+ differentiation; F: Gfil null mice exhibit a relative increase in single 
positive CD8 T compared to CD4 T cells. G: inhibition of induction of p21 by Gfil following PMA stimu­
lation was shown in Jurkat T cells; H: Gfi1 regulates alternative splicing of CD45 though direct inter­
action with the splice factor U2AF26. Disturbed splicing in Gfi1 null mice is observed in central memory 
and effector memory CD4+ and CD8+ T cells. I. Gfi1 does not regulate GATA3 gene expression but 
prevents proteasomal degradation of the GATA3 protein.
Furthermore, G fil may control the expression of the G filb  gene and vice versa40-42, 
although the biological relevance of this cross-regulation is poorly understood as in some 
cell types both proteins are expressed. G fil and G filb  gene expression is co-regulated by 
other transcription factors including Ajuba for G f il43 and G A TA i, NF-Y, O cti and HMGB2 
for G filb 39;4l;44. G fil protein expression is also regulated by microRNAs45. Thus, expression 
of G fil and G filb  is tightly regulated at multiple levels.
Gfil and G filb  in transcriptional regulation, RNA splicing and signaling
DNA-sequence-specific transcription factors are important regulators of gene 
expression. They recruit proteins that modify DNA or DNA-bound histones in order to 
render chromatin accessible or in-accessible for active gene transcription46. G fil and 
G filb  bind DNA and suppress gene expression through recruitment of histone deacety- 
lases and (de)methylases. In addition to proteins that directly modify histones, a series 
of co-repressors known to contribute to histone de-acetylation and (de)-methylation 
interact with G fil and G filb  (Figures 2 and 3a)43;47-49. Together, these complexes remove 
transcription promoting histone modifications and apply repressing marks in order 
to prevent transcription (Figures 2 and 3)29;39;47;48;50-52. However, it should be noted that 
examples have been reported in which G fil and G filb  can activate gene expression39;42;50;53. 
G fil and G filb  also physically interact through their Zinc fingers with other transcription
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factors to co-regulate gene expression (Figures 2 and 3)41;50;54-57. For example, Gfi1 
directly interacts with ETS1 to repress the Bax gene through adjacent DNA binding 
sites54. Gfi1 may also mediate repression independently of DNA binding through inter­
actions with the transcription factors M iz-1 and Pu.155;56. Similarly, Gfi1b controls the 
activity of the transcription factor GATA1 through direct protein-protein interactions 
on DNA41;58. Apart from transcription regulation Gfi1 also regulates protein expression 
at another level. Gfi1 mediates alternative splicing of CD45 transcripts and thereby 
controls T  cell receptor signaling59. Gfi1 also controls post translational protein modifi­
cations. This is achieved through a direct interaction with PIAS3, an inhibitor of STAT3 
signaling60. As a consequence of binding to Gfi1, the interaction between PIAS3 and 
STAT3 is abrogated allowing STAT3 to function as a transcriptional activator. PIAS3 can 
control gene expression through SUMOylation of transcriptional regulators61. Whether 
Gfi1 is SUMOylated by PIAS3 is unknown. Interestingly, a recent study showed that 
binding of the co-repressor protein CoREST1 to SUMO conjugated proteins is required 
for repression62. As Gfi1 binds both CoREST1 and PIAS3, it is tempting to speculate that 
Gfi1 might recruit PIAS3 in order to facil­
itate SUMOylation of Gfi1 bound proteins 
(or itself). In turn, this might be important 
for recruitment of CoREST1 to repress gene 
transcription. If this hypothesis turns out to 
be true, this would add yet another level of 
control to Gfi1-mediated gene repression.
Biological roles of Gfi1 and Gfilb
Gfil preserves hematopoietic stem cell 
integrity
Hematopoietic stem cells (HSCs) 
are quiescent cells that have the unique 
capacity of unlimited self renewal. There 
is much interest in identifying factors that 
control self renewal, quiescence and differ­
entiation of HSCs because many hema­
tological malignancies arise at the stem 
cell level. Earlier it has been shown that
Figure 3A
Transcription
Figure 3. Modes of transcriptional action of Gfil. A. Gfil recruits chromatin modifying enzymes 
to (de)mark histones. Methylation of lysine (K) on position 4 and acetylation of lysine on position 9 of 
histone 3 are marks for active transcription. Upon binding to DNA Gfil may recruit histone deacetylases 
(HDACs) and demethylases (like LSD1) resulting in removal of these transcription promoting modifi­
cations. Recruitment of the methyltransferase enzyme G9A by Gfil facilitates methylation of lysine 9, 
resulting in stable long-term silencing of the locus. Model adapted from Saleque et al.29.
B. 1. Gfil cooperates with other transcription factors to exert its function. Gfil binds to ETS1 and to 
DNA to repress the BA X  gene. 2. Miz-1 is part of a repressor complex. Gfil binds to Miz-1 to repress 
expression of the cell cycle regulator CDKN2B without direct binding to DNA. For full CDKN2B gene 
repression Gfil cooperates with Myc. A mutant form of G fil, identified in a patient with SCN, cannot bind 
DNA. This mutant can still repress genes through interaction with Miz-155. 3. Pu.1 can trans-activate 
the CSFR1 gene. Gfil binds to Pu.1 to repress expression of the CSFR1 gene without direct binding to 
DNA. 4. Gfil competes with transcriptional activators (like Pu.1) for promoter binding. Binding of Gfil 
will inhibit binding of other transcription (promoting) factors and will result in repression of transcription. 
5. C/EBPe (CCAAT enhancer binding protein epsilon) activates expression of the neutrophil collagenase 
MMP8 gene. Together with Gfi1, C/EBPe synergizes in transactivating the MMP8 gene. The activation 
requires both Gfi1 and C/EBPe binding sites in the MMP8 promoter. Whether Gfi1 and C/EBPe physi­
cally interact is unknown.
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D endriticcell
G filb erythro-megakaryopoiesis
Figure 4. Gfi1 and Gfi1b play a broad role in hematopoiesis. Gfil is an essential transcription factor 
during various stages of hematopoiesis in both the lymphoid (light blue shading) and the myeloid (dark 
blue) lineage. G fil is required for either proliferation (green curved arrows) or differentiation from one 
hematopoietic subset towards another (straight green arrows). Gfil inhibits differentiation (straight red 
arrow) or inhibits proliferation (red curved arrow). G filB  is essential for megakaryopoiesis and eryth- 
ropoiesis (red shading) as indicated by the dashed green lines. HSC = hematopoietic stem cell, NK 
= natural killer cell, CLP = common lymphoid progenitor, CMP = common myeloid progenitor, MEP = 
megakaryocyte-erythroid progenitor, GMP = granulocyte-macrophage progenitor, Th = T helper cell and 
iTreg = inducible regulatory T cell.
Gfi1 preserves HSC quiescence (Figure 4)63;64. More recently a function in maintaining 
HSC quiescence has also been described for the tumor suppressor p5365. Mice that lack 
p53 show increased numbers of HSCs but a decreased proportion of cells that exhibit a 
quiescent phenotype. Importantly, G fii was identified as one of the p53 target genes in 
HSCs (Table 3). Consequently, G fii expression is significantly down modulated in p53 
null HSCs which may in part explain the impaired HSC quiescence seen in p53 null mice. 
Together, these studies indicate that Gfi1 is part of a network of intrinsic factors that 
control HSC fate and that Gfi1 is directly regulated by p53 to control the quiescence of 
HSCs.
Gfi1 in neutropenia, myeloid leukemia and hyper inflammatory responses
Possibly one of the most profound phenotypes of loss of Gfi1 function is found 
in neutrophil development. In humans, rarely occurring inherited mutations in G fii have 
been shown to cause severe congenital neutropenia (SCN) and non-immune chronic 
idiopathic neutropenia of adults (Figure 4)66;67. In addition, diminished Gfi1 expression 
may contribute to the development of neutrophil-specific granule deficiency by causing 
reduced levels of secondary granule protein expression53. Human SCN is recapitulated 
in mice that lack Gfi1 or that express the mutated form of Gfi1 that is found in a SCN 
patient68-70. This strongly suggests that the mutated SCN-causing form of Gfi1 functions 
in a dominant-negative manner over wild type Gfi1. In the myeloid compartment, Gfi1 is 
part of a regulatory network that determines lineage fate decision between granulocyte 
versus monocyte/macrophage development. In this compartment, Gfi1 antagonizes 
the function of the transcription factor Pu.1. Pu.1 promotes monocytic differentiation, 
whereas Gfi1 enhances granulocytic differentiation. Gfi1 and Pu.1 inhibit each other's 
function by competing for DNA binding in promoters of target genes23;71. However, Gfi1 
also inhibits Pu.1 by direct repression of the Pu.1 gene71 and by antagonizing Pu.1 function 
through a protein-protein interaction56. Conversely, Pu.1 enhances the expression of tran­
scription factors that inhibit Gfi1 gene expression23. Thus, loss of Gfi1 function in SCN 
patients may tip the balance towards Pu.1 mediated monocytic development explaining 
the neutropenia. This also implies that genes that are normally repressed by Gfi1 may be 
induced in patients with Gfi1 mutations. ELA2, encoding neutrophil elastase (NE) is a Gfi1 
target gene66;72. In line with these findings, increased NE expression and activity has been 
observed in myeloid colonies and in peripheral blood of individuals with a Gfi1 mutation66. 
Currently, it is unclear whether increased NE activity contributes to neutropenia
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following loss of G F Ii function. The fact that ELA2 mutations cause congenital neutro­
penia73 warrants further functional studies to determine whether increases in wild type 
NE expression contribute to neutropenia in patients with G fii mutations. Apart from NE, 
expression of other genes was shown to be affected by the expression of mutated G fii. 
C S F i is a cytokine that promotes monocytic and represses granulocytic development. 
In myeloid precursor cells C S Fi is repressed by G fii. Both in SCN patient cells and in 
murine bone marrow cells that lack functional G fii, C S F i is over-expressed because G fii- 
mediated repression is lacking70. In mice that expressed the SCN-related mutated form 
of G fii, neutrophilic differentiation was partly restored in a C S F i null background or upon 
inhibition of C S F i signaling. This suggests that lack of functional G fii may, at least in part, 
cause defective granulocytic differentiation because C S F i is over-expressed. A recent 
study indicates that G f ii actively promotes neutrophilic differentiation by enhancing 
RasGRPi expression74. This augments G-CSF-m ediated neutrophilic differentiation. In G fii 
null cells, RasGRPi expression is diminished. Forced RasGRPi expression in G fii null cells 
partly restores neutrophilic differentiation. It is remarkable that in G F Ii null cells RasGRPi 
is lacking and that G fii has a positive effect on RasGRPi gene expression. Whether G fii 
directly activates R asG RPi gene expression or indirectly by repressing an inhibitor of 
RasG RPi remains to be determined. In addition to protein encoding genes, a recent study 
suggested that G fii can also directly repress murine microRNAs that promote mono­
cytic differentiation and repress granulocytic differentiation. The expression of these 
microRNAs is induced when G fii function is defective75. Together, these studies indicate 
that loss of G fii functions results in increases in genes that favor monocytic differenti­
ation and decreases of genes that enhance granulocytic differentiation.
In addition to neutropenia, an accumulation of an aberrant population of myeloid 
progenitors is observed in SCN patients with G fii mutations and G fii null mice68;69i76. 
The increase of murine promyelocytic precursor numbers in G fii null mice is abro­
gated in a Homeobox A9 (HoxAg) hemizygous and null background. This indicates that 
the expansion of the immature myeloid population in G fii null mice depends on HoxA9 
induction76. Indeed, G fii directly represses HoxAg gene expression and this repression 
is lost in cells lacking functional G fii (Table 3). In line with the finding that HoxA9 over­
expression triggers myeloid malignancies in mice™78, G fii null mice exhibit features that 
are reminiscent of acute myeloid leukemia (AML). They show uncontrolled proliferation 
of myeloid progenitors that are blocked in their differentiation. A recent study showed 
that lack of G fii induces progression of mutant K-ras induced myeloproliferative disease
towards AML. This suggests that diminished G fii expression may be associated with 
myeloid transformation. Low expression of G f ii has been found in subtypes of patients 
with myelodysplastic syndromes79. Conversely, elevated expression of G fii has been 
reported in patients with CML80 and a large variation of G fii expression has been detected 
in different AML subtypes81. It will therefore be important to study whether aberrant 
G fii expression contributes to the development of human myeloid malignancies. Very 
recently, a polymorphism in G fii has been found that predisposes to AML development 
in humans82. The G fii variant that is characterized by the substitution of a serine by an 
asparagine at amino acid position 36, does not affect its repressive properties, but does 
cause the protein to adapt an aberrant nuclear localization. The altered localization may 
imply that the variant form of G fii is part of other protein complexes as compared to 
the common form of G fii. How this predisposes to leukemia formation remains subject 
of further study. Together, the findings summarized here define a role for G fii in myeloid 
leukemia.
G fii also plays a role in macrophages and dendritic cells. G fii shows dynamic 
changes in expression during the development of myeloid but also plasmacytoid DCs 
(mDCs and pDCs, respectively)83. Possibly as a result of defective STAT3 signalling (Table 
3)60;83, G fii null mice have lower mDC and pDC numbers, show impaired DC maturation 
and their mDCs show increased cytokine production. In vitro differentiation experiments 
show that G fii null progenitor cells are unable to develop into mDCs but instead develop 
into macrophages (Figure 4)83. In mature macrophages G fii inhibits the production of pro- 
inflammatory cytokines upon exposure to Gram-negative bacteria or the bacterial endo­
toxin LPS34;35;68. As a result of uncontrolled release of these cytokines34, G fii null mice 
suffer from sepsis and rapidly die upon infection (Figure 4, Table 3).
Gfi1 in T cell development, allergy and lymphoma
In addition to the myeloid lineage, G fii is also implicated in lymphoid devel­
opment. G fii is required at various stages during T cell development, ranging from early 
to common lymphoid progenitors to mature functional T cells. Patients that suffer from 
SCN due to mutations in the G fii gene display decreased absolute numbers of T cells66. 
These findings are similar to those observed in G fii null mice (Figure 4, Table 3)68;69;84;85. 
Following their activation, T cells can differentiate into cytokine expressing CD4+ and 
cytotoxic CD8+ T cells. Depending on the type of stimulus, naive CD4+ T cells differen­
tiate into various cytokine expressing T cells subsets including T helper (Th) i ,  2, and i7
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as well as inducible regulatory T cells (iTregs)(Figure 4). T h i cell expansion is only mildly 
affected upon loss of G fii function, whereas Th2 cell expansion is severely abrogated86;87. 
In contrast to the requirement of G fii for the expansion of Th2 cells, G fii suppresses the 
formation of T h i7  cells and iTreg cells88-90. Like Th cells, iTregs are derived from CD4+ 
T cells but in contrast to helper T cells, iTregs suppress immune responses9i. Because 
G fii inhibits the expansion of iTregs, mice that lack G fii have more iTregs90. In line with 
this increase in iTreg cell numbers, G fii null mice show a delayed onset of experimental 
allergic encephalitis.
Naive CD8+ T cells develop into cytotoxic effector T cells (CTLs) upon their acti­
vation. The activation of these cells is associated with down-modulation of IL-7Ra 
expression92. CTLs expand following infection, but as soon as the infection ceases, the 
majority of these cells undergo apoptosis. Small subsets of CD8+ T cells with high IL-7Ra 
expression remain alive to form memory T cells that can be reactivated upon recurrent 
infections. G fii is required for sustained IL-7Ra repression in late-stage CTLs and loss 
of G fii results in increased IL-7Ra expression in these cells (Table 3)93. As a result, G fii 
null mice show a relative increase in phenotypically defined memory CD8+ T cells94. The 
finding that G f ii null mice are able to raise CD8+ T cell-mediated anti-viral responses, 
shows that these cells are indeed functional. Upon prolonged viral infection G fii null mice 
exhibit increased numbers of virus-specific CD8+ T cells compared to wild type mice94. 
Whether this is due to decreased apoptosis as a consequence of high IL-7Ra expression or 
due to increased viral loads that are observed in G f ii null mice remains to be elucidated.
The effects of G fii on the expansion and development of different T cell subsets 
have been attributed to differential expression of growth factors, their receptors and 
anti-apoptotic genes (Table 3). Conversely, the expression of the G fii gene itself is regu­
lated by antigens and growth factors. For example, G fii expression is induced following 
Th2 cell activation by antigens and further stimulated by cytokines implicated in Th2 cell 
expansion87;90. G fii subsequently suppresses genes that are required for the development 
of T h i7  and iTreg cells90. Although some genes, like IL-iy, are directly repressed by G fii, 
others are indirectly repressed95. In contrast to the activation following antigen exposure, 
G fii expression is down-modulated by Transforming Growth Factor (TGF)P that promotes 
T h i7  and iTreg development90. As a consequence, genes essential for the development of 
these T cell subsets are not repressed by G fii (Table 3).
As discussed above, G fii positively regulates proliferation of various T cell 
subsets. The relevance of these findings is underscored by the fact that G fii is one of
the most frequently activated genes in retrovirally induced lymphomas in mice96-99. 
G fii over-expression inhibits apoptosis through repression of pro-apoptotic genesi00. 
In addition, G fii enhances cell cycle entrance through inhibition of negative regulators 
of the cell cyclei0i. Thus lack of G fii contributes to progression of myeloid leukemia in 
murine models, whereas forced G fii expression induces lymphomas. This indicates that 
depending on the cellular context G fii acts as tumor suppressor or oncogenei02. G f ii can 
also cooperate with other oncogenes in lymphomagenesis. This is based on the fact that 
the time to tumor development upon G fii overexpression is significantly shortened when 
mice express other oncogenes like Myc and Pimi03‘i05. G fii may exert p53 dependent func­
tions to limit the proliferation of HSC65. These functions are likely not operational in G fii- 
induced lymphoma. Indeed, a recent study suggests that G fii can function independently 
of p53 tumor suppressor pathways because integrations in the G fii locus in virally induced 
T cell lymphomas were as frequent in p53 null mice as in wild type mice99. In conclusion, 
G fii is essential for the development of early T cell subsets and is an important regulator 
of adaptive immune responses by both enhancing and inhibiting different mature T cell 
subsets. Furthermore aberrant expression of G f ii contributes to lymphoma development.
Gfi1 in B cell development and auto-immunity
In the bone marrow, common lymphoid progenitors develop through distinct 
progenitor B cell populations towards mature B cells. Following their activation, B cells 
secrete specific antibodies. G fii is expressed in early B-cells and expression decreases as 
B cells mature37;i06. Mice that lack G fii show diminished immature B cell populations69. In 
vitro B cell differentiation and proliferation of G fii null cells is severely impaired but can 
be rescued by ectopically expressing G fii. Conversely, forced expression of G fii in multi­
potent progenitor cells increases the number of developing B cells7i. Comparable to its 
function in myeloid development where G fii favors neutrophil over macrophage devel- 
opment23, G fii expression favors B cell development over myeloid development by inhib­
iting the transcription factor Pu.i 71. Hemizygous loss of P u .i in a G fii null background can 
rescue B cell development. These data define G fii and P u .i as important transcription 
factors that determine lineage fate decisions at the multipotent progenitor level.
IL-7 is a crucial factor for B cell differentiation and proliferation. In G fii null cells 
IL-7-mediated signaling is disturbed. This is potentially caused by lack of Gfii-m ediated 
repression of inhibitors of IL-7 signaling pathways (Table 3). In G fii null cells IL-7Ra 
signaling is hampered by inhibition of STAT5 signaling, possibly as a result of increased
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expression of the STAT inhibitor SOCS3“ 6. Furthermore, as discussed above, G fii directly 
represses lL-7Ra expression. Consequently, IL-7Ra expression is high in G fii null B cells. 
As high IL-7Ra levels may inhibit B cell development“7, the increased levels of IL-7Ra may 
also contribute to the impaired B cell development that is found in G fii null cells.
In G fii null mice, peripheral B cells display an aberrant hyper-activated 
phenotype and some mice show plasmacytosis69;i06. Following antigen stimulation of B 
cells G fii expression is induced (Table i) . G fii null B cells show enhanced TGFb production, 
a factor important for immunoglobulin secretion“ 8. As a result, the secretion of several 
immunoglobulin G (IgGs) is increasedi08;i09. In line with the disturbed B cell function, 
G fii null mice have been reported to develop a wide spectrum of auto-immune diseases 
including eczema and colitis“9.
Gfi1b in erythroid and megakaryocytic development and leukemia and lymphoma
The closely related paralogue of G fii, G fiib  is highly expressed in erythroid 
and megakaryocytic precursors. G fii expression is undetectable in these cells. In line 
with these findings, it has been shown that G fiib  is essential for the development of the 
erythroid and megakaryocytic lineages. Mice that lack G fiib  die during embryogenesis 
due to lack of definitive erythropoiesis, preventing a detailed analysis at what stages 
G fiib  is important. To study this in more detail G fiib  has been overexpressed and silenced 
in various immature precursor subsets. This showed that silencing of G fiib  in CD34+ 
cells resulted in decreased proliferation of progenitor cells and inhibition of differenti­
ation towards erythroblasts and megakaryocytes“0. In contrast, forced G fiib  expression 
in human CD34+ cells enhanced expansion of immature erythroblasts, but did not 
induce erythroid commitment and inhibited differentiation beyond the pro-erythroblast 
sta g e d  However, enforced G fiib  expression in more differentiated CD367GPA' erythroid 
precursors inhibited proliferation and induced erythroid differentiation“ 2. This indicates 
that depending on the developmental stage, G fiib  triggers opposing phenotypes during 
erythropoiesis. In immature CD34+ cells, G fii expression is sustained upon loss of G fiib  
expression. Despite the expression of G fii, erythropoiesis and megakaryopoiesis are not 
rescuedii0. This suggests that G fii cannot compensate for the effects of loss of G fiib  in 
erythroid development.
Because loss of function models for G fiib  have been reported only very recently, 
the molecular mechanism through which G fiib  controls erythropoiesis and megakaryo­
poiesis is poorly understood. Recently it was stated that G fiib  may control erythropoiesis
by directly repressing the expression of the transforming growth factor p receptor III 
(TGFPR3) gene and thereby regulating TGFp signaling (Table 3)110. G fiib  is also expressed 
in common myeloid progenitors and in specific B and T cell subsets113. Whether G fiib  is 
essential for the development of these lineages in vivo is currently unknown.
Although the contribution of loss of function of G fiib  to leukemia formation 
has not been studied in murine models, G fiib  has been implicated in chronic myeloid 
leukemia (CML) in humans114. This disease is characterized by the constitutively active 
tyrosine kinase BCR-ABL. Inhibition of this kinase with the drug Imatinib results in down- 
regulation of anti-apoptotic Bcl-XL which contributes to apoptosis of the leukemic cells. 
Following treatment with Imatinib, Gfi1b is induced and triggers the down-modulation 
of the Bcl-XL gene in CML cells58;114. The relevance of the Gfi1b induction was underscored 
by the fact that Gfi1b silencing inhibited Imatinib-induced apoptosis. As in leukemia, 
down-regulation of Gfi1b may also contribute to lymphoma development. G fiib  gene 
expression is directly regulated by the tumor suppressor E2A. In lymphomas with loss of 
E2A function Gfi1b expression is lost. However, forced Gfi1b expression inhibited prolifer­
ation and survival of lymphoma cells115. In conclusion, Gfi1b is essential for erythroid and 
megakaryocytic development and its induction triggers apoptosis of CML and lymphoma 
cells.
Control of Gfi1 activity and protein levels
Gfi1 and Gfi1b function both upstream and downstream of cytokine signaling 
processes, defining these proteins as important factors that connect extracellular signals 
to intracellular mechanisms. Both proteins play a crucial role in lineage fate decisions. 
Whereas Gfi1b is essential for erythroid and megakaryocytic differentiation, Gfi1 is impli­
cated in the development of almost all other blood cell types. In addition, the prolifer­
ation of different hematopoietic subsets as well as lymphocyte activation is regulated by 
Gfi1. To fully understand how Gfi1 and Gfi1b control hematopoiesis, it will be important to 
identify more relevant target genes. Likewise, it is relevant to determine what co-factors 
are used by Gfi1 and Gfi1b in the various hematopoietic subsets and how its function is 
regulated. Despite multiple extensive studies on the molecular and biological function of 
the GFI1 protein, to date little is known on how the protein activity and stability is regu­
lated. The activity of many crucial transcription factors is regulated through post-trans­
lational modifications such as acetylation, phosphorylation, sumoylation or ubiquiti- 
nation. For example the tumor suppressor protein p53 can be modified by all of the
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above described modifications that together regulate activity, localization and stability 
of the p53 protein (reviewed by Bode and Dong116). Phosphorylation of the transcription 
factor C/EBPa plays an important role in regulating its function and deregulation of this 
process may even contribute to leukemic transformation117. The activity of C/EBPa is, 
next to phosphorylation, regulated by sumoylation where the covalent binding of a Sumo 
protein alters the binding site for C/EBPa interacting proteins and thereby interferes with 
the composition and activity of the transcription factor complex (reviewed by Khanna- 
Gupta118. Although GFI1 interacts with a set of proteins that is involved in sumoylation 
(see above), to date there is no other experimental evidence that GFI1 is a target of, or 
implicated in sumoylation. Also the process of phosphorylation has not been implicated in 
regulation of GFI1 function. This the work presented in this thesis is primarily focused on 
the modification of GFI1 by ubiquitination.
Ubiquitination, a post-translational modification involved in many 
cellular processes
Ubiquitination, the modification of a protein with one or more ubiquitin 
moieties, is a reversible post-translational process that has received a dramatic increase 
in interest over the past decade. Although originally identified as a process that targets
Figure 5. Process of ubiquitination. The process of ubiquitination requires subsequent action of 
multiple enzymes. The E1 ubiquitin activating enzyme captures and binds ubiquitin in an ATP dependent 
manner. The ubiquitin is then transferred to an E2 ubiquitin conjugating enzyme. The E3 ubiquitin 
ligase binds both the substrate and the E2-ubiquitin complex to facilitate transfer of the ubiquitin to the 
substrate. In most cases, the E3 does not bind ubiquitin. Only in the case of HECT ubiquitin ligases, the 
ubiquitin is transferred onto the ubiquitin ligase before being bound to the substrate (dashed arrows). 
Ubiquitination is a reversible process. De-ubiquitinating proteins (DUBs) can remove the ubiquitin 
(chain) from the substrate protein.
proteins for proteasomal degradation in a controlled, ATP-dependent manner119-122, it is 
now clear that ubiquitination is a complex process that modifies substrate proteins with 
the signaling molecule ubiquitin that, next to degradation, is implicated in many more 
biological processes.
Protein ubiquitination is achieved through a multi-step process
Ubiquitin is a small 76 amino acid peptide. With only a three amino acid 
difference between yeast and mammalian ubiquitin, it is one of the most conserved 
proteins in nature123. The process of substrate protein modification with ubiquitin is 
strongly conserved. It can be found in algae, yeast, all multicellular organisms and even in 
some bacterial species. This suggests that ubiquitination is a crucial biological process124.
The covalent attachment of ubiquitin to cellular proteins requires the subse­
quent action of multiple enzymes (Figure 5). First, free ubiquitin is activated by the 
E1 ubiquitin activating enzyme. This activation step requires energy that is provided 
by ATP hydrolysis. The activated ubiquitin is then coupled to an E2 ubiquitin conju­
gating enzyme. Finally, the ubiquitin ligase (E3) facilitates the transfer of ubiquitin from 
the E2 to the substrate. As the E3 ligase serves as a scaffold molecule that interacts 
with both the target protein and the E2, this enzyme determines the substrate speci­
ficity of the process. Both the complexity and specificity of this process is illustrated by 
the presence of a large number (□ 1000) of ubiquitin ligases encoded in the mammalian 
genome. In contrast, only approximately 50 distinct E2 enzymes and only one (two in 
some organisms125) E1 enzyme have been identified126. The E3 enzymes can be subdivided 
into subclasses based on their protein structure. One group contains intrinsic ubiquitin 
ligase activity as a single polypeptide, which is sufficient for binding the E2-ubiquitin 
complex and the substrate. These enzymes contain a RING, HECT or U-box domain that 
is essential for the ligase function. Other proteins only display ligase activity as part of 
large multi-protein complex. Among these are the SOCS-box, F-box and Cullin proteins. 
A part from the great number of E3 ubiquitin ligases found in the genome, an extra level 
of complexity is added by the fact that a single substrate may be targeted by multiple E3 
enzymes and a single E3 ligase may target more than one substrate for ubiquitination.
Protein ubiquitination determines the fate of the substrate
The process of ubiquitination involves the formation of an covalent isopeptide 
bond between ubiquitin and a substrate protein. The C-terminal glycine of the ubiquitin
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protein is used to couple ubiquitin to the substrate protein. Multiple residues within a 
substrate may be targeted for ubiquitination. Although cystein ubiquitination has been 
reported127, the coupling of ubiquitin to a substrate usually involves one or multiple lysine 
residues in the substrate protein. In some cases, ubiquitin is coupled to the N-terminal 
amino acid of the substrate protein. While conjugated to a substrate protein, ubiquitin 
itself may be subject to ubiquitination onto one of its seven lysine residues (Figure 6a), 
resulting in the formation of poly-ubiquitin chains. Importantly, it is now clear that all 
seven lysines within ubiquitin are used for poly-ubiquitin chain formation, resulting in 
an almost unlimited number of possible variations of poly-ubiquitin chains. In fact, as is 
determined by mass spectrometry, the most studied forms of poly-ubiquitination (linked 
through lysine residues at position 48 and 63, as will be discussed below) together do not
Figure 6. Different forms of ubiquitination. A. The ubiquitin protein contains multiple lysine (K) 
residues that may all be used for the formation of poly-ubiquitin chains. The C-terminal glycine is used 
to couple the ubiquitin to the substrate protein (or, in the case of poly-ubiquitin chain, the preceeding 
ubiquitin) The percentages indicate the relative abundance of linkage in yeast, as determined by mass 
spectrometry128. B. Multiple ways of ubiquitination are known. Substrate proteins may be marked with 
a single ubiquitin on one or more position (1). Mono-ubiquitination is regarded as a functional modifi­
cation that will not lead to recognition by the proteasome for degradation. The formation of homotypic 
poly-ubiquitin chains, linked through a single lysine residue (2 ) will result in degradation in the case of 
K48 linked chains. Lysine 63 linked chains are not recognized by the proteasome and are, like mono- 
ubiquitination, regarded as functional modification. Little is known about chains linked through residues 
other than lysine 48 and 63. Next to the poly-ubiquitin chains linked via lysine residues a new type of 
chain has been found (3). This chain, where the C-terminal glycine is bound to the N-terminus of the 
preceeding ubiquitin, was found to play a role in the NF-kB signaling. More recently, ubiquitin chains 
that contain binding on multiple lysine residues resulting in branched or forked chains have been iden­
tified (4). Although in in vitro assays these heterotypic poly-ubiquitin chains were found to be a substrate 
for proteasomal degradation, the in vivo function is unknown.
even represent half of the total poly-ubiquitinated fraction128, suggesting that the current 
knowledge on protein ubiquitination is "just the tip of the iceberg". Substrate proteins 
may be subjected to mono-ubiquitination, multi-mono-ubiquitination and poly-ubiquiti- 
nation on a single or multiple lysine residues (Figure 6b). Ubiquitination acts as a signaling 
molecule that, depending on the type of ubiquitination, differentially determines the fate 
of the substrate. This may include recognition and subsequent degradation by the prote- 
asome, but ubiquitin modifications may also serve as a binding site for the formation of 
multi-protein complexes.
The classical or canonical form of ubiquitination involves the formation of 
poly-ubiquitin chains that are linked through lysines at position 48 (K48) in ubiquitin. 
Substrates that are marked with this modification are both in vitro and in vivo recognized 
by the 26S proteasome. This large barrel-shaped multi-protein complex harbors different 
types of protease activity (trypsin-like, chymotrypsin-like and caspase-like) that are used 
to degrade the protein into small peptides. To prevent non-specific degradation of cellular 
proteins, the catalytic core of the proteasome is shielded by a cap that serves as a regu­
latory unit. This cap-complex facilitates recognition of ubiquitinated substrates, unfolding 
of the substrate protein and the transport of the unfolded substrate into the active site of 
the proteasome129;130. During this process, the poly-ubiquitin chain is removed and disas­
sembled into single free ubiquitin proteins that can be re-used for modification.
Another well studied form of ubiquitination is the type where poly-ubiquitin 
chains are linked through lysine 63 (K63). Although in in vitro assays the K63 linked chains 
are efficiently targeted to the proteasome for degradation131, this type of poly-ubiquitin 
chain is hardly enriched upon inhibition of the proteasome in vivo, suggesting that K63 
linked chains in general are not used to mark proteins for degradation128;132. In fact, many 
studies have now identified a regulatory role for K63 linked poly-ubiquitin chains and have 
implicated K63 linked chains in many cellular processes, including DNA repair131134, intra­
cellular trafficking135136 and signal transduction137;138.
Although the K48 and K63 linked chains are the best studied forms of poly- 
ubiquitination, in yeast these chains make up only 45% of all cellular poly-ubiquitin 
chains suggesting an important role for chains with a different structure128. Despite their 
abundant use in poly-ubiquitination, little is known about the function of poly ubiquitin 
chains linked via lysine 6, 11, 27, 29 and 33. Most of these chains are enriched by prote- 
asome inhibition, suggesting a role in regulation of protein stability although other 
studies suggest that these types of chains may also serve as a platform for protein-
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protein interactions. More recently, the linear ubiquitin chains, where the C-terminal 
glycine is linked to the N-terminal methionine residue were added to the repertoire 
of ubiquitin chains (figure 6b, part 3). These chains also serve as a binding site for other 
proteins139;140. Until recently it was generally assumed that poly-ubiquitin chains contain 
only a single type of peptide linkage, for example, chains containing only K48 linkages 
and no K63 (homotypic poly-ubiquitin chains). Another level of complexity was added 
by the discovery of heterotypic poly-ubiquitin chains. In this mixed or branched ubiquitin 
chains multiple different lysine residues within the ubiquitin protein are used for chain 
formation (figure 6b, part 4) 141'143.
As it has become increasingly clear that poly-ubiquitin chains are far more 
complex than was anticipated, the elucidation of the composition of poly-ubiquitin chains 
remains a great challenge. Currently, most of the evidence on the topology of poly- 
ubiquitin chains comes from mass-spectrometry experiments144-146. Although this tech­
nique is being improved continuously, with the current level of technology it is still not 
possible to detect all possible poly-ubiquitin chain topologies. It is, for example, a huge 
technical challenge to elucidate the exact composition of mixed ubiquitin chains where a 
K48 linkage is followed by a K63 link. The same challenges are presented for the detection 
of multiple chains with different topologies conjugated to a single substrate. Because to 
date many of the combinations of ubiquitin linkage that are theoretically possible have 
also been found, it is tempting to speculate that the combinations that have not been 
detected due to technological limitations will be present in cells.
Physiological roles o f protein ubiquitination
As mentioned above, ubiquitin chains serve as an interaction site for other 
proteins. The importance of this pathway is underlined by the fact that over 15 different 
types of ubiquitin binding domains have been identified to date147. As stated above, K48 
linked chains are recognized by the 26S proteasome. In contrast, the marking of proteins 
with a single ubiquitin or with K63 linked chains often provides the initiating signal for the 
formation of multi-protein complexes. As will be highlighted by a few examples described 
below, protein ubiquitination is implicated in many different cellular processes and 
multiple forms of ubiquitination may even be involved in the same pathway.
Rapid ubiquitin-proteasome mediated degradation can be observed in many 
different cellular processes. For example, under normal circumstances, the tumor 
suppressor p53 is ubiquitinated by the ubiquitin ligase MDM2 and rapidly degraded by
the proteasome. Upon cellular stress (for example when DNA damage has occurred) 
the ubiquitination of p53 is abrogated and the protein is allowed to perform its crucial 
function148. Ubiquitination is also closely involved in the regulation of the cell cycle. 
The cell cycle is tightly controlled by many proteins and cell cycle progression critically 
requires the presence of certain proteins and absence of other proteins. Cyclin degra­
dation is a key step for cells to exit from mitosis and to progress into the next cell cycle. 
Almost two decades ago it was found that the ubiquitin-proteasome route is respon­
sible for cyclin degradation149. Later, a protein complex termed the anaphase promoting 
complex (APC) was identified as the ubiquitin ligase responsible for this degradation150. 
Following the discovery of the APC, many ubiquitin ligase enzymes and complexes have 
been identified that control the cell cycle by targeting crucial factors for degradation, 
demonstrating the importance of ubiquitination mediated degradation in this process151. 
The proteasome mediated degradation also plays a crucial role in the immune response 
as the proteasome is the central cytoplasmic processing unit for the generation of 
peptides for the MHC class I antigen presentation pathway152.
The K63 linked ubiquitin polymers are, in contrast to the K48 linked chains, 
not recognized by the 26S proteasome but serve as an interaction platform to facilitate 
protein-protein interactions that precede a functional modification or translocation of the 
substrate protein. The downregulation of cell-surface receptors via internalization typi­
cally relies on the K63 linked poly-ubiquitination153-155. K63 linked chains are also critical 
components of signal transduction cascades. Interestingly, also the recently identified 
linear ubiquitin chains are implicated in signal transduction, in particular the activation 
of NF-kB. The canonical pathway of NF-kB is an important signal transduction route 
that translates receptor activation (including TNF receptor and Toll-like receptor) into an 
altered transcription program. Prior to the discovery of linear ubiquitin chains, ubiquiti­
nation was already assigned an important role in NF-kB signaling (reviewed by Bhoj et 
al. 156). In fact, the NF-kB signaling route provides an excellent example of cooperation 
between many forms of post-translational modifications, including different forms of 
ubiquitination (Figure 7).
Apart from modification with poly-ubiquitin chains, substrates may also be 
marked with a single ubiquitin residue on one (mono-ubiquitination) or more lysine 
residues (multi-mono-ubiquitination) (figure 6b, part 1). Comparable to modification 
with the K63 coupled chains, mono-ubiquitination of a substrate does not result in degra­
dation. Instead, mono-ubiquitination serves as a functional modification involved in
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Figure 7. Ubiquitination contro ls NFkB signaling. Protein ubiquitination plays a crucial role in the 
NFkB signaling pathway. The NF-kB transcription factor complex is retained in an inactive state in the 
cytoplasm by binding to the IkB protein. Activation of the NF-kB is initiated by the signal-induced degra­
dation of IkB proteins. This requires a tightly orchestrated series of events that include phosphorylation 
and the formation of poly-ubiquitin chains of different topology, including K48, K63 and linear ubiquitin 
chains. Ligand binding induced receptor activation leads to the recruitment, dimerization and activation
of signal transduction proteins including a member of the TRAF protein family, TRAF6 . The ubiquitin 
ligase TRAF6 catalyzes the formation of K63 linked poly-ubiquitin chains on both substrate proteins 
and itself216. The K63 linked chain on TRAF6 serves as a docking site for the kinase TAK1 that upon 
binding may dimerize and become active through trans-phosphorylation. Apart from the auto-ubiqui- 
tination, TRAF6 was shown to mark NEMO, the regulatory subunit of the IKK (IkB kinase) complex, with 
K63 linked chains. Active TAK1 is recruited to the IKK complex through binding to the K63 linked poly- 
ubiquitin chain on NEMO and is responsible for the phosphorylation and thereby activation of the IKK 
complex. In turn, activation of IKK through leads to phosphorylation of the IkB protein. This phosphate 
serves as a recognition site for a ubiquitin ligase complex (SCF-pTrCP), the complex that catalyzes the 
formation of K48 linked poly-ubiquitin chains on the IkB protein to target it for degradation. This degra­
dation allows the release of NF-kB and its translocation into the nucleus where it can activate tran­
scription. Earlier it was reported that activation of IKK required K63 linked poly-ubiquitination of NEMO 
as these chains may serve as a binding motif for activated TAK1. More recently it was found that NEMO 
may also be modified with linear ubiquitin chains by the E3 ubiquitin ligase complex LUBAC140. Whether 
both types of chains are involved simultaneously or that ubiquitin chain formation promotes NFkB 
signaling differentially remains subject of further study.
trafficking of cellular proteins, (in)activation of protein function and DNA repair. The 
process of mono-ubiquitination has received special interest in the context of epigenetic 
regulation. As described above, gene transcription is controlled via regulation of the 
accessibility of the chromatin. This is regulated via the addition and removal of post- 
translational modifications on histone proteins. Mono-ubiquitination of histones acts as 
an important activation signal that facilitates transcription157.
Ubiquitination is a reversible process
The process of ubiquitination involves the covalent binding of ubiquitin to a 
substrate. Despite the presence of a strong chemical bond, ubiquitination is a reversible 
process. De-ubiquitinating proteins (DUBs) are enzymes that can remove the bond 
between ubiquitin and the substrate. This may result in removal of single ubiquitin 
molecules or complete ubiquitin chains. The human genome encodes an estimated 
100 DUBs158. The 26S proteasome has de-ubiquitinating activity. Prior to the enzymatic 
cleavage of the substrate protein, poly ubiquitin chains are removed from the ubiquiti- 
nated substrates and subsequently disassembled. This is performed by three DUBs that 
are associated with the proteasome in the cap-protein complex159. DUBs also play an 
important role in modulation of signal transduction. As mentioned above, ubiquitination 
plays a crucial role in NF-kB signaling. It is therefore not surprising that this process is 
also regulated by DUBs. The de-ubiquitinating enzyme A20 is a K63-linked ubiquitin chain
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specific DUB that is crucial for the attenuation of the inflammatory response by inhib­
iting NF-k B activation160;161. Interestingly, the A20 protein also contains a domain that 
exhibits ubiquitin ligase function, suggesting that the ubiquitin ligase and de-ubiqui- 
tinating activity of this protein is a coupled process. The biological role of this ubiquitin 
ligase activity is unclear.
In conclusion, the post-translational modification of substrate proteins with 
ubiquitin is a complex reversible process that may result in different types of modi­
fications. In general, the ubiquitin is regarded as an interacting motif that allows the 
substrate to bind to a different set of proteins162. Proteins that are modified may be recog­
nized by the proteasome and degraded. Next to degradation, ubiquitination can result in 
internalization, activation or translocation.
Ubiquitination in normal and malignant hematopoiesis
Ubiquitination is implicated in many different cellular processes where it 
provides an important molecular signal that determines the fate of substrate proteins. It 
is therefore not surprisingly that ubiquitination is involved in many aspects of the tightly 
regulated process of hematopoiesis. Multiple proteins that are crucial for blood cell devel­
opment are known to be subjected to ubiquitination. Furthermore, as can be expected 
from examples of many other important molecular processes, errors in the process of 
ubiquitination have been found to contribute to hematological disease. These irregular­
ities may occur at various levels in the multi-step process of ubiquitination and include 
misexpression of E3s, resulting in altered substrate ubiquitination and degradation, inac-
y
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Figure 8. Alterations in ubiquitination. As ubiquiti­
nation is crucial to many cellular processes, alterations 
in this route may contribute strongly to pathogenesis. 
A. Misexpression of a ubiquitin ligase or mutations in 
the substrate can result in increased ubiquitination and 
accelerated degradation. B. Loss of function muta­
tions of a ubiquitin ligase or mutations in the substrate 
protein that prevent ubiquitination may result in accumu­
lation of the substrate protein. C. Aberrant ubiquitination 
may result in altered activity of the substrate protein. D. 
If ubiquitin provides a localization signal, aberrant ubiqui­
tination will result in defective targeting of the substrate 
protein.
tivating mutations in E3s, causing loss of substrate ubiquitination and further stabili­
zation, mutations in substrates, that either prevent their ubiquitination and degradation 
or cause increased ubiquitination and subsequent excessive degradation (Figure 8). Here 
the relevance of protein ubiquitination for hematopoiesis is illustrated by few examples 
where defective ubiquitination contributes to aberrant hematopoiesis.
The widely studied form of ubiquitination, the formation of K48 linked poly- 
ubiquitin chains has been implicated in many aspects of hematopoiesis. For example, 
this process is involved in control of proliferation of HSCs. Ubiquitin ligase Cul4A regu­
lates crucial regulators of HSC proliferation HoxA9163 and p27164. The importance of Cul4A 
mediated ubiquitination is illustrated by the finding that loss of Cul4A inhibits prolif­
eration and severely decreases viability of HSC165;166. The tumor suppressor p53 plays a 
crucial role in maintaining cellular integrity by controlling the balance between prolifer­
ation, quiescence and apoptosis. Mutations in TP53, the gene encoding p53 are frequently 
found in solid tumors. These mutations diminish p53 expression or result in expression 
of a non-functional protein. In leukemia, p53 mutations are found less frequently as 
compared to solid tumors. However, overexpression of the ubiquitin ligase MDM2, that 
targets p53 for degradation, is found in hematological malignancies167-170. This accelerated 
degradation prevents p53 from performing its control function and contributes greatly to 
the oncogenic transformation.
Next to control of proliferation, ubiquitin mediated degradation is implicated in 
differentiation and activation of hematopoietic cells. Important transcription factors that 
regulate differentiation are known to be subjected to ubiquitin mediated degradation, 
including AML1171, GATA-2172 and C/EBPa173. But upstream of transcription regulation, 
in the receptor signaling, there is also an important role for ubiquitination. The intracel­
lular domain of growth factor receptors is usually modified upon binding of the ligand, 
resulting in activation of the signal transduction route towards the nucleus. Suppressors 
of cytokine signaling (SOCS) proteins are crucial factors for attenuation of this receptor 
signaling. SOCS proteins recruit a complex that exhibits ubiquitin ligase activity to acti­
vated receptors. Upon ubiquitination, the activated receptors are internalized where 
they can be recycled to the cell membrane or be targeted for degradation. This mech­
anism of SOCS mediated silencing of signal transduction has been shown for many 
receptor signaling routes, including Toll-like receptor174, insulin receptor175;176 and inter­
feron receptor177 signaling but also for intermediates such as JAK/STAT kinase activity178. 
With their function of inhibiting growth factor receptor signaling, the SOCS proteins
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may be regarded as tumor suppressor proteins as constitutive growth factor signaling 
is a hallmark of leukemic cells. Indeed, mutations that result in loss of function of SOCS 
proteins are found in patients suffering from hematological malignancies179-182. In 
contrast, ectopic expression of SOCS proteins can inhibit the constitutive activation of 
mutated receptors and signaling molecules that are found in leukemic cells179;183. Impor­
tantly, in sharp contrast to its suppressing properties in tumor development, upreg- 
ulation of SOCS expression may also be beneficial to the tumor. Increase of SOCS 
expression may be used by tumor cells as a mechanism to evade targeting by thera­
peutic compounds. Some current forms of targeted therapy are based on the delivery of 
toxins and other forms chemotherapy to tumor cells by using antibodies that recognize 
tumor specific expression of cell surface receptors. Tumor cells may evade this therapy by 
increasing expression of SOCS proteins and thereby removing the surface markers that 
are targeted184.
In addition to the SOCS proteins the ubiquitin ligase Cbl is another protein 
that mediates growth factor signaling including IL-6185, CSF186, SCF187. Similar to SOCS 
proteins, inactivating mutations in Cbl are associated with leukemia188-191. Recent studies 
showed that introduction of mutant forms of Cbl into a model system induced a more 
profound phenotype effects as compared to loss of function by gene deletion alone. This 
suggests a gain-of-function of mutant Cbl which may also play a role in leukemic trans­
formation192. Recently, F box and WD repeat containing 7 (FBXW7), the substrate recog­
nition domain part of ubiquitin ligase complex has received great attention. The FBXW7 
ubiquitin ligase complex targets many substrates for degradation, including cell cycle 
regulator Cyclin E193, and transcription factors c-Myc194, Jun195 and Notch196. With recog­
nition of substrates that are already tightly involved in oncogenesis, it is not surprisingly 
that mutations in FBXW7 contribute to cancer development. Mutations in FBXWy have 
been detected in many tumors, including acute leukemia that involves precursor T cells 
(T-ALL)197;198. With FBXW7 being a direct target of p53199, its expression may be reduced 
in all tumors baring a p53 deletion or mutation. Even with the already high mutation rate 
in the FBXWy gene itself, the role of this F-box protein in oncogenesis may be underesti­
mated as a result of the defective p53 mediated regulation. Interestingly, not only muta­
tions of the ubiquitin ligase that targets c-Myc, but also mutation of the c-Myc protein 
itself may result in accumulation of the protein. Mutations in c-Myc that are commonly 
found in lymphomas frequently inhibit the ubiquitin mediated degradation200;201. The 
examples above show that mutations both in substrates and ubiquitin ligases that are
found in leukemic cells can result in diminished degradation. Alternatively, accelerated 
degradation may also contribute to malignant transformation. TGF^ signaling plays a 
central role in the regulation of proliferation, differentiation and apoptosis. Inactivation 
of genes involved in the TGF^ signal transduction pathway inhibits HSC quiescence and 
promotes cell-cycle progression. The Smad proteins mediate TGF^ signaling from the cell 
membrane to the nucleus and are therefore critical components of the TGF^ signaling 
pathway. Analogous to the NFkB signaling pathway, protein ubiquitination is critically 
implicated in the TGF^ signaling pathway202;203. Ubiquitin mediated degradation of Smad 
proteins attenuates TGF^ signalling. Mutations in the Smad4 gene have been identified 
in many different cancers, including AML, and involve deletions, nonsense and missense 
mutations204. Interestingly, some of these mutations result in enhanced turnover of the 
Smad4 protein due to increased binding affinity to the E3 ubiquitin ligase205.
Apart from tumor development, ubiquitination has also been implicated in 
defective hematopoiesis. In congenital polycythemia patients, the ubiquitin ligase Von 
Hippel Lindau is mutated206;207. As a result, its substrate, transcription factor H ifia, accu­
mulates. This leads to an increased expression of erythropoietin (EPO), a transcriptional 
target of H ifia 208. This increase of EPO promotes erythrocyte formation and thus is 
believed to be causative to the congenital polycythemia vera.
In conclusion, ubiquitin mediated degradation is implicated in control of prolif­
eration, differentiation and activation of hematopoietic cells. Both accelerated turn-over 
and diminished degradation as a result of mutations or misexpression of both substrate 
and ubiquitin ligases have been implicated aberrant and malignant hematopoiesis.
Non-canonical ubiquitination in hematopoiesis
Also other forms of protein ubiquitination, have been shown to play a crucial role 
in hematopoiesis. As stated above, both linear and K63-linked poly-ubiquitin chains are 
important for NFkB mediated lymphocyte activation. However, non-canonical ubiqui­
tination, other than lysine 48 poly-ubiquitination, is also critically implicated in the 
development of hematopoietic cells. Complete loss of Ubci3, the sole ubiquitin conju­
gating enzyme that is linked to K63 chain formation thus far, leads to fatal errors in early 
embryonic development209. The use of elegant conditional knockout models is therefore 
required to study the role of K63-linked ubiquitination in hematopoiesis. Loss of Ubci3 
expression in healthy adult mice leads to rapid degeneration of the bone marrow which 
is accompanied by an almost complete loss of white blood cell and platelet counts and
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a strong reduction in red blood cell numbers210. Loss of Ubci3 expression causes a defect 
in development of multiple lineages which may in part be explained by aberrant Wnt 
signaling, a signaling pathway that is crucial for normal hematopoiesis211;212. Although 
the exact mechanism remains subject of additional studies, the use of this condi­
tional knockout model clearly proves that non-canonical ubiquitination is crucial for the 
proper development of blood cells. In addition, few other examples are available to illus­
trate the importance of non-canonical ubiquitination in hematopoiesis. Fanconi Anemia 
(FA) patients show chromosomal instability and are predisposed to develop malig­
nancies. FA patients carry a mutation in one of the proteins that make up a ubiquitin 
ligase complex that is responsible for the mono-ubiquitination of FANCD2, a protein that 
is part of the DNA repair machinery. This mono-ubiquitination is an essential step in the 
initiation of DNA repair after DNA damage. In FA patients this step is affected resulting 
in inefficient DNA repair and accumulation of DNA damage. This accumulation of DNA 
damage obviously is a cancer initiating event213. Thus, like the ubiquitination that targets 
substrates for degradation, the non-canonical forms of ubiquitination play a crucial role in 
hematopoiesis.
Although the process of ubiquitination without any doubt is important for 
proper hematopoiesis and has received great attention, the counterpart, de-ubiqui- 
tination is gaining in interest as a potential oncogenic or tumor suppressive process and 
has recently been implicated in leukemia development. As mentioned above the NF-kB 
signaling pathway is tightly regulated by ubiquitination. The A20 protein, a de-ubiquiti- 
nating enzyme that is an important regulator in NF-kB signaling, was shown to function 
as a tumor suppressor protein in lymphoma development, highlighting the importance of 
de-ubiquitination in maintaining cellular integrity214;215.
In conclusion, ubiquitination plays a crucial role in the complex process of hema­
topoiesis. Important regulators of both proliferation and differentiation are controlled by 
ubiquitination. Deregulation of this process is implicated in aberrant hematopoiesis and 
may contribute to malignant transformation.
Outline of this thesis
Hematopoiesis is a highly efficient, tightly controlled process of proliferation and 
differentiation. This process is influenced by extrinsic factors, like growth factors, that via 
receptor signaling translate into activation of different transcriptional programs, each
driving the developing cell towards a certain mature lineage. Gfii is a transcription factor 
that plays an important role in many aspects of hematopoiesis, from the HSC to the acti­
vated mature effector cells. Many studies have focused on elucidating the biological 
role of Gfii in hematopoietic cells. This has lead to an increased understanding on how 
G FIi controls hematopoiesis. Also the molecular basis of this regulation has received 
great attention, including the identification of Gfii target genes and, to a lesser extent, 
the regulation of GFIi expression itself. Surprisingly little is known on how Gfii function 
is regulated at the protein level. We hypothesized that like other important transcription 
factors, Gfii protein function would be regulated by post-translational modification, in 
particular ubiquitination. We found that Gfii is indeed ubiquitinated. In chapter 2 we 
describe that ubiquitination of G fii plays an important regulatory function in controlling 
G fii protein levels in mature myeloid cells. To further understand how this ubiquitination 
is regulated, we defined the minimal domain in the G fii protein that is required for its 
ubiquitin mediated degradation. This is described in chapter 3. To gain more insight in 
how Gfii ubiquitination is regulated we aimed to find components of the ubiquitination 
machinery that control G fii ubiquitination. In chapter 4 we describe that the ubiquitin 
ligase Triadi, which is expressed during myeloid differentiation, controls Gfii protein 
stability by specifically inhibiting G fii ubiquitination. To gain more insight into how Triadi 
may regulate protein ubiquitination we have characterized the enzymatic properties of 
this ubiquitin ligase. This is described in chapter 5.
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Chapter 2, Diminished 
proteasomal degradation 
results in accumulation of Gfil 
protein levels in monocytes
The results described in this chapter were published in Blood, 2007 vol. 
109 (1), pages 100-108
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Abstract
Gfi1 is a transcriptional repressor essential during myeloid differentiation. Gfi1 
null mice exhibit a block in myeloid differentiation resulting in the accumulation of an 
immature myelo-monocytic cell population and the complete absence of mature neutro­
phils. Even though mRNA levels of Gfi1 appear to be very low in monocytes, Gfi1 might 
play a role in the monocytic lineage as Gfi1 null mice exhibit diminished monocyte- 
derived dendritic cells and disturbed cytokine production by macrophages in response to 
LPS. We show here that Gfi1 protein levels are mainly regulated by the ubiquitin-prote- 
asome system. Upon forced monocytic differentiation of U937 cells Gfi1 mRNA levels 
dropped but protein levels increased due to diminished proteasomal turnover. Similarly, 
Gfi1 mRNA levels are low in primary monocytes while the protein is clearly detectable. 
Conversely, Gfi1 mRNA levels are high in granulocytes but the protein is swiftly degraded 
by the proteasome in these cells. Chromatin immunoprecipitation experiments showed 
that Gfi1 binds to the promoter of several granulocytic specific genes in primary mono­
cytes, including C/EBPa, neutrophil elastase and Gfi1 itself. The binding of the repressor 
Gfi1 to these promoters correlated with low expression of these genes in monocytes 
compared to granulocytes. Our data fit a model in which Gfi1 protein levels are induced 
in primary monocytes, due to diminished proteasomal degradation, to repress genes that 
play a role in granulocytic differentation.
Introduction
The generation of mature myeloid cells from hematopoietic stem cells (HSC) is a 
tightly regulated process. HSC may differentiate in common myeloid progenitors (CMP) 
that in turn differentiate towards common granulocyte/monocyte progenitor cells (GMP). 
These latter cells may differentiate into mature, functional myeloid blood cells. Different 
regulatory mechanisms are responsible for maintaining the correct levels of mature blood 
cells. Lineage determining factors stimulate specific transcription factors that direct 
progenitors cells towards a specific cell type, while simultaneously they may actively 
suppress alternative lineage programs. In myelopoiesis, several transcriptional regulators 
have been found to play an essential role including PU.1 i;2, C/EBPa 3 and C/EBPs 4.
Recently, the transcription factor Growth factor independence 1 (Gfii) has also 
been shown to play an essential role during myelopoiesis. Gfii null knockout mice are 
severely neutropenic and exhibit a block in myeloid differentiation resulting in the accu­
mulation of an atypical immature myeloid cell population 5;6. This is in line with reported 
heterozygous GFIi missense mutations in patients suffering from hereditary neutropenia
7. Gfii may function as a transcriptional repressor and regulates genes that play a role in 
cell cycle regulation like E2F5 and cMyc and in granulopoiesis like C/EBPa, C/EBPs and 
neutrophil elastase 8. Furthermore, G fii can repress its own promoter and the promoter 
of its paralogue GfiiB 9;i0.
Gfii was originally identified as a proviral insertion site resulting in IL2 inde­
pendent growth of T-cells “ . Overexpressed Gfii acts as a dominant oncogene and coop­
erates with known oncoproteins like Myc and Pim-i in lymphoma development i2;i3. 
In normal hematopoiesis, Gfii is essential for T-cell development and for self-renewal 
and long term reconstituting potential of HSC 5;i4;i5. Recently, G fii was also shown to be 
important for lymphocyte-derived dendritic cell (DC) development i6.
Whether G fii plays a role in the monocytic lineage is under debate. Although 
the immature atypical myeloid population in G fii null mice exhibits both granulocytic 
and monocytic characteristics, it has been speculated that G fii is not relevant in mono­
cytic differentiation. This is mainly based on low Gfii mRNA expression patterns in the 
monocytic lineage as measured by RT-PCR or indirectly by measuring Gfii promoter 
activity using GFP:Gfii knock-in mice. During granulocytic and monocytic differentiation 
G fii mRNA expression is strongly induced at the GMP stage and expression is detected in 
mature granulocytes, while low expression is found in monocytic/macrophage cells 6;i5;i7. 
However, recent studies suggest a role for G fii in monocyte-derived DC differentiation.
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Gfii null progenitor cells fail to differentiate into DCs in in vitro assays i6 . In addition, Gfii 
null macrophages exhibit aberrant cytokine expression profiles and are hyper-responsive 
to LPS 6;i8. These data suggest that Gfii may be important in the monocytic lineage. To 
clarify this issue, we analyzed G fii protein expression and found that Gfii is very effi­
ciently targeted for ubiquitin-proteasomal degradation in immature myeloid cells and 
that diminished proteasomal degradation in primary monocytes results in significant Gfii 
protein levels, despite low RNA levels.
Materials and Methods
Cell culture and selection
U937, NB4 and HL60 cells were grown in RPMI i640 medium (Life Technol­
ogies) supplemented with io%  fetal calf serum (Invitrogen), 50 I.U./ml penicillin and 50 
|ag/ml streptomycin (ICN). Cells were differentiated for indicated time points with i0  M 
ATRA (all-irans retinoic acid) (Sigma) or i0  ng/ml PMA (Phorbol i2-myristate i3-acetate ) 
(Sigma). The 26S proteasome activity was inhibited overnight with 5 |aM MGi32. For Gfii 
half-life determination, cycloheximide was used at a concentration of 25 |ag/ml. COS-i 
and HEK293 cells were grown in IMDM (Life Technologies) supplemented as described 
above. All cells were grown at 37°C at 5% CO2. Differentiation of U937 cells was assessed 
by the expression of C D iic  (Immunotech, Marseille, France). Apoptosis was determined 
by flowcytometer using AnnexinV (Molecular Probes, Eugene, OR) and propidium iodide 
staining, respectively. Primary cells were obtained from healthy volunteers. Human 
monocytes, used for RNA isolation, were stained with CDi4 antibodies and isolated by 
FACS sorting and granulocytes were FACS sorted based on CD45 positivity and scatter 
characteristics. For Chromatin Immunoprecipitation (ChIP), degradation assays and 
Western blot analysis monocytes were MACS sorted using CDi4 magnetic beads and 
granulocytes were isolated using Ficoll i077 density gradient centrifugation followed by 
erythrocyte lysis using NH4Cl. Cell purities were confirmed to be more than 95% by flow 
cytometric analysis.
Plasmids
Gfii expression plasmids containing FLAG-Gfii, FLAG-GfiiAZn, FLAG-Gfii-Zn 
(Dr. Osawa ) Gfi-GFP and Gfii-FLAG (Dr. T. Móróy) and Gfii wild type and G fii A382S and 
K403R point mutants (Dr. M. Horwitz ) were used as indicated. Expression plasmids for 
His-tagged ubiquitin (His-Ub) and FLAG-tagged ubiquitin (FLAG-Ub) were obtained from
Dr. M. Scheffner 19'
Quantitative PCR
RNA from cell lines was isolated at different time points during differentiation 
using RNA-bee (ISO-TEX Diagnostics). At all time points cell death was less than 10% as 
assessed by Annexin V and propidium positivity measured by flowcytometer. RNA from 
primary cells was isolated using the mini RNA isolation II kit (Zymo research). cDNA was 
generated in a reverse transcription reaction as previously described . Gfi1 mRNA levels 
were measured with real-time quantitative PCR using the primers: Gfi1-F: 5'-GAGCCTG- 
GAGCAGCACAAAG-3' and Gfi1-R: 5'-GTGGATGACCTCTTGAAGCTCTTC-3'. Ela2 mRNA 
levels were measured with real-time quantitative PCR using primers: Ela2-F: 5'-CACT- 
GCGTGGCGAATGTAAA-3' and Ela2-R: 5'-CGACGTGCCGCTTGTGG-3'. C/EBPa mRNA 
expression was measured using pre-developed TaqMan Gene Expression Assay no. 
Hsoo269972_s1 (Applied Biosystems). PCRs were performed in universal master mix 
using SYBR-green (Roche). Conditions were as follows: 10 min. 95°C followed by 45 cycles 
of 15 sec. 95°C and 1 min. 62°C. For normalization fe-actin or 18S rRNA was used as a 
reference gene (Applied Biosystems) 21.
Co-immunoprecipitation and Immunoblotting assays
For co-immunoprecipitations, COS-1 cells were grown in 10-cm culture dishes 
and transiently transfected with FLAG-Ub and GFP-Gfi1 using the calcium phosphate 
precipitation method. Cells were lysed 36 hours after transfection in RIPA buffer with 
Complete protease inhibitors (Roche) and lysates were incubated with GFP-antibody 
and Prot-A beads for 4 hours at 4°C with gentle rotation. Beads were washed 5 times 
with RIPA. Bound proteins were eluted in loading buffer by heating for 5 min at 95°C. 
The immunoprecipitates were resolved by SDS-page, transferred to PVDF membranes, 
blocked with 2% ELK (Campina) and 0.5% BSA (Sigma) and immunoblotted with an 
a-FLAG antibody (M2, Sigma). Proteins were visualized using ECL (BIO-RAD). Protein 
levels on Western blot were quantified using ImageJ software (NIH, Bethesda). For 
detection of endogenous Gfi1, C/EBPa, C/EBPs, Actin, Lamin and Ubiquitin Western blots 
were stained with a-Gfi1 (N-20, Santa Cruz Biotechnology), C/EBPa (Santa Cruz Biotech­
nology), C/EBPs (Santa Cruz Biotechnology), a-Actin (Sigma), a-Lamin (Becton Dick­
inson) and a-Ubiquitin (6C1, Sigma) antibodies, respectively. For preparation of lysates, 
granulocytes were treated with 10% trichloroacetic acid (Sigma) for 30 minutes at 4°C,
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followed by lysis in 50 | l  2 times loadingbuffer (including 5 | l  1 M Tris) and heated at 95°C 
for 5 minutes 22.
In vitro degradation assay
Hematopoietic cell lines, granulocytes and MACS sorted CD14+ cells were lysed 
in RIPA buffer supplemented with Complete protease inhibitor mix (Roche). Cell lysates 
taken at different time points during differentiation were normalized for equal protein 
content using the Bradford protein quantification assay. 2 | l  of 35S methionine labeled in 
vitro translated Gfi1, made using the rabbit reticulocyte lysate TnT Quick Coupled Tran­
scription/Translation System (Promega), was added to cell lysate containing 100 |g  
protein (BioRad protein quantification assay) in a total volume of 35 | l .  100 |M  MG132, 
100 |M  Velcade (PS341/bortezomib) or DMSO (1|l/m l vehicle) was added prior to incu­
bation at 37°C. Reactions were stopped at the indicated time-points by the addition 
of loading buffer and heating the samples for 5 min at 95°C. Samples were resolved by 
SDS-PAGE, gels were fixed, treated with NAMP-100 (Amersham), dried and exposed.
Proteasome activity assay
Proteasome activity was determined in U937 cell lysates after PMA-induced 
differentiation. 67.5 |g  protein (concentration determined using BioRad protein quanti­
fication assay) was incubated with the proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC 
(Boston Biochem) for 2 hrs at 37°C as described 21;23. AMC liberated from the substrate by 
proteasome activity was determined by measuring fluorescence (Fluorstar, BMG, Isogen 
Life Sciences).
In vivo ubiquitination assay
COS-1 cells grown in 10-cm dishes were transfected with 10 |g  of His-Ub and 10 
|g  of human Gfi1-FLAG expression constructs, using calcium phosphate precipitation. 36 
hours after transfection, cells from each dish were collected in two aliquots. One aliquot 
(10%) was used in Western blotting to assess the expression of transfected proteins, while 
the remaining cells (90%) were used for purification of His-tagged proteins by His-select 
(NTA) beads (Sigma). The cell pellet was lysed in buffer A (6 M guanidinium-HCl, 0.1 M 
Na2HPO4, 10 mM imidazole, 10 mM ^-mercaptoethanol, Complete protease inhibitor 
(Roche)) and incubated with His-Select beads (Sigma) for 4 h at 4°C. The beads were 
washed 2 times with buffer A, 2 times with a mixture of 4 parts buffer A, and 1 part of
buffer B (50mM Tris pH 6.8, 20 mM imidazole) and 2 times with buffer B. Bound proteins 
were eluted with 200 mM imidazole in loading buffer. Ub-conjugated Gfi1 was visualized 
on Western blot using an a-FLAG antibody.
Electrophoretic Mobility-Shift Assay (EMSAs)
FLAG-Gfi1 was synthesized in vitro by using the TnT SP6 transcription/translation 
system (Promega). Double-stranded oligonucleotides (5' ACCATCACCACATAAATCACT- 
GCCTATCCTGTG-3') were 32P end-labeled using T4 polynucleotide kinase. Binding reac­
tions (10 | l  vol) contained labeled DNA probes in 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 
mM MgCl , 1 mM ZnSO , 0.5 mM DTT, 0.5 mM EDTA, 10% glycerol, 0.05% Nonidet P-40,
2 4
and 1 |g  of poly(dI-dC), with 1 | l  of the synthesized protein and were performed for 20 
min at room temperature.
Chromatin immunoprecipitation
24
Chromatin immunoprecipitations (ChIP) were executed as described previously . 
Cells were cross-linked for 30 min at 37°C by adding formaldehyde (1%) to the culture 
medium. Cross-linking was stopped by the addition of glycine to a final concentration of 
125 mM. Cells were washed with cold phosphate-buffered saline, buffer B (10 mM EDTA,
0.5 mM EGTA, 0.25% Triton X-100, 20 mM HEPES [pH 7.6]), buffer C (1 mM EDTA, 0.5 
mM EGTA, 0.15 M NaCl, 50 mM HEPES [pH 7.6] ) and incubated in buffer D (0.15% SDS, 
1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6] and 
complete protease inhibitor (Roche)) at 33*106 cells/ml. Chromatin was sonicated using 
the Bioruptor (Cosmo Bio, Tokyo, Japan), high, for 15 min with 0.5 min interval. Insoluble 
material was removed by centrifugation at 13k at 4°C for 15 min. 100 | l  of chromatin was 
incubated with 15 | l  protein G sepharose beads (Amersham), 0.1% BSA, 36 | l  5* buffer 
D, complete protease inhibitors (Roche) and 10 | l  antibody and rocked at 4°C for 16 
hours. The beads were harvested by centrifugation and washed twice with wash-buffer 1 
(0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA and 
20 mM HEPES [pH 7.6]), once with wash-buffer 2 (0.1% SDS, 0.1% NaDOC, 1% Triton 
X-100, 0.5 M NaCl, 1 mM EDTA, 0.5 mM EGTA and 20 mM HEPES [pH 7.6]), once with 
wash-buffer 3 (0.25 M LiCl, 0.5% NaDOC, 0.5% NP-40, 1 mM EDTA, 0.5 mM EGTA and 20 
mM HEPES [pH 7.6]), and twice with wash-buffer 4 (1 mM EDTA, 0.5 mM EGTA and 20 
mM HEPES [pH 7.6]). Chromatin antibody complexes were eluted from the G Sepharose 
beads by addition of 1% SDS and 0.1 M NaHCO3 to the pellet and incubated for 20 min at
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room temperature. Cross-linking was reversed by addition of NaCl (0.44 M final concen­
tration) and incubation of the eluted samples for 4 hours at 65°C. DNA was recovered 
by a phenol-chloroform-isoamylalcohol extraction followed by a chloroform-isoamylal- 
cohol extraction and precipitation with sodium acetate (pH 5.2) and ethanol. Precipi­
tated DNA was subject to quantitative PCR. Total DNA from the IP input was included in 
the PCR and all PCR signals were corrected for this. Quantitative PCR following ChIP was 
done using SYBR green PCR (Applied Biosystems). Genomic primer sequences for the 
Gfi1 target genes were: Gfi1-F2: 5'-TTCTCTCGCTGCGGAGTCT-3', Gfi1-R2: 5'-AGGCAC- 
TAGAAATGACTTGA AAGAAAA-3', C/EBPa-F: 5'-AGATCAGAGCTAGGAGACGCAGA-3', C/ 
EBPa-R: 5'- ATTCTCTTTCAAAGCCAGAACCA-3', ELA2-F2 5'-CAAGTCCCTCAGGTCTAGGT 
TTG -3', ELA2-R2 5'-GGGCTGGTCTCGACGTTTT-3'. Quantitave PCR for the ALBUMIN 
promoter was performed using probe ALB-VIC: 5'-TGCTGAAACATTCACCTTCCAT 
GCAGA-3' with the primers ALB-F: 5'-TGAAACATACGTTCCCAAAGAGTTT-3', ALB-R: 
5'-CTCTCCTTCTCAGAAAGTGTGCATAT-3'.
Results
Gfi1 protein levels increase during monocytic differentiation by post-transcriptional 
mechanisms
Although Gfi1 may play a role in the monocytic lineage, the mRNA expression 
is very low in macrophages. To study this issue in more detail, we analyzed Gfi1 mRNA 
and protein expression during forced differentiation of U937 and HL60 cells. During PMA 
induced monocytic differentiation of these cells Gfi1 mRNA levels dropped as measured 
with quantitative RT-PCR (Figure 1A). Also during ATRA induced granulocytic differ­
entiation of HL60 cells Gfi1 mRNA levels decreased, however to a lesser extent as was 
observed during PMA induced differentiation. Remarkably, upon terminal monocytic 
differentiation of PMA treated U937 cells Gfi1 protein levels increased (Figure 1B). To 
determine the length of time required for PMA to induce Gfi1 and monocytic differenti­
ation, we exposed U937 cells for various time intervals to PMA. This showed that a pulse 
with PMA for only four hours already resulted in Gfi1 protein induction after 72 hours of 
culturing. The Gfi1 protein induction correlated with the extent of differentiation as deter­
mined by C D u c staining (Figure 1C).
To compare Gfi1 proteins levels during monocytic and granulocytic differenti­
ation we analyzed Gfi1 expression in HL60 cells that can be forced along the monocytic 
and granulocytic lineage with respectively, PMA and ATRA. As in U937 cells, upon mono-
Figure 1A
■ 0 hours
10----□ 24 hour
 ^ _______________ ■ _______________ ^ H ^ D 7 2 " c u r
: 11 I k  h
0 ----------------------------------
Figure 1B Figure 1D
72 48 24 0 24 48 72 hours
Figure 1C Figure 1E
72 hours ATRA 
u-Gfi1
Figure 1. Gfil mRNA levels decrease, Gfil protein levels increase during monocytic 
differentiation.
(A), G fil quantitative RT-PCR was performed on RNA samples of U937 and HL60 cells during PMA or 
ATRA induced differentiation (n=3). Gfil expression levels in untreated HL60 and U937 cells were set at 
1 0 0 % and values were normalized for p-actin expression.
(B), Cell lysates of PMA differentiated U937 cells taken at indicated time points were immunoblotted and 
stained with an a-Gfi1 antibody (N20, Santa Cruz Biotechnology).
(C), U937 cells were incubated with PMA. After the indicated pulse times cells were washed and 
harvested 72 hours after the beginning of the experiment. Numbers below the blot indicate the x-mean 
of CD11c expression.
(D) Gfi1 levels in HL60 cell lysates taken after 24, 48, 72 hours treatment with ATRA or PMA were 
compared with untreated cells showing that Gfi1 is strongly induced upon monocytic differentiation. 
Lamin staining shows equal loading.
(E) A 5 times more protein input of lysates from ATRA treated HL60 cells resulted in the detection of a 
modest increase in Gfi1 protein levels although the levels are significantly lower compared to monocytic 
differentiation (see panel D).
73
ch
a
p
te
r 2
74
ch
a
p
te
r 
2
cytic differentiation of HL60 cells a clear Gfi1 protein induction was observed (Figure 1D). 
During ATRA forced differentiation Gfi1 was not detectable. However, when 5 times more 
protein was used in Western blotting a modest increase in Gfi1 protein levels became 
detectable upon granulocytic differentiation of HL60 cells (Figure 1E). This indicates 
that the Gfi1 protein induction is most prominent during monocytic differentiation. The 
observed differences between the expression of Gfi1 mRNA and protein levels suggests 
that Gfi1 protein expression is regulated at the post-transcriptional level during myeloid 
cell differentiation.
Gfi1 is targeted for degradation by the ubiquitin-proteasome pathway
The ubiquitin-proteasome system is an important system through which the 
half-life of various proteins is regulated, including transcription factors 25. To study 
whether Gfi1 is targeted for degradation by the ubiquitin-proteasome system we trans­
Figure 2A Figure 2B
MG132
Figure 2. Gfil is degraded by the ubiquitin-proteasome system.
(A), HEK293 cells were split after transfection with Gfi1-GFP and overnight grown with or without 
MG132. Cells were measured with the FACS and the mean fluorescence index (MFI) of untreated cells 
was set at 100%. After proteasome inhibition (5 ^M MG132) a clear increase of Gfi1-GFP levels per cell 
was observed indicated as MFI.
(B). COS-1 cells were transfected with FLAG-Ub, Gfi1-GFP or with empty vector, followed by immuno- 
precipitation with an a-GFP antibody. Subsequent immunoblotting with an a-FLAG antibody results in 
the detection of a high molecular smear of proteins [(Ub)n] indicating that Gfi1 is present in ubiquitinated 
complexes, or is ubiquitinated itself. ( ^ )  Indicates the height of unmodified Gfi1-GFP. Lower panel with 
a-GFP staining of whole cell extract (WCE) shows a clear distinct Gfi1-GFP band.
(C), COS-1 cells were transfected with His-Ub and FLAG-Gfi1 and MG123 was added as indicated. 
Ubiquitinated proteins were selected with His-select beads, under denaturing conditions, and immu- 
noblotted for a-FLAG. Clearly visible are the ubiquitinated forms of Gfi1 [(Gfi1-Ub)n], especially after 
proteasome inhibition. Whole cell lysate was stained for FLAG confirming equal loading. (*) indicates 
a-specific binding of unmodified Gfi1 to His-select beads.
fected HEK293 cells with a Gfi1-GFP expression construct. The mean fluorescence of 
these cells is a measure for the amount of GFP tagged Gfi1. FACS analysis of cells treated 
with the proteasome inhibitor MG132 resulted in a 4-fold increase in the mean fluores­
cence showing an accumulation of Gfi1-GFP protein levels compared to untreated cells 
(Figure 2A). As proteasome inhibition of cells transfected with GFP alone did not result in 
an increase in fluorescence (data not shown), these data suggest that Gfi1 protein levels 
are regulated by 26S proteasome activity.
Proteins destined for proteasomal degradation are usually tagged by covalently 
linked poly-ubiquitin chains. To test whether Gfi1 can be ubiquitinated, FLAG-Ub was 
co-transfected with Gfi1-GFP in COS-1 cells, followed by GFP immunoprecipitation and 
FLAG staining. This revealed a smear of ubiquitinated proteins representing ubiquitinated 
Gfi1 species or Gfi1 in a complex with other ubiquitinated proteins (Figure 2B). In addition, 
we studied the ubiquitination of Gfi1 in an in vivo ubiquitination experiment. COS-1 
cells were transfected with Gfi1-FLAG and His-tagged ubiquitin (Ub-His). Under dena­
turing conditions, proteins with covalently linked ubiquitin were isolated using His-select 
beads. Subsequent staining for Gfi1 in Western blot analysis detected a protein smear 
consisting of (poly-) ubiquitinated forms of Gfi1. An increase of ubiquitinated Gfi1 forms 
was observed after proteasome inhibition with MG132, indicating that ubiquitinated Gfi1 
is targeted for degradation by the 26S proteasome. The latter finding was confirmed by 
a higher total amount of Gfi1 in the whole cell lysate after proteasome inhibition (Figure 
2C). Similar result were obtained with Gfi1-FLAG in HEK293 cells (data not shown).
Gfi1 is degraded in U937 cells in a proteasome-dependent manner
To investigate whether proteasomal degradation of Gfi1 could explain the 
lower Gfi1 protein levels in immature hematopoietic cells despite high mRNA levels, we 
developed an in vitro degradation assay. In this assay the stability of a fixed amount of 
35S labeled in vitro translated Gfi1 was studied by incubation for different time points 
with cell lysates derived from hematopoietic cell lines 26;27. First, the correct folding of 
Gfi1 was verified by testing the DNA-binding capacity of in vitro translated Gfi1 in an 
electrophoretic mobility shift assay using a Gfi1 binding consensus sequence as probe 
(Figure 3A). Gfi1 stability was next assayed using lysates of undifferentiated U937 cells. 
After 5 minutes most of the Gfi1 was degraded suggesting that Gfi1 has a short half-life in 
immature blood cells. To show that the observed degradation was caused by enzymatic 
factors present in U937 lysate and not by factors from the rabbit reticulocyte lysate, the
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same assay was performed with U937 extracts heated at ioo°C for 5 minutes. In these 
lysates Gfii was not degraded, indicating that the degradation of G fii is dependent on 
protein activity present in U937 cells. When degradation experiments were performed in 
the presence of the proteasome inhibitors MG132 or Velcade the degradation of G fii was 
almost completely blocked. This showed that the transcriptional repressor G fii is rapidly 
degraded by the 26S proteasome in lysates from hematopoietic cell lines (Figure 3B).
The G fii protein consists of a N-terminal SNAG repressor domain followed by a 
central domain with unknown function and a C-terminal DNA binding domain containing 
6 zinc fingers. Computer based prediction (https://embi.bcc.univie.ac.at/toolbox/ 
pestfind/pestfind-analysis-webtool.htm) identified 2 putative PEST regions in Gfii, 
located in the N-terminal non-zinc finger part at amino acid positions 54-66 and 90-i02 
(Figure 3C). PEST domains are associated with ubiquitin proteasome mediated turnover 
and are found in several short-lived transcription factors 28. To determine the involvement
Figure 3A
Figure 3C
Figure 3B
Figure 3D
MPRSFLVKSKKAHSYHQPRSPGPDYSLRLENVPAPSRADSTSNAGGAKAE 50 
PRDRLS PE SQLTEAPDRASAS PRQLRS SVCERS S E FED FWRPPS PSAS PA 100 
SEKSMCPSLDEAQPFPLPFKPYSWSGLAGSDLRHLVQSYRPCGA1ERGAG 150 
LGLFCEPAPEPGHPAALYGPKRAAGGAGAGAPGNCIAGAGATAGPGLGLY 200 
GDFGSAAAGLYEKPTAAAGLLYPERGHRLHANKGAGVKVE SELLCTRLLL 250 
GGGSYKCIKCSKVFSTPHGLEVHVRRSHSGTRPFACEMCGKTFGHAVSLE 300 
QHKAVHSQERSFDCKICGKSFKRSSTLSTHLLIHSDTRPYPCQYCGKRFH 350 
QKSDMKKHTFIHTGEKLHKCQVCGKAFS QS SNLITH SRKHTGFKPFGCDL 400 
CGKGFQRKVDLRRHRETQHGLK 422
Figure 3. Gfii is degraded by the 26S proteasome in hematopoietic cells.
(A), The DNA binding activity of in vitro translated Gfi1 was checked using EMSA after incubation with 
32P labeled oligos containing a consensus Gfi1 binding site. A clear band shift ( ^ )  was only found in 
the lanes containing 1^l or 3^l of Gfi1 programmed reticulocyte lysate. Unprogrammed reticulocyte 
lysate was used as negative control (NC).
(B), An in vitro degradation assay using 35S labeled in vitro translated Gfi1 incubated with U937 lysates 
at 37°C in the presence of vehicle, or the proteasome inhibitors MG132 or Velcade or denatured cell 
lysate (5 min 100°C). At the indicated time points, samples were inactivated in loading buffer and 
resolved by SDS-page.
(C), The localization of two putative PEST domains in Homo sapiens Gfi1 are underlined.
(D), 35S labeled in vitro translated full length Gfi1, the zinc finger domain of Gfi1 (ZN Gfi1) and the 
non-zinc finger domain of Gfi1 (AZN Gfi1) were used in an in vitro degradation assay as described in
(B).
of the putative PEST domains in Gfii degradation, two independent Gfii constructs 
containing either the zinc fingers (ZN Gfii) or the SNAG and non-zinc finger domain (AZN 
Gfii) were used in the degradation assay. This showed that the zinc finger part of Gfii is 
degraded at a similar rate as the full-length protein, while the non-zinc finger part of Gfii 
was not affected by the ubiquitin-proteasome system (Figure 3D). This suggests that the 
proteasomal degradation of Gfii takes place at the zinc finger domain of G fii and is inde­
pendent of the putative PEST domains.
Gfi1 degradation is diminished upon monocytic differentiation of U937 cells
To examine whether the induction of G fii protein levels during myeloid differ­
entiation could be explained by a difference in Gfii turnover, the degradation of Gfii 
was examined with the in vitro degradation assay using lysates from 0, 24 and 72 hours 
PMA stimulated U937 cells. As is shown in Figure 4A, the turnover rate of Gfii was clearly 
diminished after induction of monocytic differentiation of U937 cells with PMA. This indi­
cates that the degradation of Gfii depends on the differentiation status of the hemato­
poietic cell. To investigate whether the observed increase in half-life of Gfii was generally 
seen during differentiation and not a differentiation independent effect of PMA, U937 
cells were also differentiated towards the monocytic lineage with ATRA. Lysates from 
U937 cells induced with ATRA showed a similar prolonged half-life of Gfii, comparable 
with PMA stimulated cells (data not shown).
The observed stabilization upon differentiation was further studied by analyzing 
the proteasomal turnover of endogenous Gfii protein levels in U937 cells. Gfii protein 
levels could only be detected upon proteasome inhibition of immature U937 cells. This 
indicates that G fii is degraded in a proteasome-dependent manner (Figure 4B). The same 
result was observed in immature HL60 cells (Figure 4C). However, in U937 cells treated 
for 72 hours with PMA, G fii levels were not significantly induced after MGi32 treatment, 
while an a-ubiquitin staining showed that the 26S proteasome was successfully inhibited. 
This indicates that in differentiated U937 cells endogenous Gfii is no longer subject to effi­
cient proteasomal degradation. Subsequently, the half-life of endogenous Gfii protein 
was determined in undifferentiated and 48 hours PMA treated U937 cells using the 
protein translation inhibitor cycloheximide. In immature U937 cells Gfii has a half-life 
shorter than i  hour, while in differentiated cells the half-life is more than 4 hours (after 
4 hours 80% of the original amount of Gfii was still present, (Figure 4D). Together these 
data confirm the result obtained with the in vitro degradation assays and also explain the
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Figure 4. Proteasomal Gfil degradation is diminished during differentiation.
(A), U937 cells were differentiated with PMA and collected at the indicated time points. Cell lysates were 
normalized using Bradford protein quantification assay and used in an in vitro degradation assay with 
35S labeled in vitro translated full length Gfi1.
(B), Differentiated and undifferentiated U937 cells were overnight treated with MG132. Endogenous 
Gfi1, ubiquitin and lamin levels were quantified by Western blot. Note the clear increase in Gfi1 levels in 
undifferentiated U937 cells after proteasome inhibition. Lamin staining was used as a control for equal 
loading, ubiquitin staining was used as a control for proteasome inhibition.
(C), Also in undifferentiated HL60 cells proteasome inhibition results in an accumulation of Gfi1 protein 
levels. The same controls were used as in figure 4 B.
(D), The stability of endogenous Gfi1 was studied in undiffentiated and 48 hours of PMA treated U937 
cells. Cells were treated with 25 |jg/ml cycloheximide for the indicated times. Lamin staining was used 
to check for equal loading and the density of Gfi1 bands was quantified using ImageJ software. The 
relative protein amount was plotted against the time of cycloheximide treatment. Triangles indicate the 
relative amount of Gfi1 in untreated cells and squares indicate the relative amount of Gfi1 in 48 hours 
PMA differentiated cells.
(E), 26S proteasome function in lysates from differentiated U937 cells was analyzed by measuring the 
cleavage of Suc-Leu-Leu-Val-Tyr-AMC in the lysate for 2 hours at 37°C.
(F), U937 cell lysates were immunoblotted and stained for ubiquitin. Cell lysates treated over night with 
MG132 were used as a positive control for decreased proteasome activity. Equal loading was confirmed 
with actin staining.
(G), In vitro translated wild type Gfi1 (WT), and the Gfi1 point mutants A382S and K403R were used in 
an in vitro degradation assay with 72 hours ATRA treated and untreated U937 cell lysates for indicated 
time points. Cell lysates were normalized using Biorad protein quantification assay.
observed upregulation of Gfii protein levels during differentiation, in spite of decreasing 
mRNA levels. We conclude that G fii is rapidly degraded by the proteasome in immature 
myeloid cells, whereas in mature monocytic cells Gfii degradation is diminished.
The decreased turnover of Gfii might be due to decreased overall proteasomal 
activity during myeloid differentiation. To investigate this, we measured the chymo­
trypsin activity of the 26S proteasome in U937 cell lysates by measuring the cleavage of 
the 26S proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC. The proteasomal activity did 
not decrease but rather slightly increased during differentiation (Figure 4E). These results 
were confirmed by ubiquitin staining of whole cell lysates of PMA-differentiated U937 
cells. No significant differences in the total amount of high molecular mass ubiquitinated 
proteins could be detected between differentiated and undifferentiated cells, while prote­
asome inhibition of these cells resulted in a clear accumulation of ubiquitinated proteins 
(Figure 4F). Together, these observations show that the difference in G fii turnover during 
differentiation is not due to overall differences in proteasomal activity, indicating that Gfii 
is specifically targeted by the ubiquitin-proteasome system.
Two Gfii missense mutations have recently been identified in patients suffering 
from neutropenia 7. The two mutations, N382S and K403R, occur in the zinc fingers of 
Gfii, the region that is targeted for degradation. The K403R mutation results in the loss of 
a lysine in the zinc finger region. Since lysine residues are the primary targets for ubiquitin
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Figure 5. Gfil protein levels are high in monocytes compared to granulocytes due to decreased 
proteasomal degradation.
(A), HL60 cells were differentiated with ATRA towards granulocytes for 72 hours. PMA was used to stim­
ulate HL60 cells for monocytic differentiation. Cell lysates were used in an in vitro degradation assay.
(B), Lysates of primary monocytes and granulocytes were used in an in vitro degradation assay with 35S 
labeled Gfi1.
(C), The Gfi1 turnover in granulocyte lysate in an in vitro degradation assay was depended on 26S 
proteasome activity.
(D), Quantitative Gfi1 RT-PCR was performed on RNA from primary monocytes and granulocytes (n=3).
(E), Cell lysates of isolated monocytes and granulocytes were immunoblotted and stained with a-Gfi1 
antibody and a-actin staining was used to check for equal loading. a-C/EBPa and a-C/EBPs protein 
levels were stained as positive control for the used protein lysates. Cell lysates were normalized using 
BioRad protein quantification assay.
modification, especially the lysine mutation might affect the protein half-life. Therefore, 
the turnover of the two mutated Gfii proteins were compared with the wild type protein 
in an in vitro degradation assay. No clear differences in the degradation of normal and 
mutated G fii in both undifferentiated and ATRA differentiated U937 cells was observed. 
This suggests that these mutations have no effect on the proteasomal degradation of Gfii 
(Figure 4G).
Gfi1 is stable in mature primary monocytes and rapidly degraded in granulocytes
To study the differences in Gfii stability during monocytic and granulocytic 
differentiation, lysates from bipotential HL60 cells differentiated towards monocytes 
with PMA and towards granulocytes with ATRA were compared. G fii was stabilized 
during both monocytic as well as granulocytic differentiation. However, the increase 
in stability of G fii during granulocytic differentiation is significantly less compared to 
monocytic differentiation (Figure 5A). This explains the higher amount of G fii protein 
levels after monocytic differentiation compared to granulocytic differentiation in these 
cells (Figure iC). These data also suggest that the observed diminished G fii degradation 
is playing a more important role during monocytic differentiation than during granulo­
cytic differentiation. We tested whether this difference in Gfii turnover was also present 
in primary monocytes compared to granulocytes. To this end, cell lysates of monocytes 
and granulocytes were used in an in vitro Gfii degradation assay. G fii was more stable in 
lysates from CDi4+ sorted monocytes compared to granulocytes (Figure 5B). G fii degra­
dation in lysates from primary granulocytes could be inhibited by the addition of Velcade 
indicating that the observed degradation of Gfii was due to 26S proteasomal activity 
(Figure 5C). In accordance with earlier studies 6;i0;i5;i7 we found a 6o-fold higher Gfii mRNA 
expression in granulocytes compared to monocytes (Figure 5D). Strikingly, at the protein 
level we could detect Gfii only in lysates from monocytes and not from granulocytes 
(Figure 5E). As control, the same lysates were stained for C/EBPa and C/EBPs indicating 
that other nuclear transcription factors could be correctly detected in granulocytes. We 
conclude that due to diminished proteasomal degradation, Gfii protein levels are high in 
primary monocytes despite low mRNA levels.
Gfi1 may repress specific target genes in mature monocytes
Gfii is known to repress its own promoter 9;i0;i6 and is present on the promoter 
of several granulocyte-specific genes 8. To study whether Gfii binds to the promoter of
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Figure 6. Gfil is present on Gfil target genes in monocytes.
(A), ChIP analysis on sonicated chromatin of primary monocytes was performed using a a-Gfi1 
antibody or a goat IgG antibody as control (n=2). Quantitative PCR was used to measure the amount 
of immunoprecipitated promoter, which was compared to the control genomic sequence of Albumin. The 
percentage of recovery of the ChlP-ed promoters was plotted as the fold increase over the percentage 
of recovery of Albumin.
(B) The mRNA levels of Gfi1 regulated genes were measured using quantitative RT-PCR on mRNA from 
monocytes (n=5) and granulocytes (n=6 ).
(C), ELA2 and C/EBPa quantitative RT-PCR was performed on RNA samples of HL60 cells during PMA 
or ATRA induced differentiation (n=2). ELA2 and C/EBPa expression levels in untreated HL60 and U937 
cells were set at 1 0 0 % and values were normalized for p-actin expression.
(D), ELA2, C/EBPa and Gfi1 mRNA expression was measured using quantitative RT-PCR and were 
normalized for 18S rRNA expression. The levels in untreated cells (-MG132) were set at 100% and 
compared with MG132 treated HL60 cells.
known G fii target genes we performed chromatin immunoprecipitation (ChIP) exper­
iments using primary monocytes. Of the analyzed genes GFI1, ELA2 and C/EBPa, all 
promoters could be immunoprecipitated with the a-Gfii antibody (Figure 6A). In line 
with this, the mRNA expression of these genes was lower in monocytes compared with 
granulocytes (Figures 5D and 6B). Together these data indicate that G fii is present on 
the promoters of granulocyte-specific genes in monocytes, suggesting that Gfii might 
function to repress the granulocytic phenotype in these cells. This hypothesis is in line 
with the observation that during monocytic (PMA) differentiation of HL60 cells the 
expression of the Gfii target genes ELA2 and C/EBPa are lower when compared with 
granulocytic (ATRA) differentiation (Figure 6C). This is also the case for G fii itself (Figure 
1A). Also when G fii protein levels increase after proteasome inhibition of HL60 cells, the 
mRNA expression of ELA2, C/EBPa and Gfii are decreased (Figure 6D). The inverse corre­
lation between Gfii protein levels and the expression of its target genes might imply an 
important role for the here observed proteasomal regulation mechanism of Gfii during 
monocytic differentiation.
Discussion
Transcription factors play a crucial role during hematopoiesis by regulating 
specific differentiation programs. G fii knock out studies have shown that Gfii plays 
important roles during different stages of hematopoiesis. G fii null mice show a block 
in myeloid cell differentiation and lack neutrophils, indicating that Gfii is essential for 
neutrophilic differentiation 5;6. Recent studies also showed abnormal monocyte-derived
DCs and macrophages in Gfii null mice, implying a role for Gfii in the monocytic lineage
6;i6;i8
We show here that G fii protein levels are mainly regulated by the ubiquitin 
proteasome pathway during monocytic differentiation. The proteasomal degradation 
of G fii is diminished upon monocytic differentiation of U937 and HL60 cells, resulting 
in an accumulation of protein levels (Figures i  and 4). The dimished proteasomal degra­
dation during monocytic differentiation is not caused by a decrease in general protea­
somal activity (Figures 4C and D). This strongly suggests that a specific mechanism exists 
that regulates G fii protein turn-over. The stability of proteins targeted for 26S protea­
somal degradation can be regulated at different levels, for example by de-ubiquitination 
enzymes or by other post-translational modifications with e.g. SUMO 29. Alternatively, 
alterations in E3 ubiquitin ligase activity may cause G fii stabilization during monocytic
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differentiation. Which E3 ubiquitin ligase(s) specifically mark Gfii for proteasomal degra­
dation is unknown. It was recently shown that Ataxin-1 expression correlates with an 
increase in proteasomal degradation of Gfii 30. While Ataxin-1 has no known E3 ligase 
activity by itself, it may be part of a multi-protein complex containing ubiquitin ligase 
activity.
We show that the zinc finger domain of Gfii is specifically targeted for protea­
somal degradation (Figure 3D). The G fii paralog GfiiB, is an essential transcription factor 
for erythroid and megakarocyte differentiation 31;32. Especially the zinc finger containing 
DNA-binding region of GfiiB is very homologous to Gfii (97%). Therefore, it may be spec­
ulated that GfiiB is also subject to proteasomal degradation and it would be interesting to 
study whether GfiiB protein levels are regulated in a similar way during erythroid/mega- 
karyocytic differentiation.
Gfii null mice exhibit a block in neutrophilic differentiation, resulting in the accu­
mulation of an immature myelo-monocytic population featuring both monocytic as well 
as granulocytic characteristics. The observed differentiation block results in the absence 
of mature neutrophils and takes place just after the promyelocyte stage, demonstrating 
that Gfii is essential during the first steps of GMP differentiation towards the promy­
elocyte stage. Whether Gfii is required after this stage of differentiation is currently not 
known. In primary monocytes Gfii is more stable compared to primary granulocytes, in 
which G fii is swiftly degraded by the 26S proteasome. This results in higher G fii protein 
levels in monocytes compared to granulocytes, despite 6o-fold higher mRNA levels in 
granulocytes (Figure 5). Whether the observed rapid degradation of G fii in mature granu­
locytes is essential for terminal granulocytic function remains to be elucidated. A possible 
role for the proteasomal down-regulation of Gfii in mature granulocytes may be the 
release of Gfii-dependent repression of granulocyte-specific genes, like C/EBPa, C/EBPs 
and ELA-2.
The presence of Gfii in primary monocytes suggests a role for Gfii in these 
cells. Gfii might serve to repress granulocytic-specific genes thereby inhibiting granu­
locytic traits in monocytes. This is in line with the observation that Gfii target genes (C/ 
EBPa and ELA-2) were expressed at higher levels in granulocytes compared to monocytes 
(Figure 6B). Moreover, ChIP experiments showed that Gfii is present on the promoter of 
these genes in primary monocytes (Figure 6A). The ChIP experiments also showed that 
G fii is present on its own promoter, suggesting that Gfii is capable of regulating its own 
expression in myeloid cells. If so, this could explain the high G fii mRNA levels in granulo­
cytes, due to the lack of repression by Gfii, while in mature monocytes Gfii represses its 
own promoter resulting in low mRNA expression.
The accumulated myelomonocytic population in G fii null mice featuring both 
monocytic as well as granulocytic characteristics was originally assumed to consist of 
arrested differentiating neutrophils. However a partial block during monocytic differenti­
ation could not be dismissed 5;6. This latter explanation was suggested to be unlikely since 
Gfii mRNA was not detected in macrophages and G fii mRNA levels are down regulated 
during monocytic differentiation of HL60 cells 33. As our results show that the G fii protein 
is present in monocytes it will be interesting to readdress this question and study whether 
the mixed myeloid population in G fii null mice also consists of arrested monocytes. As 
Gfii functions in many steps during hematopoiesis but also in the development of the 
intestine 34 and inner ear 35;36, it will be interestingly to test whether the here described 
degradation of Gfii also plays an important regulatory role in these processes.
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Abstract
Growth factor independence 1 (Gfii) is a transcription factor that plays an 
important role in both normal and malignant hematopoiesis. Earlier, we showed that 
G fii protein expression is controlled by the ubiquitin proteasome system during myeloid 
differentiation. By using a combination of in vitro and in vivo degradation assays we show 
here that the C-terminal Zinc finger domain of G fii is required for its degradation. This 
domain, which is not implicated in DNA binding or gene repression, contains a degra­
dation signal which is not transferable to other proteins strongly suggesting that other 
domains in Gfii are also essential for degradation. These results provide new under­
standing in the regulation of Gfi1 protein levels and may provide a target for interfering 
with its protein levels.
Introduction
Hematopoiesis is a tightly regulated process of proliferation and differenti­
ation. The control of proper spatial-temporal expression of the factors which drive this 
process is essential to prevent defective or malignant hematopoiesis. The ubiquitin prote- 
asome system contributes to the maintenance of functional protein levels. Nowadays, 
there are many examples where defective function of the ubiquitin proteasome pathway 
contributes to hematological diseases (reviewed in *).
The transcription factor Growth Factor Independence 1 (Gfii) plays a crucial 
role in many aspects of hematopoiesis. Although originally identified to be involved in 
lymphomagenesis2-4, more recent studies using murine knockout strains showed that Gfii 
is also essential for correct development and function of many other cell types, including 
granulocytes, dendritic cells, B-cells, T-cells and stem cells (reviewed in 5-7). In men, muta­
tions in the Gfii gene are known to cause severe neutropenia8;9. The Gfii protein consists 
of an N-terminal SNAG repressor domain that interacts with co-repressorsi0 and six 
Zinc (Zn) finger domains in the C-terminal region that facilitate DNA binding (Figure
i, ii;i2). Although little is known about the function of the intermediate part separating 
the repressor domain from the Zn fingers, a recent study showed that this region binds 
co-repressor proteins to contribute to transcriptional repression, in addition to the SNAG 
domaini3. Gfii does not only function as transcriptional repressor but may function as 
transcriptional activatori4-ie and may also play a role in RNA splicingi7. We have previously 
shown that G fii protein levels are regulated by the ubiquitin-proteasome routei8. During 
monocytic differentiation, G fii turnover is decreased, resulting in a significant increase in 
protein levels, despite decreasing mRNA levels. Because the degradation plays such an 
important role in regulating G fii protein levels, we studied which domains are responsible 
for the regulation of G fii turnover. Here, we identify the C-terminal Zn finger of G fii to be 
required for the degradation of the protein.
Methods
Plasmids
The plasmid encoding wild type murine Gfii (kindly provided by Dr T. Moroy) was 
used to generate G fii truncation mutants (Figure i,  mutants 2-8) by PCR. Additional Gfii 
mutants in the 6th Zn finger were made by using mutated PCR primers (Figure i,  mutants
i4, is). Individual Zn fingers were cloned using PCR and fused in frame with GFP. A SV40 
nuclear localization signal was introduced at the N-terminus of GFP to ensure nuclear
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Figure 1: Schematic overview of used Gfi1 mutants
Schematic representation of Gfi1 mutants. Gfi1 mutants 4-8 were generated based on murine full length 
Gfi1 using PCR to introduce stop codons and alternative start sites at relevant places. Sequences were 
verified by DNA sequencing and cloned into the pcDNA3.1 vector. Mutants 9-13 were kindly provided by 
Dr H.L. Grimes. Mutants 14 and 15 containing point mutations were generated using PCR. Individual Zn 
finger domains from Gfi1 were cloned in frame with GFP for stability testing (constructs 16-19)
expression (Figure i,  mutants i6 -i9 ). Primer sequences can be found in supplemental 
table i.  All fragments were checked by sequence analysis and cloned into the pcDNA3.i 
expression vector (Invitrogen, Carlsbad, CA, USA). Plasmids encoding the G fii mutants 
lacking single Zinc finger domain (Figure i,  mutants 9-i3) were kindly provided by Dr H. L. 
Grimes.
In vitro degradation assays
Gfii in vitro degradation assays were performed as described previously using 
U937 lysates and in vitro translated 35S labeled G fiii8. After incubation, samples were 
separated by SDS-PAGE and analysed using a Personal Molecular Imager FX, (BioRad, 
Hercules, CA, USA). Signals were quantified using Quantity One imaging software 
(BioRad).
Cell based stability assay
U937, HL60, Hep3b and Cos-i cells were maintained as described previouslyi8;i9. 
HL60 cells were allowed to adhere to retronectin (Takara, Kyoto, Japan) coated plates 
and transfected using Lipofectamine 2000 (invitrogen) according to the manufacturer's 
instructions. For Gfii stability testing, Cos-i and HL60 cells were transfected as indicated. 
40 hours after transfection cells were incubated with i00|ag/ml cycloheximide (CHX, 
Sigma) for the indicated timepoints. GFP expression was quantified using the FC500 flow- 
cytometer (Beckman Coulter, Woerden, The Netherlands). Whole cell lysates were made 
in RIPA (radio-immunoprecipitation assay) buffer supplemented with complete protease 
inhibitor cocktail (Roche, Basel, Switzerland), and separated by SDS-PAGE, followed by 
Western blotting. Blots were probed with antibodies against Gfii (clone 2.5D, Sigma) or 
GFP (Roche).
Ubiquitination assay
Cos-i cells were transfected using Polyethylenimine (PEI, Sigma, St Louis, 
MO, USA) as described20. At 36 hours after transfection, cells were harvested for purifi­
cation of His-tagged proteins. The cell pellet was lysed in buffer A (6 M guanidinium-HCl,
0.i M Na2HPO4, i0  mM imidazole, i0  mM ^-mercaptoethanol, and complete protease 
inhibitor (Roche) and incubated with His-select NTA beads (Sigma) for 4 hours at 4°C. 
The beads were washed 2 times with buffer A, 2 times with a mixture of 4 parts buffer 
A and i  part of buffer B (50 mM Tris [pH 6.8] and 20 mM imidazole) and 2 times with
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buffer B. Bound proteins were eluted with 200 mM imidazole in Laemli buffer. The eluted 
proteins were analyzed by immunoblotting for the presence of Ub-conjugated Gfii using, 
-Ubiquitin (clone 6C1, Sigma), or -Gfii antibodies.
Immune fluorescence
For localization studies, Hep3B cells were grown on coverslips and transfected 
using Polyethylenimine. 48 hours after transfection cells were fixed and embedded in 
Vectashield with DAPI (4',6-diamidino-2-phenylindole, Vector Lab, Burlingame, CA, USA). 
Pictures were obtained using a Leica DMRBE microscope and Leica FW4000 software 
(Leica Microsystems, Rijswijk, the Netherlands).
Transrepression assay
Transrepression assays were performed as described previously19;21. The 
B30x2-Gl4 construct was generated by cloning the B30x2 synthetic promoter from the 
B30X2-CAT (a kind gift from Dr. M. Horwitz ) into pGL4.io (Promega, Madison, WI, USA). 
pGL4.73 (Promega) was used to correct for transfection differences. Both luciferase 
reporter constructs were a kind gift from Dr C. Clevenger.
Results and Discussion
The C-terminal Zn finger is necessary for degradation of Gfi1
In our previous studies we showed that Gfii is rapidly degraded in immature 
myeloid cells. We showed that exogenously added in vitro translated Gfii is degraded very 
efficiently in lysates of immature myeloid cells. This degradation is dependent on prote- 
asome activity as addition of proteasome inhibitors completely blocked degradation 
(supplemental Figure S i and 18). Using this assay we showed earlier that the C-terminal 
half of Gfii, which is comprised of six Zn finger domains, is targeted for degradation. This 
is in sharp contrast to the N-terminal half including the SNAG repressor domain, which is 
very stablei8. Based on these results we hypothesized that the C-terminal part contains a 
domain that is responsible for the degradation of Gfii. To investigate this, we generated 
a variety of Gfii mutants that lack parts of the C-terminus. First, we tested the stability 
of several in vitro translated C-terminal truncation mutants in U937 lysates. As described 
previously, the N-terminal part of Gfii, lacking all of the six Zn finger domains, is very 
stable in this assay. Adding back an increasing part of the C-terminus did not yield a 
less stable protein. Only the addition of all six Zn finger domains could restore the rapid
degradation of Gfii in this assay (Figure 2A). These data indicate that loss of the 6th Zn 
finger results in Gfii stabilization. To study whether this effect is specific for the most 
C-terminal Zn finger domain or whether loss of any part of the Zn finger containing region 
results in stabilization of the protein, we tested the stability of individual G fii Zn finger 
deletion mutants (Figure 2B). The results clearly showed that loss of either one of the first 
five Zn finger domains had no effect on Gfii stability. Again, deletion of the 6th Zn finger 
resulted in a protein that is significantly more resistant to proteasomal degradation. To 
determine the increase in G fii half life we quantified the intensity of the signals. Based 
on the average of three independent experiments we found that the deletion of the 6th 
Zn finger increased the half-life of the protein by 2-fold (supplemental Figure S2). We 
have previously shown that G fii is efficiently ubiquitinated in Cos-i cells2*. To confirm the 
results of our in vitro degradation assays in a cell-based assay, we transfected Cos-i cells 
with G fii or the mutant lacking the 6th Zn finger and treated the cells with cycloheximide 
for the indicated times followed by measurement of G fii protein levels. This showed that 
loss of the 6th Zn finger resulted in stabilization of the G fii protein compared to the wild 
type protein (Figure 2C, left panels). Also in a similar experiment using the myeloid cell 
line HL60, G fii lacking the 6th Zn finger domain is more stable (Figure 2C, right panels). 
As Gfii is a target of ubiquitin mediated proteasomal degradation^, we hypothesized 
that loss of the 6th Zn finger would inhibit Gfii ubiquitination. To test this, we trans­
fected Gfii or Gfii-DZn6 together with His-tagged-ubiquitin. Equal amounts of ubiquiti­
nated proteins were isolated under denaturing conditions and subsequently analyzed on 
Western blot. This showed that the amount of ubiquitinated Gfii-DZn6 was dramatically 
reduced as compared to wild type G fii (Figure 2D). Based on these results we conclude 
that the most C-terminal Zn finger domain of Gfii is required for ubiquitin mediated 
protein degradation.
The 6th Zn finger domain o f Gfi1 is not required for transcriptional repression
The deletion of the 6th Zn finger domain increased the half-life of the G fii protein. 
As the structure of the G fii protein has not yet been elucidated, it is difficult to predict 
what the consequence of loss of this domain would be to the structural integrity of the 
remaining protein. To exclude the possibility that loss of the 6th Zn finger domain renders 
an unfolded and non-functional stable protein we tested whether G fii lacking the 6th Zn 
finger domain can function as a transcriptional repressor. We performed repression assays 
using a Gfii responsive element that controls the expression of a luciferase reporter gene.
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Figure 2: The 6th zinc finger domain is required for proteasomal degradation of Gfi1 A and B, In vitro 
degradation assays using 35S-labeled in vitro-translated Gfi1 mutants incubated with U937 lysates 
at 37°C. At the indicated time points, samples were inactivated in loading buffer and resolved by 
SDS-PAGE. C, Cos-1 and HL60 cells were transfected with mGfil or mGfil - Zn6 . 40 hours after trans­
fection cells were treated with 100^g/ml cycloheximide for the indicated times. Samples were resolved 
by SDS-PAGE and Western blotting and stained for Gfi1. D, Cos-1 cells were transfected as indicated. 
Ubiquitinated proteins were isolated with His-select beads under denaturing conditions (6 M guanidium 
chloride). The high molecular weight smear (upper pannel) represents poly-ubiquitinated forms of Gfi1. 
E, An in vitro degradation assay to test the stability of the putative Gfi1 degron (PD) and double lysine 
mutants.
Expression of wild type G fii resulted in 60% repression (Figure S3). Previous studies have 
shown that Zn finger domains 3, 4 and 5 are responsible for DNA binding11. As expected, 
all mutants that lack either one or more of these Zn finger domains did not repress gene 
transcription. Importantly, the mutant that lacks the most C-terminal Zn finger domain 
repressed transcription equally efficient as wild type Gfii, indicating that this mutant is 
functional.
Involvement of putative destabilizing elements in the 6th Zn finger domain
The domains that regulate ubiquitin-mediated stability of proteins may be 
both a docking site for the enzymes that facilitate ubiquitination but may also contain 
lysine residues that are subject to ubiquitination. To study how the 6th Zn finger domain 
contributes to Gfi1 degradation, we compared this domain to other known degradation 
elements or degrons. We found similarity with a region in the huntingtin (HTT) and 
androgen receptor (AR) proteins which is sufficient to target both proteins for protea- 
somal degradation (Figure S4, 22). To test whether this region regulates Gfii stability we 
mutated this putative degradation signal in G fii in a similar manner to what has been 
described for HTT and AR (mutant mGfii-DPD, Figure 1). Although the introduced muta­
tions of a comparable domain in HTT and AR were shown to be sufficient to stabilize 
these proteins 22, the mutation of this domain in Gfii had no effect on its stability (Figure 
2E, upper panel). The Zn finger domains of Gfii contain 20 lysine residues which all may 
be subject to ubiquitination. Sequence alignment revealed that the 6th Zn finger domain 
contains two lysine residues that are not conserved as compared to the other Zn finger 
domains (Figure S5). We hypothesized that these lysine residues might be subject 
to ubiquitination and thereby play a crucial role in destabilizing Gfii. To test this, we 
mutated both lysines into arginine residues and tested the stability of these mutants in 
our in vitro degradation assay (Figure 2E, lower panel). The results indicate that the two 
lysine residues in the 6th Zn finger region do not influence the stability of the protein as 
the mutated protein was still rapidly degraded when incubated in lysates from U937 cells.
Degradation signals or degrons are defined as the minimal part within a protein 
that is sufficient for recognition and degradation23. Usually degrons are transferrable to 
other proteins. To test whether the 6th Zn finger domain of G fii contains a degron, we 
cloned the individual Zn finger domains in frame with the C-terminus of the GFP protein 
and tested whether addition of this domain decreases the stability of the GFP fusion. A 
SV40 nuclear localization signal was introduced to ensure nuclear expression24 (Figure
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S6A). In the in vitro assays (data not shown) nor in transfected HL60 cells (supplemental 
Figure S6B and C) we could detect any increase in GFP turnover.
Altogether, our results show that the most C-terminal Zn finger domain provides 
a context dependent degradation signal. Because coupling of the 6th Zn finger to GFP 
does not render GFP unstable, these data suggest that this domain provides an inter­
action site for an ubiquitin ligase but by itself is not sufficient for degradation. Also 
the mutation of the two lysine residues within the 6th Zn finger domain that discrim­
inate this domain from the other Zn fingers does not result in a more stable protein 
(Figure 2E). Because deletion of any other single Zn finger domain does not stabilize 
the protein either, we expect that other lysine residues distributed over more than one 
Zn finger domain are subject to ubiquitination, a phenomenon that is not uncommon25. 
An earlier report described that Gfii protein levels are negatively regulated by Ataxin- 
126. It is unclear whether this degradation is ubiquitin mediated. Furthermore, Ataxin-i 
was shown to interact with the N-terminal part of Gfii, which is very stable in our exper­
iments. The Zn finger domain of G fii that lacks the Ataxin-i interacting domain on 
the other hand is rapidly degraded in our assays. It is therefore unlikely that Ataxin-i is 
involved in the ubiquitin mediated degradation process that we have reported here. For 
further understanding on how Gfii degradation is regulated, it will be crucial to identify its 
ubiquitin ligase. A better understanding of the processes of protein degradation of crucial 
transcription factors such as G fii may shed light on how the delicate balance of factors 
that regulate hematopoietic fate decisions is maintained.
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Abstract
Growth factor independence i  (Gfii) is a transcriptional repressor essential 
for the function and development of many different hematopoietic lineages. The Gfii 
protein expression is regulated by the ubiquitin-proteasome system. In granulocytes 
G fii is rapidly degraded by the proteasome, while it is more stable in monocytes. How 
the ubiquitination and degradation of G fii is regulated is unclear. Here we show that the 
ubiquitin ligase Triadi interacts with the DNA binding domain of Gfii. Unexpectedly, we 
found that Triadi inhibited G fii ubiquitination resulting in a prolonged half-life. Downreg- 
ulation of endogenous Triadi by siRNAs resulted in increased G fii ubi-quitination. In U937 
cells, Triadi caused an increase in endogenous G fii protein levels and slowed cell prolif­
eration in a similar manner when G fii itself was expressed. A Triadi mutant that lacks the 
Gfii binding domain did not affect Gfii levels and prolife-ration. Because neither prote- 
asome- nor Triadi ubiquitin ligase activity was required for the inhibition of G fii ubiqui­
tination, these data suggest that Triadi competes for G fii binding with as yet to be iden­
tified E3 ubiquitin ligases that do mark Gfii for proteasomal degradation. The fine-tuning 
of G fii protein levels regulated by Triadi defines an unexpected role for this protein in 
hematopoiesis.
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Introduction
Hematopoiesis is characterized by the continuous generation of mature, func­
tional blood cells from a pool of stem cells that reside in the bone marrow. To date, 
several transcription factors have been identified to play an essential role in hema­
topoiesis like PU.i1;2, C/EBPa3 and C/EBPe4. The transcriptional repressor Gfii is also 
essential for proper hematopoiesis. G fii was originally identified as a proviral insertion 
site resulting in IL2 independent growth of T-cells5. The mammalian Gfi1 gene encodes a 
55-kDa nuclear protein that contains six C-terminal C2-H2 zinc finger domains important 
for DNA binding and a characteristic N-terminal 20-amino acid SNAG-domain essential 
for transcriptional repression. Overexpressed Gfii acts as a dominant oncogene and coop­
erates with known oncoproteins like Myc and Pim -i in lymphoma development*^7. In 
normal hematopoiesis, Gfii is essential for B- and T-cell development and regulates the 
self-renewal and long term reconstituting potential of hematopoietic stem cells8;9;i0. Gfii 
was also shown to be important for lymphocyte-derived dendritic cell development“ . 
Furthermore, Gfii plays an essential role during granulocytic differentiation. Gfii-/- 
knockout mice are severely neutropenic due to a block in myeloid differentiation, which 
results in the accumulation of an atypical immature myeloid cell population12;13. Recently 
also other essential G fii functions outside the hematopoietic system were identified, like 
in the inner ear14;15 and in intestinal secretory lineage differentiationi6.
As has been shown for other key regulators of hematopoietic differentiation like 
AMLi 17, C/EBPai8 and RARai9, it was recently shown that Gfii protein levels are controlled 
by the ubiquitin proteasome system (UPS)20;21. This system catalyzes the conjugation of 
ubiquitin to substrate molecules in a multi-enzyme process. First, the E i enzyme acti­
vates free ubiquitin, a small peptide of 76 amino acids. The activated ubiquitin is subse­
quently transferred to an E2 ubiquitin-conjugating enzyme. In concert with the E2 
enzyme, E3 ubiquitin ligases catalyze the covalent conjugation of ubiquitin to specific 
substrate proteins22;23. Depending on the type of ubiquitin chain conjugated to the 
substrate, ubiquitination can regulate the activity or stability of substrate proteins24. A 
crucial role of ubiquitin E3 ligases is the specific recognition of substrate proteins, which 
should be marked with ubiquitin. Therefore, the specificity of the UPS is mainly deter­
mined by the activity of E3 ubiquitin ligases.
Gfii protein levels are regulated by the UPS during myeloid differentiation20. The 
G fii protein is relatively stable in primary monocytes, while in mature granulocytes it is 
efficiently degraded by the 26S proteasome. This results in low G fii protein levels in gran­
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ulocytes, while mRNA levels are high. However, in primary monocytes Gfii protein levels 
are much higher while mRNA levels are significantly lower compared to granulocytes20. 
Recent work showed that Gfii protein levels are also controlled by the UPS in neuronal 
cells. In these studies it was shown that Ataxin-i (Atx-i) interacts with Gfii resulting in 
enhanced degradation via the 26S proteasome. Mutations of Atx-i in spinocerebellar 
ataxia type 1 result in decreased Gfii levels in neuronal cells, which is implicated in the 
onset of this neurodegenerative disease21. However, no E3 ligase activity of Atx-i has 
been described. While G fii protein levels are regulated by the UPS in different cellular 
processes, the proteins involved are unknown. In this report we show that Gfii interacts 
with the ubiquitin E3 ligase Triadi and that Triadi controls Gfii protein levels.
Materials and Methods
Yeast tw o hybrid screening
The pretransformed matchmaker two-hybrid system (Clontech) was used for 
yeast two hybrid analyses. Sequences encoding amino acids 109-493 of Triadi were 
cloned in pGBD as described25 and the plasmid was transformed to yeast strain AH109. 
AH109 yeast cells were used to mate with the Y187 yeast strain that was pre-transformed 
with a human bone marrow cDNA library in pACT2 (Clontech). Mating and yeast-two- 
hybrid screening was performed according to the manufacturer's instruction. Putative 
interactions in yeast were defined by growth of blue colonies within 12 days after plating 
the cells on leucine, tryptophane, adenine and histidine deficient SD medium, containing 
X-a-gal. Plasmids were isolated from positive yeast colonies using the plasmid mini kit 
(Qiagen), with an additional pre-incubation step with lysozyme. Isolated plasmid DNA 
was tested in rescreens to confirm the specificity of the interaction. The GfiiB clone 
isolated from the yeast two-hybrid screen was cloned in the pGBD vector to perform the 
reciprocal yeast-two-hybrid test with Triadi in pGAD. For the fine mapping of protein 
interacting domains a panel of Triadi deletion constructs was generated lacking either 
the entire TRIAD domain, the N- or C-terminal RING finger domains or the DRIL domain 
using primers indicated in supplementary Table 1 in sexual PCR as described26. Triadi 
lacking the two C-terminal coiled coil domains was generated by PCR using a primer 
introducing a stop codon (see supplementary Tablei for primer sequences). The Triadi 
deletion mutants were subsequently cloned in pGAD and the integrity of all constructs 
was confirmed by sequence analysis.
Constructs, cell culture and retroviral transduction
Triadi and Gfii constructs were described earlier20;25. For in vitro protein trans­
lation GfiiB-Flag, GfiiBDzinc finger-Flag and GfiiB-6 zinc finger-Flag kindly provided by 
Dr. M. Osawa were used27. Flag-Gfii and Gfii-GFP were kindly provided by Dr. T. Moroy. 
The retroviral Gfii-IRES-GFP construct was kindly provided by Dr. R. Dahl28. Full length 
Triadi and the mutant lacking the C-terminal RING finger (TriadidR2) were cloned into 
the pLZRS-IRES-DNGFR retroviral expression vector29. The IRES (internal ribosomal entry 
site) allows for separate expression of Triadi or its mutant and a truncated version of the 
nerve growth factor receptor (DNGFR) that lacks intracellular domains. The generation of 
retroviruses and retroviral transduction was performed as described2529. The percentage 
of GFP and DNGFR positive cells after transduction was monitored by FACS analysis 
(FC500, Beckman Coulter). NGFR positive cells were sorted using magnetic activated cell 
sorting (MACS) as described29. COS-i cells were cultured in Iscove's Modified Dulbecco's 
Medium (IMDM) (Life Technologies, Gaithersburg, MD) supplemented with 10% fetal 
calf serum (FCS), penicillin (50 I.U./ml) and streptomycin (50 ug/ml) (Life Technologies). 
HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Life Technol­
ogies) supplemented similar as described for IMDM with the addition of 2mM glutamine. 
Where indicated, cells were treated with 50-i00|mg/ml cycloheximide (Sigma) for the indi­
cated time. U937 cells were cultured in RPMI supplemented with 10% FCS and pen/strep. 
Sf-9 and Hi-5 insect cells were grown at 27°C in a completely humidified atmosphere in 
TNM-FH medium (Sigma) supplemented as indicated for IMDM. For Sf-9 cells, 0.5% 
Bovine serum albumine was added. Hi-5 cells were grown to 75% confluency and infected 
with baculovirus.
In vitro pull down assays
His-tagged Triadi was isolated from 4-5 days infected Hi-5 cells, which were 
lysed in RIPA buffer (PBS containing i%  Nonidet P-40 (NP-40), 0.5% natrium-deoxy- 
cholaat, 0.1% SDS and complete protease inhibitor cocktail (Roche Diagnostics, Basel, 
Switzerland)) followed by 2 hours incubation at 4°C with pre-washed His-select beads 
(Sigma) in the presence of 5 mM imidazole (Sigma). Beads were washed 4 times with 
RIPA buffer supplemented with 10 mM imidazole. His-Triadi loaded beads were incu­
bated with 10 ml in vitro translated, 35S methionine labeled proteins for 16 hours at 
4°C. The labeled proteins were produced using the rabbit reticulocyte lysate TnT Quick 
Coupled Transcription/Translation System (Promega). After four wash steps with RIPA
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in the presence of 10 mM imidazole. Proteins were eluted by the addition of 2 x laem- 
nibuffer and heating of the samples for 5 min at 95°C. Samples were resolved by 
SDS-PAGE, gels were fixed, treated with NAMP-100 (Amersham), dried and exposed.
Co-immunoprecipitation and Western blotting
COS-i cells cultured in 10-cm dishes were transiently transfected as indicated 
using the calcium phosphate precipitation method. Cells were lysed 36 hours after trans­
fection in RIPA buffer with complete protease inhibitors (Roche). GFP tagged proteins 
were incubated with GFP-antibody (Roche, clones 7.1 and 13.1) and Prot-A beads for 4 
hours at 4°C with gentle rotation. Beads were washed 5 times with RIPA. Bound proteins 
were eluted in loading buffer by heating for 5 min at 95°C. Immunoprecipitates and 
protein lysates were separated on SDS-polyacrylamide gels, electrophoretically trans­
ferred onto polyvinylidenefluoride (PVDF) membranes (Bio-Rad, Hercules, CA) and 
blocked with 2% ELK (Campina) and 0.5% BSA (Sigma). Blots were probed with anti­
bodies to G fii (N20, Santa Cruz biotechnology), Flag (M2, Sigma), Actin (AC40, Sigma), 
Ubiquitin (6Ci, Sigma), His-tag (penta-his, Qiagen), Triadi25 or GFP (clones 7.1 and 13.1, 
Roche, used in all experiments except where indicated another GFP antibody was used 
(sc-8334, Santa Cruz biotechnology)).
Transfection and in vivo ubiquitination assays
COS-i cells grown in 10-cm dishes were transfected with 10 |ag of His-Ub and 
10 |ag of human Gfii-GFP or Flag-Gfii expression constructs, using calcium phosphate 
precipitation. For ubiquitination assays in which siRNAs were used, HEK293 cells were 
cotransfected with the indicated siRNAs with or without His-Ub and with or without GFP 
constructs using lipofectamine 2000 (Invitrogen). Where indicated, cells were sorted 
based on GFP positivity by FACS (Epics Altra, Beckman Coulter). The following siRNAs 
were used. Triadi siRNAi: uugugaggaagaggaagaa, Triadi siRNA2: aauugugaggaagag- 
gaagaa, siRNA GFP: gcaagcugacccugaaguucau, a control siRNA: aggaguugguggcaauaau 
(designed against Spi) and a control scrambled siRNA: aauugugaggaagaggaagaa (Allstar 
control, Qiagen). Where indicated, proteasome activity was inhibited by the addition of 
MG132 16 hours prior to harvesting cells. 36 hours after transfection cells were harvested 
for purification of His-tagged proteins. The cell pellet was lysed in buffer A (6 M guani- 
dinium-HCl, 0.1 M Na2HPO4, 10 mM imidazole, 10 mM ^-mercaptoethanol, complete 
protease inhibitor (Roche)) and incubated with His-select NTA beads (Sigma) for 4 h
at 4°C. The beads were washed 2 times with buffer A, 2 times with a mixture of 4 parts 
buffer A, and 1 part of buffer B (50mM Tris pH 6.8, 20 mM imidazole) and 2 times with 
buffer B. Bound proteins were eluted with 200 mM imidazole in laemlibuffer. The eluted 
proteins were analyzed by immunoblotting for the presence of Ub-conjugated G fii using 
a- Flag, a-His or a-G fii antibodies. For measurements of Gfii stability by flowcytometry, 
HEK293 cells were transfected with Gfii-GFP and Triadi as indicated and GFP intensities 
were measured 24-30 hrs after transfection.
Results
Triadi interacts w ith  the zinc fingers of Gfii and G filB
Triadi, is an E3 ubiquitin ligase implicated in myelopoiesis25. To identify Triadi 
binding partners we searched for interacting proteins by screening a human bone marrow 
cDNA library in a yeast-two-hybrid assay using amino acids 109-493 of Triadi as bait. This 
part of Triadi comprises the TRIAD domain and the two coiled coils regions25. Candidate 
Triadi interacting proteins were identified by screening 5.8*10® transformants on SD 
medium without adenine and histidine in the presence of X-a-gal. From blue stained
Figure 1A
Empty
vector
Triad1
Figure 1B
ACC1+2
ARING2
Empty
vector Triad1
ATRIAD
ARING1
ADRIL
AD: Gfi1B 
BD: Triad1
AD: Triad1 
BD: Gfi1B
Figure 1, G filB binds Triadi in yeast-two-hybrid assays
A. Yeast-two-hybrid screen with the G filB  clone that interacts with Triadi (aa 109-493) and not with the 
empty vector control on double histidine and adenine selection medium containing X-a-gal.
B. G filB  was cloned into pGBD and tested for interaction in the reciprocal experiment with full length 
Triadi or deletion constructs in pGAD. The C-terminal RING finger (RING2) of Triadi was the smallest 
essential domain for G filB  interaction. Used Triadi mutants either lack the entire TRIAD domain 
(ATRIAD), the N- or C-terminal RING finger (respectively, ARING1 and ARING2), the DRIL domain 
(ADRIL) or both C-terminal coiled coil regions (ACC1+2).
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yeast colonies, pACT plasmid DNA was isolated and sequenced. One of the positive inter­
acting proteins was identified as Growth factor indepence iB  (GfiiB)30. The interacting 
clone spanned amino acids 91 to 330, containing 6 C2H2 zinc fingers of the DNA binding 
domain. GfiiB interacted specifically with Triadi and not with the empty vector (Figure 
1A). The interaction was validated by the reciprocal experiment using GfiiB cloned in the 
pGBD bait vector and Triadi in the pGAD prey vector (Figure iB). To pinpoint the inter­
acting domains we tested the interaction of GfiiB with various Triadi deletion constructs. 
Deletion of the N-terminal RING, DRIL/IBR domain or both coiled-coils of Triadi did not 
influence the interaction. In contrast, deletion of the C-terminal RING finger abolished the 
observed interaction with GfiiB, indicating that this domain ofTriadi is essential for the 
GfiiB interaction (Figure iB).
To confirm the Triadi GfiiB interaction with alternative methods, full-length His­
t a gged Triadi was expressed in Hi-5 insect cells and purified with His-select beads (Fig ure 
2A). Western blot analysis indicated that the purified band represented His-Triadi (data
Figure 2A
infected Hi-5 - +
SDS-page commassie 
brilliant blue
Figure 2B
35S in vitro translated
—__________
10% Empty Triad1 
input beads beads
Figure 2C
Full length Gfi1B 
Azinc finger Gfi1B 
6 zinc finger Gfi1B
GFP-Triad1
GFP
Flag-Gfi1B
Figure 2, GfiiB interactswith Triadi
A. His-Triad1 was isolated from baculovirus infected Hi-5 cells using His-Select beads. Proteins bound 
to beads were detected with SDS-page followed by coomassie staining. A clear His-Triad1 band 
is visible, while no proteins can be detected when beads were incubated with uninfected Hi-5 cells.
B. In vitro translated and 35S labeled G fiiB  was incubated with empty beads or His-Triad1 loaded 
114 beads. Full length G fiiB  and the 6 zinc-finger domain interacted with Triadi, but not the Azinc finger
domain. C. GFP-Triadi or GFP was cotransfected with Flag-GfilB in COS cells. a-GFP immunopre- 
cipitated proteins (a-GFP clones 7.1 and 13.1, Roche) were immunoblotted and stained with a different 
a-GFP antibody (sc-8334, Santa Cruz biotechnology) to check the immunopreciptiation. a-Flag staining 
showed that Gfi1B interacts with GFP-Triad1 but not with GFP alone. Whole cell extract (wce) was 
blotted with a-Flag antibody to show equal Gfi1B expression.
not shown). The His-Triadi beads were incubated in RIPA buffer with 35S labeled in vitro 
translated GfiiB. As depicted in Figure 2B, GfiiB interacted with Triadi but not with the 
control beads. In vitro translated fragments of GfiiB were used to detect the part of GfiiB 
responsible for interaction with Triadi. As expected, the GfiiB zinc finger part interacted 
with Triadi while the GfiiB fragment containing the SNAG and non zinc finger domain did 
not (Figure 2B). The interaction was further verified by co-expressing GFP or GFP-tagged 
Triadi with N-terminally Flag-tagged GfiiB in COS cells followed by GFP immunoprecip- 
itation. The subsequent Flag staining (Figure 2C) showed that GfiiB interacts with GFP- 
Triadi and did not interact with GFP alone. Together, these d ata indicate that the zinc 
finger domain of GfiiB interacts with the C-terminal RIN G finger of Triadi.
GfiiB is a transcriptional repressor essential for proper erythroid and megakaryo- 
cytic differentiation and plays a role in T-cell activation3i;32. The Triadi interacting zinc 
finger domain of GfiiB is 97% identical to the DNA binding domain of the GfiiB homo­
logue Gfii (Figure 3A)33. To test whether Gfii also interacts with Triadi we performed in 
vitro pull down experiments. This showed that 35S in vitro translated Gfii also interacted 
with purified Triadi on His-select beads via its zinc finger domain (Figure 3B). This inter-
Figure 3A
Azinc finger 6zinc finger
I I I I I I !  Gfi1: 422 aa 
I I I I I T~| GfiiB: 330 aa 
----------------  Y2H clone
I  = zinc finger 
I  = repressor domain
Figure 3B 55S in vitro translated Figure 3C
wce
Full length Gfii
»mm Azinc finger Gfii —
6 zinc finger Gfii
IP a-GFP WB a-Flag
IP a-GFP WB a-GFP
10% Empty 
input beads
Triadi
beads»
GFP-Triad1 -
GFP + 
Flag-Gfi1 +
Figure 3, Gfii interactswith Triadi
A. Schematic representation of Gfii and GfiiB. The Triadi interacting part of G fiiB  found in yeast two 
hybrid (indicated with the solid line Y2H), contains the 6 zinc-fingers that are 97% identical to G fii.
B. Like G fiiB  also full length and the 6 zinc finger domain of Gfii interacts with His-Triadi. No inter­
action was detected with the Azine finggr domain of G fii. C. GFP-Triadi or GFP was cotransfected 
with Flag-Gfii in COS cells. a-Flag staining of whole cell extract (wce) showed equal expression of G fii. 
a-Flag staining of the a-GFP immunoprecipitates showed that Gfii interacts with Triadi but not with 
GFP alone. a-GFP staining (a-GFP sc-8334, Santa cruz) of the immunoprecipitated proteins showed 
successful immunoprecipitation.
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action was verified by co-immunoprecipitating N-terminally Flag-tagged Gfii with GFP or 
GFP-Triadi in transfected COS cell lysates. Gfii co-immunoprecipitated with GFP-Triadi, 
but not with GFP (Figure 3C). Expression constructs encoding only the zinc-finger domain 
of G fii and GfiiB could also be co-immunoprecipitated with Triadi (data not shown). 
These experiments show that, similar to GfiiB, the zinc-fingers of G fii interact with 
Triadi. Co-immunoprecipitation experiments showing endogenous interactions between 
GfiiB and Gfii with Triadi using lysates from U937 and other hematopoietic cell lines 
appeared negative possibly due to the transient nature of interaction and low expression 
of the proteins (data not shown).
Triadi inhibits the ubiquitination of Gfii
Since Triadi functions as an ubiquitin E3 ligase in myelopoiesis25 and G fii was 
found to be ubiquitinated and degraded by the 26S proteasome in myeloid cells20, we 
studied whether Triadi ubiquitinates Gfii. To this end, we transfected COS cells with 
Gfii-GFP, Flag-Ub with or without Triadi. After GFP immunoprecipitation the amount of 
ubiquitinated proteins bound to G fii and ubiquitinated forms of Gfii itself were revealed 
by Flag staining in Western blot analysis. This resulted in a protein smear including 
proteins with a lower molecular mass compared to Gfii-GFP probably representing 
ubiquitinated proteins bound to Gfii. This indicates that Gfii is present in ubiquitinated 
protein complexes (Figure 4A). The intensity of the protein smear increases dramatically 
above the size of Gfii-GFP, which suggest that Gfii itself is ubiquitinated. Remarkably, 
co-expression of Triadi resulted in a severe reduction in the amount of ubiquitinated 
proteins.
We performed additional in vivo ubiquitination assays to further study the effect 
of Triadi on Gfii ubiquitination. His-tagged ubiquitin (His-Ub) was transfected with 
Gfii-GFP with or without Triadi. Under denaturing conditions ubiquitinated proteins were 
isolated and subsequently analyzed on Western blot. This showed that the amount of 
ubiquitinated G fii was clearly diminished upon co-expression of Triadi (Figure 4B). Also 
the expression of the Hi58A Triadi mutant, which can not interact with the E2 conju­
gating enzyme UbcH725, diminished G fii ubiquitination. This suggests that the inhi­
bition of G fii ubiquitination is independent of the E3 ligase activity of Triadi. Addition 
of the proteasome inhibitor MGi32 resulted in a clear increase in ubiquitinated forms of 
Gfii indicating that ubiquitination of G fii results in 26S proteasomal degradation. In the 
presence of MGi32 Triadi still inhibited the ubiquitination of Gfii, indicating that prote-
Figure 4A
IP a-GFP 
WB a-Flag
Gfi1-GFP
WB a-GFP
Figure 4B
NTA bead pulldown 
WB a-His
His-Ub
Triad1
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Figure 4, Triadi inhibits Gfii ubiquitination
A. Gfii-GFP and Flag-Ub were cotransfected with 
or without Triadi. Gfii was immunoprecipitated with 
a-GFP. Ubiquitinated Gfii or ubiquitinated proteins 
bound to Gfii were detected by a-Flag staining. The high 
molecular smear suggests that ubiquitinated proteins 
are bound to G fii, or that G fii itself is ubiquitinated ( ^  
marks molecular weight of unmodified Gfii-GFP). The 
co-expression of Triadi severely reduces the amount of 
ubiquitinated Gfii or ubiquitinated proteins bound to G fii. 
a-GFP staining of whole cell extract (wce) was used to 
check for equal expression.
B. COS cells were transfected as indicated. Ubiquiti­
nated proteins were isolated with His-select beads under 
denaturing conditions (6 M guanidium chloride). The high 
m o* cular smear represents poly-ubiquitinated forms of 
G f ii.  Co-expression of Triadi or the H i58A point mutant 
s everely inhibited the ubiquitination of G fii. Incubation of 
cells with MGi32 resulted in an accumulation of ubiqui­
tinated forms of Gfii indicating that poly-ubiquitination 
of Gfii results in proteasomal degradation. Triadi also 
inhibited the ubiquitination of Gfii in the presence of 
the proteasome inhibitor MGi32. (*) Marks non-specific 
interaction of G fii with the His-select beads.
C. In vivo ubiquitination assay of endogenous proteins 
with His-Ub. Selection of ubiquitinated proteins (His- 
select beads) followed by an a-His staining showed 
that overall ubiquitination is not inhibited by Triadi. The 
a-ubiquitin staining of whole cell extract (wce) in the 
lower panel showed equal expression of His-tagged 
ubiquitin. The lower band is endogenous ubiquitin, the 
slower migrating band is His-Ub.
WB a-Ub
Gfi1-GFP - + + + + + +
His-Ub + -  + + + + +
Triadi - - -  + - -  +
Triadi H158A - - - -  + - -
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asome activity is not necessary for the observed effect. Similar results were obtained 
when Flag-Gfii instead of Gfii-GFP was used (supplementary Figure 1) thereby excluding 
any non-specific effects in ubiquitination due to the GFP tag.
To rule out the possibility that the observed decrease of G fii ubiquitination by 
Triadi was caused by a non-specific effect on total cellular-ubiquitination, the effect of 
Triadi on the total amount of ubiquitinated proteins was studied. To this end, His-Ub 
was transfected in COS cells with or without Triadi, followed by capture and staining of 
ubiquitinated proteins in Western blotting. As can be seen in Figure 4C the total amount 
of ubiquitinated proteins was not altered upon co-expression of Triadi. Together, these 
data indicate that Triadi specifically inhibits the ubiquitination of Gfii.
Figure 5A I Wb a- Triadi
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Figure 5, Inhibition of Triadi expression results in increased Gfii ubiquitination
A. HEK293 cells were not transfected or transfected with indicated siRNAs against Triadi or a control 
siRNA (scrambled control Qiagen) and GFP. 48 hours after transfection, GFP pbsitive o f lls were sorted 
118 by FACS ann eqoal amounts of cells were lysed and stained for Triadi exprnssioo showing efficient 
downmodolation of endogenouo Tria01. T0e same blots were probed with an actinantibody to demon­
strate equal loadiof . B. In vivo ubiquitination experiments in HE0293 cells showedthat Tfiadi siRNA 
expression resulted in increased poly-ubiquitination of G fii. Co-transfection with a control siRNA (left 
panel siRNA against Spl, right panel scrambled siRNA (Qiagen)) had no effect on Gfii ubiquitination. 
wce = whole cell extract.
Downregulation of Triadl levels results in an increase of Gfil ubiquitination
Synthetic siRNAs were developed to down regulate endogenous Triadi levels in 
HEK293 cells. The efficiency of these siRNAs was first tested by co-expressing them with 
GFP-Triadi. Two siRNAs designed to downregulate Triadi were equally efficient in down 
regulating GFP-Triadi as a control siRNA targeting GFP (supplementary Figure 2). In 
addition, co-expression of either construct with GFP followed by FACS sorting of trans­
duced cells and staining for Triadi indicated that both constructs resulted in downregu- 
lation of endogenous Triadi protein levels in HEK293 cells (Figure 5A). Subsequently we 
tested whether Triadi dowmodulation affected G fii ubiquitination. To study this, the 
Triadi siRNAs were co-transfected with Flag-Gfii and His-Ub followed by capture of 
ubiquitinated proteins and staining for G fii in Western blot analysis. This showed that 
knocking down endogenous levels of Triadi resulted in a clear increase in ubiquitinated 
forms of G fii (Figure 5B). Control siRNAs (one against Spi, left panel and a scrambled 
siRNA, right panel, Figure 5B) had no effect on G fii ubiquitination. These data show that 
decreasing endogenous Triadi levels results in increased Gfii ubiquitination and indicate 
that limitation of essential cofactors is not the cause of the observed inhibition of Gfii 
ubiquitination when Triadi is overexpressed (Figure 4). Together, these data indicate that 
Triadi specifically inhibits the ubiquitination of Gfii.
Triadi inhibits Gfil protein turnover
The ubiquitination of Gfii, which results in proteasomal degradation, was 
inhibited by Triadi. Therefore, we studied the effect of Triadi on Gfii protein levels. 
To address this question we co-expressed Gfii-GFP with different amounts of Triadi. 
Gfii-GFP protein amounts were measured at the single cell level by flow cytometry. 
Relative Gfii-GFP protein levels were increased after Triadi co-expression, while Triadi 
had no effect on GFP alone (Figure 6A). The increase of G fii protein levels caused by 
Triadi suggests that Triadi stabilizes G fii by inhibiting its proteasomal degradation. 
To study the effect of Triadi on Gfii stability we transfected Flag-Gfii to COS cells with 
or without Triadi. The stability of Flag-Gfii protein was determined in the presence or 
absence of Triadi after addition of the inhibitor of protein translation cycloheximide. In 
these experiments we found that Triadi resulted in a concentration dependent increase 
in the half-life of Gfii (Figure 6B). To test the relevance of Gfii stabilization in hema- 
topoiesis we made use of U937 cells because we recently found that G fii is efficiently 
targeted for proteasomal degradation in these cells20. We generated a retroviral construct
ch
a
p
te
r 
4
ch
a
p
te
r 
4
1 2 0
Figure 6A
i0,0pg Triadi 
0,1pg Triadi 
0,5pg Triadi 
■ 1,0pg Triadi
WB a-Triad1
o.o 0.1 0.5 1.0 o.o o . 1 0.5 1.0 Triadi (jug)
Figure 6 B
no Triadi 1:1 Triadi:Gfii 7.5:1 Triadi:C5fi1
Figure 6C
Figure 6 D
Gfi1,Wb a-dlag 
Triad 1, Wb a-Triad1 
Actin, Wb a-Actin
0  15 30 6 0  1 2 0 2 4 0  0  15 30 6 0  1 2 0 2 4 0  0  15 30 6 0  1 2 0  240 Cycloheximide (min)
- a-Gfid
a-Triadl 
* -  o-Actin 
+ Triadd
H P  < -  a-Gfi1
M i  a-Actin
+ Triadd
- Triadd-dA2
D a ys a fte r  tra n s d u c tio n
Figure 6, Triadi controls Gfi 1 stability
A. GFP, or Gfil-GFP was transfected with different amounts <^ 1TTriadi in HEK293 cells. 24 hours after 
transfection the Gfii-GFP protein levels per cell were measured by flow cytometer. The MFI of trans­
fected cells without Triadi was set at i00%. The relative Gfii-GFP protein levels increased when Triadi 
was co-expressed, while Triadi co-expression had no effect on the MFI of GFP transfected cells. Triadi 
expression was checked in Western blot analysis (right panel). B. HEK293 cells were transfected with i 
mg Flag-Gfii with or without Triadi at indicated ratios. 48 hours after transfection cells were transferred 
to 6 well-plates and allowed to adhere for i 6 hrs. Next, cells were treated with cycloheximide for indi-
cated time points. Total cell lysates were analyzed by Western blotting followed by an a-Flag staining. 
The Gfii half life increased in a Triadi concentration dependent manner. The same samples were 
were reloaded for Actin and Triadi staining on one and the same blot to demonstrate equal loading 
and Triadi expression. C. U937 cells were transduced with Triadi or TriadidR2 encoding viruses. 48 
hours after transduction, cells were sorted based on NGFR expression using MACS. Equal amounts 
of NGFR positive cells were lysed and used in Western blot analysis to detect endogenous Gfii (N20 
staining). To show equal loading for the left panel the samples were reloaded and stained for Actin. The 
blot was reprobed with a Triadi antibody to demonstre Triadi expression. For the right panel the same 
blot was restained for Actin to show equal loading. As a control to demonstrate retroviral Triadi and 
TriadidR2 expression we transduced NIH3T3 cells followed by a Triadi staining (Supplementary Figure
3). D. U937 cells were transduced with G fii, Triadi, TriadidR2 or control viruses (encoding GFP and 
tNGFR). After transduction, cells were maintained as a mixed culture (containing transduced and non­
transduced cells). Four days after transduction the transduction efficiencies ranged from 6-67% based 
on either GFP positivity (Gfii and control vector) or NGFR positivity (Triadi and TriadidR2). At that 
time the amount of GFP or NGFR positive cells was set at i00%. The relative amount of positive cells 
relative to this value was plotted in time. Both Gfii and Triadi (based on GFP and NGFR positivity, 
respectively) positive cells were rapidly overgrown by non-transduced cells while the relative amount of 
control and TriadidR2 positive cells remained stable during the culturing period. Gfii expression in Gfii 
transduced cells was confirmed at day six by Western blot analysis (Supplementary Figure 4).
containing an expression cassette coding for Triadi followed by an IRES and a truncated 
version of the nerve growth factor receptor (NGFR) allowing for separate Triadi and 
NGFR expression (see also "Materials and methods"). As control, we generated a similar 
construct containing Triadi lacking coding sequences for the C-terminal RING finger 
(TriadidR2) that are required for Gfii interaction. Both constructs were retrovirally trans­
duced to U937 cells. NGFR positive cells were sorted and Gfii protein levels were deter­
mined in Western blot analysis. This showed that Triadi expression resulted in increased 
endogenous Gfii protein levels compared to non transduced cells (Figure 6C). Expression 
of the TriadidR2 mutant that lack the Gfii binding domain did not cause an increase in 
Gfii protein levels.
Triadi inhibits the proliferation of immature myeloid murine bone marrow 
cells and inhibits clonogenic growth of these cells in CFU-GM assays25. These effects 
could be mediated through stabilization of Gfii. As Triadi inhibits the proliferation of 
immature myeloid cells and stabilizes Gfii in U937 cells, we first tested whether forced 
G fii expression inhibits proliferation of U937 cells. To this end, U937 cells were retrovirally 
transduced using a retroviral vector coding for Gfii and GFP28. Proliferation assays using 
mixed cultures showed that Gfii positive U937 cells were rapidly overgrown by non-trans-
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duced cells. Cells transduced with a control vector were not overgrown but proliferated at 
a similar rate as non-transduced cells. Next we tested whether Triadi also inhibits prolifer­
ation and whether the Triadi mutant that can not bind to G fii does not. Triadi transduced 
U937 cells were overgrown by non-transduced cells in a similar rate as Gfii positive cells. 
In contrast, TriadidR2 transduced cells continued to proliferate at a similar rate as non­
transduced cells. We conclude that Gfii is stabilized by Triadi due to decreased ubiquiti- 
nation and proteasomal degradation. The stabilization mediated by Triadi depends on its 
G fii interacting domain. Expression of both Triadi and Gfii but not the TriadidR2 mutant 
inhibits U937 cell growth suggesting that Triadi regulates the proliferation of immature 
myeloid blood cells by fine tuning G fii protein expression.
1 2 2
Discussion
Triadi was recently reported as an ubiquitin E3 ligase implicated in hemato- 
poiesis25. Triadi is the founding member of a subclass of RING finger E3 ligases34;35. This 
subclass contains a TRIAD domain which is characterized by a RING-DRIL/IBR-RING 
signature34;36;37. Recent studies showed that the N-terminal RING finger of Triadi interacts 
with the E2 conjugating enzyme UbcHy. UbcH7 mediates poly-ubiquitin chain formation 
linked via lysine-48 of ubiquitin. In line with this interaction we showed that Triadi func­
tions as ubiquitin ligase and that it can catalyze the formation of poly-ubiquitin chains 
(linked via lysine-48), that mark proteins for proteasomal degradation25. Triadi is upreg- 
ulated upon monocytic and granulocytic differentiation and Triadi expression resulted 
in a severe reduction of clonogenic growth of primary murine bone marrow cells which 
could be partially rescued by proteasome inhibitors25. Furthermore, the interaction with 
the E2 conjugating enzyme UbcH7 was essential for the observed Triadi effect. In this 
report, we show that the C-terminal RING finger of Triadi interacts with the zinc fingers 
of Gfii (Figure 3). Strikingly, we found that Triadi inhibits the ubiquitination of Gfii (Figure
4). This indicates that Triadi does not mark Gfii for proteasomal degradation and that 
other, currently unknown, E3 ligases must exist that regulate Gfii turnover. Triadi may 
inhibit the ubiquitination of Gfii by ubiquitinating these Gfii E3 ligases. Such a mech­
anism was recently described for the TRIAD E3 ligase Hoil-i that interacts with SOCS638. 
Hoil-i stabilizes the SOCS6 protein by mediating the ubiquitination and degradation of 
SOCS6 associated proteins39. These associated proteins are normally responsible for the 
degradation of SOCS6. Our results show that the Triadi Hi58A point mutant, which has 
lost its ability to bind with UbcH725, or wild type Triadi in the presence of proteasome 
inhibitors could still inhibit the ubiquitination of Gfii (Figure 4b). Together, these data 
strongly suggest that Triadi inhibits the ubiquitination of Gfii independent of its E3 ligase 
activity. Such a model, in which an E3 ligase inhibits protein ubiquitination independent 
of its ligase activity, was recently described for the Von Hippel-Lindau E3 protein (pVHL). 
The pVHL ligase as well as a mutant lacking E3 ligase activity inhibited the ubiquitination 
of the tumor supressor p53 by disturbing the interaction between the ubiquitin ligase 
MDM2 and p5 340. As indicated above, Triadi inhibits Gfii ubiquitination in the presence 
of proteasome inhibitors and does not require UbcH7 to do this. This suggests that Triadi 
competes for G fii binding with other ubiquitin ligases that do mark G fii for ubiquitination 
and subsequent proteasomal degradation. It also indicates that E3 ligases feature more 
functions than solely ubiquitinating proteins.
123
ch
a
p
te
r 
4
ch
a
p
te
r 
4
124
The Gfii protein levels are mainly regulated by the ubiquitin proteasome route 
during myelopoiesis20. Gfii is efficiently degraded in granulocytes by the 26S prote­
asome. However, in CD14+ monocytes it is more stable due to diminished proteasomal 
degradation resulting in an accumulation of Gfii protein levels20. Triadi protein levels are 
induced during terminal monocytic differentiation25. Thus, Triadi may inhibit the ubiqui- 
tination of Gfii in mature monocytes, which could result in the accumulation of Gfii 
protein levels. Indeed, forced expression of Triadi in U937 cells resulted in an increase 
in endogenous G fii protein levels (Figure 6C). In addition, Triadi inhibited U937 cell 
expansian in a similar manner as Gfii while a Triadi mutant lacking the Gfii interacting 
domain (TriadidR2) did not (Figure 6D). Together, these data suggest that Triadi may 
control myeloid proliferation through regulation of Gfii protein levels. However, in gran­
ulocytes Triadi is also significantly expressed although G fii protein levels are low20;25. A 
possible reason why Triadi does not protect G fii for degradation in mature granulocytes 
is the fact that the proteins may not colocalize. Triadi localizes to specific sub-nuclear 
DAPI dull-regions (euchromatin) in the nucleus of granulocytes25. Recent studies showed 
that the Gfii paralogue GfiiB localizes to heterochromatin4i. If Gfii localizes to the same 
compartment as GfiiB this implies that Triadi and Gfii are located in different sub-cellular 
structures in mature granulocytes which may hamper the inhibitory effects of Triadi on 
G fii ubiquitination. Recently, it was also shown that Atx-i influences Gfii protein stability 
in neuronal cells2i. In contrast to Triadi, Atx-i destabilized Gfii by enhancing its degra­
dation via the proteasome although it is unclear whether Atx-i functions as E3 ubiquitin 
ligase. Upon granulocytic differentiation Atx-i levels are induced42. We found that Atx-i 
mRNA expression levels are 4-fold higher in granulocytes compared to monocytes 
(supplementary Figure 5). The higher Atx-i expression in granulocytes might overcome 
Triadi-mediated inhibition of Gfii ubiquitination, while Triadi can stabilize Gfii in mono­
cytes due to lower Atx-i expression.
In this report we have described that the ubiquitin E3 ligase Triadi can stabilize 
Gfii, which results in an accumulation of Gfii protein levels. This suggests that Triadi is 
an important post-transcriptional regulator of the transcriptional repressor Gfii and in 
this way may regulate Gfii function. Because Triadi and G fii are not only expressed in the 
hematopoietic compartment these effects may also play a role in the nervous systemi4i2i, 
lung development43 and intestinei6. To better understand how Triadi and Atx-i affect the 
ubiquitination and protein stability of Gfii it will be important to identify the ubiquitin E3 
ligase(s) that mark G fii for proteasomal degradation.
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Abstract
Ubiquitination plays a major role in many aspects of hematopoiesis. Alterations 
in ubiquitination have been implicated in hematological cancer. The ubiquitin ligase Triadi 
controls the proliferation of myeloid cells. Here we show that two RING domains in Triadi 
differentially bind ubiquitin conjugating enzymes UbcH7 and Ubci3. UbcH7 and Ubci3 
are known to catalyze the formation of different poly-ubiquitin chains. These chains 
mark proteins for proteasomal degradation or serve crucial non-proteolytic functions, 
respectively. In line with the dual Ubc interactions, we observed that Triadi catalyzes the 
formation of both types of ubiquitin chains. The biological relevance of this finding was 
studied by testing Triadi mutants in myeloid clonogenic assays. Full-length Triadi and 
three mutants lacking conserved domains inhibited myeloid colony formation by over 
50%. Strikingly, deletion of either RING finger completely abrogated the inhibitory effect 
of Triadi in clonogenic growth. We conclude that Triadi exhibits dual ubiquitin ligase 
activity and that both of its RING domains are crucial to inhibit myeloid cell proliferation. 
The differential interaction of the RINGs with Ubcs strongly suggests that the ubiquiti­
nation mediated through UbcH7 as well as Ubci3 plays a major role in myelopoiesis.
134
Introduction
Ubiquitination plays a major role in many aspects of cell biology, including cell 
division, signaling, movement and apoptosis(i). The conjugation of one or more ubiquitin 
peptides to a specific substrate protein can regulate the substrate's activity or may result 
in its recognition and degradation by the 26S proteasome. In normal hematopoiesis, the 
ubiquitin proteasome route regulates the fate of many proteins, including for example 
growth factor receptor c-kit, cyclin D, Bcl-2 (B-cell CLL/lymphoma 2) and transcription 
factors such as GATA-2, AM Li (acute myeloid leukemia i), and G fii (Growth Factor Inde­
pendence i ) (2). Deregulation of the ubiquitin proteasome route is also implicated in 
malignant hematopoiesis(2). For example, the Von Hippel-Lindau (VHL) protein is respon­
sible for poly-ubiquitination and subsequent degradation of the H ifia (hypoxia-inducible 
factor i,  alpha subunit) protein. Mutations in VHL that are found in polycythemia 
patients result in defective ubiquitination that causes stabilization of H ifia. As a result, 
expression of hypoxia induced genes, including erythropoietin, increases. High erythro­
poietin levels are believed to contribute to the high red blood cell counts that are found 
in congenital polycythemia(3). In Fanconi anemia (FA) mono-ubiquitination of the Fanconi 
anemia D2 protein is inhibited, resulting in a defect in the DNA repair mechanism. This 
results in genetic instability that predisposes FA patients to develop malignancies like 
acute myelogenous leukemia (AML)(4). Overexpression of MDM2, as found in many 
leukemia patients, results in increased poly-ubiquitination and degradation of the tumor 
suppressor protein p53(5). Recently, acquired mutations in Cbl (Casitas B-cell lymphoma) 
proteins were identified in AML. Cbl is involved in the ubiquitination and subsequent 
internalization and degradation of the activated Flt3 (fms-related tyrosine kinase 3) 
receptor. As a result of mutations in Cbl, the Flt3 receptor is no longer ubiquitinated and 
thereby no longer inactivated, resulting in a constitutive active receptor(6, 7).
Although it is clear that ubiquitination plays a crucial role in regulating the 
activity of many important proteins that control hematopoiesis, little is known about the 
enzymes that facilitate ubiquitination. The covalent coupling of ubiquitin to a substrate 
protein requires subsequent action of three enzymes. First, the E i enzyme activates 
ubiquitin, which is then transferred to an E2 ubiquitin-conjugating enzyme (Ubc). In 
concert with Ubcs, ubiquitin E3 ligases catalyze the final step by facilitating the covalent 
attachment of ubiquitin to a substrate protein or the attachment of a ubiquitin to the 
preceding ubiquitin to form poly-ubiquitin chains. The E3 ligases are responsible for the 
specificity of the ubiquitination process as they recognize the substrates(8). We have
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previously described Triadi as a ubiquitin ligase that regulates myelopoiesis through its 
ubiquitin ligase activity(9). Expression of Triadi is induced during myeloid differentiation 
and forced expression results in inhibition of proliferation of immature murine bone 
marrow cells. Triadi is the founding member of a subclass of ubiquitin ligases that contain 
two RING (Really Interesting New Gene) finger domains. The RING finger containing E3 
ligases represent the largest family of the group of proteins that have ubiquitin ligase 
activity. This family can be subdivided in E3 ligases which function as multi-subunit 
complexes like the APC/C (anaphase-promoting complex/cyclosome), SCF (Skpi-Culi- 
F-box-protein) or the CBC (cullin-2/elongin BC) subfamilies, or as single protein ubiquitin 
ligases (i- i0). The TRIAD (Two RING fingers and DRIL) protein family is characterized by a 
highly conserved TRIAD domain encompassing a conserved DRIL (Double RING Finger 
Linked a.k.a. In between RINGs (IBR)) domain flanked by two RING fingers.
Importantly, the combination of the Ubc and the ubiquitin E3 ligase determines 
the type of ubiquitin chain that is synthesized (ii- i2). These different types of ubiquiti- 
nation regulate the fate of the ubiquitinated proteins. For example, proteins marked 
with poly-ubiquitin chains linked via lysine 48 (K48) of ubiquitin are in general recognized 
by the 26S proteasome providing the cell with a specific and efficient way to eliminate 
these proteins. The addition of ubiquitin chains linked via lysine 63 (K63) of the preceding 
ubiquitin, primarily results in altered function and in general does not trigger proteasomal 
degradation of the modified protein(i3). K63-linked poly-ubiquitin chains may affect the 
subcellular localization of proteins but can also function as scaffold to bind other proteins. 
K63 linked poly-ubiquitin chains are implicated in many important biological processes 
including DNA repair(i4) and NFB (Nuclear Factor Kappa B) activation(i5). To date, it is 
generally believed that poly-ubiquitin chains are linked through a single iso-peptide 
bond (for example where ubiquitin moieties in the poly-ubiquitin chain are linked only via 
lysine 48). Interestingly, in vitro studies have shown the formation of mixed and/or forked 
ubiquitin chains in which multiple different lysine residues are used for the formation of 
poly-ubiquitin chains(i6, i7). Although a single report has described the presence of these 
kinds of forked poly-ubiquitin chains in v/W i8), the physiological relevance of these chains 
remains to be determined.
We have previously shown that the N-terminal RING domain in Triadi interacts 
with UbcH7, an E2 ubiquitin conjugating enzyme implicated in lysine 48 linked ubiquitin 
chain formation. This interaction suggests that Triadi may target substrate proteins for 
proteasomal degradation. In line with this, we found that inhibition of the proteasome
partially rescued the Triadi induced growth repressive phenotype(9). Recently, we showed 
that Triadi interacts with Gfii, a transcription factor essential to many developmental 
processes in hematopoiesis. Surprisingly, the ubiquitination and proteasomal degra­
dation of Gfii was specifically inhibited by Triadi(l9). Thus, Triadi does not seem to target 
G fii for proteasomal degradation. To gain insight into the biological role of the different 
motifs present in Triadi and their contribution to its E3 ligase activity, we tested their rele­
vance in hematopoiesis. We show differential binding of the RING domains to different 
ubiquitin conjugating enzymes and show that these interacting domains are essential for 
the biological function of Triadi in hematopoiesis.
Materials and Methods
Cell culture
U937, HEK293, COS-i and NIH3T3 cells were cultured as described*9- 20). For 
monocytic differentiation U937 cells were differentiated with ioo ng/ml PMA (Phorbol 
i2-myristate i3-acetate, Sigma, St Louis, MO, USA) or ATRA (all-trans retinoic acid)(2i). 
U937 cells were transduced as described(20) with retroviruses containing full length Triadi(9) 
and the different mutants in the pLZRS-IRES-DNGFR vector. Transduced U937 cells were 
isolated by magnetic cell sorting (MACS) on the basis of DNGFR positivity(20). Flowcyto- 
metric analysis of DNGFR (truncated nerve growth factor receptor) expression of the 
MACS-sorted cells showed a purity of more than 95% in all experiments.
Western blotting and immunofluorescence microscopy
Whole cell lysates were made in RIPA (radio-immunoprecipitation assay) buffer 
as described(20), and separated by SDS-PAGE. Blots were probed with rabbit antibodies to 
Triadi(9), Flag (M2, Sigma), GFP (Roche, Basel, Switzerland), Poly-Ubiquitin (FKi, Affinity, 
Golden, CO), Ubiquitin (6Ci, Sigma) or Actin (I-i9, Sigma). Cytospins of U937 cells were 
fixed, permeabilized and stained with anti-Triadi antibody followed by Donkey anti­
Rabbit PE (Jackson, Suffolk, United Kingdom), washed 3 times with PBS and embedded 
in Vectashield with DAPI (4',6-diamidino-2-phenylindole, Vector Lab, Burlingame, CA­
USA). NIH3T3 cells were grown on cover slips and transfected using lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). Cells were stained using a-Flag (M2, Sigma) or a-UbcH7 
(Transduction Laboratories, Lexington, KY, USA) followed by donkey-a-mouse TexasRed 
(Jackson) staining. Pictures were obtained using a Leica DMRBE microscope and Leica 
FW4000 software (Leica Microsystems, Rijswijk, the Netherlands).
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Generation of Triadl expression vectors
A full length Triadi construct as described® was used to generate Triadi mutants 
ARINGi, ADRIL, ARING2 and ATRIAD (Figure 1A) using sexual PCR as described(22) using 
Pfu and Taq polymerase (Invitrogen, Carlsbad, CA, USA). The ACC2 and CC1+2 mutants 
were made by introducing a stop codon using PCR primers. The sequences of used 
primers can be found in supplemental Table 1. All fragments were verified by sequence 
analysis. Triadi full length and deletion mutants were cloned into the pLZRS-IRES-
Figure 1A 493
H h  Full length
— 1----- M 2 I-  A Acidic
. . .H  1 H 2 h ATRIAD
1 H 2 I-  A RING1
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Figure 1, RING1 of Triad1 is essential for interaction with UbcH7 and RING2 for Ubc13
A, Schematic representation of the generated Triadl deletion constructs. The Triadl deletion constructs 
were cloned into the pGAD and pLZRS vectors and sequence verified. B, UbcH7 interactions with 
empty vector (EV), Dacidic Triadl and indicated Triadl deletion constructs were studied in yeast-two- 
hybrid assays. AH109 yeast cells were transformed and assayed for interaction by growing on histidine 
selection and X-gal positivity. The complete TRIAD domain and RING1 were essential for the interaction 
with UbcH7. The empty vector pGAD showed no interaction with the Triadl deletion constructs (data not 
shown). C, Ubc13 interaction with EV and indicated Triadl deletion constructs. Both the TRIAD domain 
and RING2 are essential for interaction with Ubc13.
ANGFR retroviral expression vector(20) and in pGAD-Ci for yeast-two-hybrid analyses. Full 
length Triad was cloned in frame with the His-tag in pFastBacT A to generate a bacmid for 
baculoviral transduction of insect cells.
Yeast-Two-Hybrid assays
UbcH7 and Ubci3 bait(23) and Triadi prey deletion constructs were transfected to 
the yeast strain AHiog (Clontech, Palo Alto, CA, USA) for yeast-two-hybrid analyses. This 
strain contains the selectable marker histidine, adenine and a lacZ reporter. A positive 
interaction in yeast was defined by growth of blue colonies after plating cells on leucine, 
tryptophane, histidine and adenine deficient SD medium containing X-a-gal.
Protein expression and purification
For in vitro ubiquitination assays with reticulocyte fraction IIA, His-tagged 
Triadi was produced using the baculovirus system (Baculovirus Bac-to-Bac Expression 
System, Invitrogen, Carlsbad, CA, USA) in Hi-5 cells(9). Three days after infection cells 
were harvested and lysed in RIPA buffer with Complete protease inhibitor cocktail 
(Roche, Basel, Switzerland). After centrifugation His-Triadi was isolated from Hi-5 cells 
using His-select spin columns followed by elution with 250 mM imidazole. Imidazole 
was removed from His-Triadi protein eluates using a Microcon YM-io filter (Amicon, 
Beverly, MA, USA) and protein concentrations were determined with the Bradford assay. 
For Surface Plasmon Resonance (SPR) studies, analytical gelfiltration and in vitro assays 
with purified proteins, His-tagged Triadi was expressed from pFastBac, using the bacu- 
lovirus expression system in Sfg cells. Cells were harvested 3 days after infection and 
lysed by sonification. The cleared lysate was incubated with Talon beads and Triadi was 
eluted from the beads in buffer A (50 mM Tris/HCl pH8, 200 mM NaCl, 2 |aM ZnCl2) + 250
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mM imidazole. Further purification was achieved by anion exchange chromatography on 
a Resource Q column using buffer A, eluting with a linear NaCl gradient to 0.5 M NaCl. 
Proteins were eluted at 350 mM, followed by size exclusion chromatography (Superdex 
200) in 20 mM Hepes pH7.5, 150 mM NaCl, 2 |aM ZnCl2, 15 |aM b-mercaptoethanol (bME).
The Ubci3-Mms2 complex was produced in E. coli BL2i(DE3) cells by 
co-expression of GST (glutathione S-transferase)-tagged Mms2 and His-tagged Ubci3 
from the pGEX4T-1 vector with both genes on a single promoter. Cells were induced 
with 0.4 mM IPTG (isopropyl-1-thio-b-D-galactopyranoside) at an OD600 of 0.8 in LB 
medium supplemented by 50 |ag/ml carbenicillin and further cultivated at 15°C. Cells were 
harvested after 15-20 hours and lysed by sonification. The cleared lysate was incubated 
with Talon beads and washed with 20 column volumes of buffer C (50 mM Tris/HCl pH7.5, 
150 mM NaCl, 5 mM bME, 5 mM imidazole). The complex was eluted in buffer C + 500 mM 
imidazole. Subsequently the complex was incubated with glutathione beads and washed 
with buffer C + 3 mM CaCl2. The GST-tag was cleaved overnight on beads by Thrombin 
protease. UbcH7 was expressed in E.coli Rosetta2 (DE3) cells from a pGEX2 vector. Cells 
were induced by autoinduction and cultivated overnight at 15°C. The cells were lysed by 
a high-pressure EmulsiFlex-C5 device (Avestin, Mannheim, Germany) and cleared lysates 
were incubated with glutathione sepharose beads. GST-tagged UbcH7 was eluted in 
20 mM Tris/HCl pH8.0, 250 mM NaCl, 15 mM bME and 50 mM Glutathione. The GST-tag 
was digested with Thrombin for 2 hours at 37°C and the reaction was terminated by the 
addition of 1 mM PMSF. Further purification of UbcH7 was achieved through gel filtration 
(Superdex 200) using 20 mM Tris/HCl pH7.5, 150 mM NaCl, 2 |aM ZnCl2, 15 mM bME. 
Final purification was achieved through gel filtration (Superdex 75) using buffer C without 
imidazole.
Co-Immunoprecipitation
For immunoprecipitations, transfected HEK293 cells were lysed in TNI buffer 
containing 0,1% Nonidet P-40, 50mM Tris-HCl pH 8,0, 1501T1M NaCl and Complete 
protease inhibitor cocktail and incubated with indicated antibodies for 15 hours at 4°C. 
Protein G sepharose beads (GE Healthcare, Zeist, the Netherlands) were washed three 
times in TNI buffer, added to the lysate and incubated for 2 hours at 4°C. Bound proteins 
were washed, eluted in loading buffer by heating for five minutes at 95°C, separated by 
SDS-PAGE, immunoblotted, and stained with relevant antibodies.
Analytical gelfiltration
Triadi-E2 interaction studies by analytical gelfiltration were performed on a 
Superdex 75 column on the SMART system (Pharmacia) in a buffer containing 20mM 
Hepes pH7.5, i50nM NaCl, 2|aM ZnCl2 and 5mM b-mercaptoethanol. 50|J of a mixture of 
Triadi and Ubci3-Mms2 at 40 |aM each was incubated for i0  min at 4°C before loading on 
the column. Eluted fractions were run onto SDS-PAGE and analyzed by coomassie blue 
staining.
Surface Plasmon resonance
Triadi-E2 interactions were analyzed quantitatively using SPR experiments. The 
SPR experiments were performed at i0°C on a Biacore T-i00 instrument (GE Healthcare, 
WI, USA). The experiments were performed in duplicate and Triadi was immobilized at 
densities of 6000 RU and i000 RU through amine coupling on a CM5 chip. The Ubci3- 
Mms2 complex was injected over the sensor chip at 30 |J/min with a i20 sec asso­
ciation phase followed by a i0  min dissociation phase. Standard double referencing 
data subtraction methods were used before data analysis. Curve fitting and other data 
analyses were performed using Biaevaluation (GE Healthcare, WI, USA) and GraphPad 
software (GraphPad Software Inc., San Diego, CA, USA).
In vitro ubiquitination assays
For the in vitro assays using purified Ei, E2 and E3, 30uL reactions were 
performed in a buffer containing 251T1M Tris pH8, i50mM NaCl, i0mM MgCl2, 2|aM ZnCl2, 
5|aM b -m e rc a p to e th a n o l, 0 . 5 t M  D T T  and 3 t M  A T P  at 30oC. Wild-type ubiquitin 
(3 |aM) was used together with i5nM Ubai, i50nM Ubci3-Mms2 and i5nM-i.5|aM Triadi. 
The samples were run on 4-i2%  NuPage gels in MOPS buffer (Invitrogen, Ca, USA) and 
were analyzed by western blotting with an a-ubiquitin antibody (P4Di, Santa Cruz 
biotechnology, CA, USA).
In vitro ubiquitination assays in lysates were performed as described previously*9' 
24) using i.6  |ag reticulocyte fraction IIA (Boston Biochem, Cambridge, MA, USA) as a 
source of E i and E2 activity. Although this fraction may not contain high levels of UbcH7 
and Ubci3, it contains sufficient E2 activity to support the formation of K48 and K63 
linked poly-ubiquitin chains(24). To test chain formation, recombinant wild type Ub, K0-Ub, 
K48-Ub or K63-Ub (Boston Biochem) was incubated together with reticulocyte fraction 
IIA and freshly prepared His-Triadi for 60 min at 37°C followed by staining of ubiquiti-
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nated proteins in Western blot analysis using a poly-ubiquitin specific antibody (FKi, 
Affinity BioReagents, Golden, CO, USA).
Colony forming assays, differentiation and cell cycle characteristics
Clonogenic growth of transduced and MACS-sorted U937 cells was measured by 
plating i000 cells/ml in semisolid (0.75% agar) culture medium. Colonies were counted 
after 6 days. Differentiation of U937 cells was assessed measuring C D iic  expression 
(Immunotech, Marseille, France). Apoptosis and DNA histograms were determined using 
AnnexinV (Molecular Probes, Eugene, OR, USA) and propidium iodide staining, respec­
tively® and the percentage of DNGFR positive cells was monitored measured using the 
a-DNGFR antibody and Goat-a-mouse PE by flowcytometry.
Results
Triad1 inhibits the clonogenic grow th o f U937 cells
Triadi is induced upon differentiation towards monocytes and granulocytes and 
inhibits the clonogenic growth of primary murine bone marrow cells(9). We tested whether 
Triadi was also induced during PMA induced monocytic differentiation of the myelo- 
monocytic cell line U937. U937 differentiation was confirmed by C D iic  expression using 
FACS analysis. Triadi became detectable after 24 hours of PMA induced monocytic differ­
entiation and protein levels increased up to 72 hours of differentiation (Figure 2A). Also 
ATRA induced differentiation of U937 cells resulted in an increase of Triadi protein levels
Figure 2A U937
a-Triad1
a-Actin
72 hours PMA
Figure 2, Triad1 is induced during monocytic differentiation of U937 cells
A, Cells were stimulated with PMA for the indicated time points and whole cell lysates were stained for 
Triadi. Triadi protein levels were induced after 24 hours upon PMA induced differentiation of U937 cells 
and were further upregulated after 72 hours of differentiation. The same blot was reprobed with actin 
antibody to demonstrate equal loading. B, Cytospins of unstimulated and PMA treated U937 cells were 
stained with Triadi antibody showing a clear induction of the nuclear Triadi protein levels. Secondary 
antibody staining alone resulted in no signal (data not shown). The nucleus was stained with DAPI.
Figure 2B
Oh 2 4 h 72 h PMA
U937 cells
(data not shown). The increase in protein expression during PMA induced differenti­
ation was confirmed by immunofluorescence microscopy. After 24 and 72 hours of differ­
entiation, Triadi protein levels were increased and Triadi protein was found to localize 
predominantly in the nucleus (Figure 2B).
Because Triadi inhibits the proliferation of immature murine bone marrow 
cells(9), we next tested whether Triadi can inhibit U937 cell growth. Triadi coding 
sequences were cloned in front of an IRES-DNGFR cassette, which allowed us to 
MACS select transduced cells using an a-NGFR antibody. Two independent batches of 
Triadi expressing retrovirusses were used (A and B), while empty vector (EV) and GFP 
expressing viruses were used as control. U937 cells were retrovirally transduced and 
MACS sorted 24 hours post-transduction resulting in more than 95% NGFR positive 
cells. Stable expression of Triadi in these cells after 2 weeks of culture was confirmed by 
Western blotting (Figure 3A). Triadi expression levels in transduced cells were compa­
rable to endogenous protein levels observed after 24 to 72 hours of PMA induced differ­
entiation, indicating that the experiments were performed with physiologically relevant 
protein levels (Figure 3B). The effect of Triadi on the clonogenic growth potential of U937 
cells was studied by seeding U937 cells in semi-solid medium directly after MACS sorting. 
The expression of Triadi in U937 cells resulted in a 50% decrease in colony numbers 
compared to the empty vector and GFP transduced control cells (Figure 3C). Moreover, 
the colonies derived from the Triadi transduced cells were significantly smaller compared 
to control transduced cells (Figure 3D).
143
ch
a
p
te
r 
5
ch
a
p
te
r 
5
144
Triad1 inhibits proliferation o f U937 cells, w ithout affecting their differentiation and 
apoptosis
The inhibitory effect of Triadi expression on colony formation may be due to a 
decrease in proliferation or due to changes in differentiation and apoptosis. Therefore, 
we tested the sensitivity to PMA induced differentiation of Triadi transduced cells. In
Figure 3A Figure 3B
Figure 3C
120
Figure 3D
GFP TriadIA Triad lB
Triad! A
Figure 3, Triad1 inhibits clonogenic growth of U937 cells
A, Whole cell lysates of EV (Empty Vector), GFP, TriadIA and B transduced and MACS sorted U937 
cells were stained for Triadi to check for correct expression. Cells were harvested 14 days after trans­
duction. Equal loading was confirmed by restaining the blot with actin antibody. B, Whole cell lysates of 
PMA treated untransduced U937 cells and Triadi transduced and MACS sorted U937 cells (24 hours 
after transduction) were immunoblotted. Triadi protein levels of transduced cells are comparable with 
the endogenous protein levels in 72 hours PMA treated U937 cells. Actin staining was used to check for 
equal loading. C, Colony forming assays were performed on EV, GFP, TriadIA and B transduced and 
MACS sorted U937 cells. 1000 cells were seeded in semi-solid medium. Colonies were counted 7 days 
after seeding. Empty vector transduced cells were set at 100. Triadi transduction resulted in a 50% 
reduction of U937 colonies. D, Pictures of the formed colonies after 7 days. Clearly visible is that the 
colonies are smaller when cells were transduced with Triadi, compared to EV or GFP transduced cells.
clonogenic assays, Triadi transduced cells were equally sensitive to PMA as control trans­
duced cells, indicating that Triadi expression does not influence the sensitivity of U937 
cells to differentiation by PMA (Figure 4A). We have previously shown that Triadi in U937 
cells showed reduced proliferation as compared to untransduced cells in competitive 
growth experiments(9). As Triadi did not affect differentiation, we repeated the compet­
itive growth experiments to investigate how Triadi affects U937 proliferation. Triadi and 
control transduced U937 cells were mixed in a i : i  ratio with non-transduced cells tested 
and analyzed for the percentage of transduced cells over a period of 20 days. While the
Figure 4A
Figure 4B
EV GFP Triadi B Triadi A
Days in Culture
Figure 4C
Figure 4, Triad1 inhibits proliferation 
of U937 cells
A, Colony forming assays were 
performed on transduced and MACS 
sorted U937 cells with the indicated 
concentrations of PMA. We used EV 
and GFP as duplicate controls and two 
independent virus batches, TriadIA 
and B as duplicates to test Triadi 
function. Colonies were counted 7 days 
after seeding. No clear difference was 
observed in sensitivity towards PMA of 
the transduced U937 cells.
B, EV, GFP, TriadIA and B transduced 
and MACS sorted cells were grown in 
a mixed culture with 50% untransduced 
U937 cells. The amount of DNGFR 
positive cells was analyzed by FACS at 
the indicated time points. The amount 
of TriadIA and B transduced cells was 
reduced to 11% and 14% respectively of 
the total amount of cells in culture after 
20 days. The percentage of GFP and 
EV transduced cells remained stable, 
indicating that Triadi inhibits prolifer­
ation of U937 cells. C, DNA histograms 
of U937 transduced and MACS sorted 
cells showed a 10% increase of Triadi 
transduced cells in G1/G0 phase of the 
cell cycle compared to GFP or EV trans­
duced cells.
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percentage of EV and GFP transduced cells remained stable, the percentage of Triadi 
transduced cells decreased to less than 15%, indicating that these cells have a growth 
disadvantage compared to non-transduced cells (Figure 4B). Differentiation, cell cycle 
status and apoptosis of transduced cells was measured in liquid medium. DNA histograms 
of the Triadi transduced cells on day 3 showed a 10% accumulation of cells in G1/G0 phase 
compared to GFP and empty vector transduced cells (Figure 4C). No effects of Triadi on 
differentiation (CD iic) or apoptosis (Annexin V) were found (Supplemental Table 2). We 
conclude that Triadi expression results in an accumulation of cells in G1/G0 but has no 
effect on differentiation, which is in line with the observed inhibitory effect of Triadi on 
the growth rate of U937 cells.
Figure 5A Figure 5B
IP a-flag
WCE
Ubc13-fiag + 
T riadt-G FP +
l-GFP
a-flag
a-GFP
a-flag
Figure 5, Triadi shows a strong interaction with Ubc13
A, HEK293 cells were transfected with Ubc13-flag and Triadl-GFP or Triadl-GFP alone. Lysates were 
incubated with anti-flag antibodies to precipitate Ubc13-flag and interacting proteins. Equal amounts of 
whole cell extract (WCE) and IP sample were subjected to immunoblot analysis to detect the presence 
of Ubc13-flag and Triad1-GFP. Triadl-GFP was only precipitated upon co-expression of Ubc13-flag.
B, Surface plasmon resonance analysis of the interaction of Triad1 with Ubc13. Triad1 was expressed in 
and isolated from Sf-9 cells. UbcH7 and the Ubc13-Mms2 complex were expressed in and isolated from 
E.coli. Triad1 was immobilized onto a CM5 chip and Ubc13-Mms2 flowed over at a range of concentra­
tions (0.04|jM - 5|jM). Binding could be detected at all concentrations. The Kd is determined at 0.8 |jM 
after fitting of a single component model (inset).
RING1 is essential for UbcH7 interaction, RING2 for Ubc13
The interaction between E2 conjugating enzymes and E3 ligases is essential for 
the ubiquitination of substrate proteins. The RING finger domain of E3 ligases is involved 
in the interaction with E2 conjugating enzymes(i0). In yeast-2-hybrid experiments Triadi 
specifically interacts with the E2 conjugating enzyme UbcH7 and weakly with Ubci3. 
The binding between Triadi and UbcH7 was confirmed using GST-Triadi captures using 
leukemia cell line lysates(9). To study whether Triadi interacts with Ubci3 in mammalian 
cells, co-immunoprecipitation experiments were performed. HEK293 cells were trans­
fected with Ubci3-flag and Triadi-GFP or Triadi-GFP alone. Ubci3-flag and interacting 
proteins were precipitated from the lysate using flag antibodies. Western blot analysis 
showed that Triadi-GFP only precipitates in the presence of Ubci3-flag (Figure 5A). To 
confirm the interaction between Ubci3 and Triadi by other means, surface plasmon 
resonance (SPR) was performed using the minimal functionally active Ubci3 complex: 
Ubci3-Mms2. Triadi was covalently bound to a CM5 chip and the Ubci3-Mms2 complex 
was flowed over the chip at different concentrations. Binding between the Ubci3-Mms2 
complex and Triadi could be clearly seen from the binding profiles at all concentra­
tions. Dissociation rates were quite fast (Ti/2= iosec ±i.2sec) (Figure 5B). The equilibrium 
responses were fitted using a one-site binding model, resulting in a KD of o.85|aM ± o.5|aM 
. This direct interaction between Ubci3-Mms2 and Triadi was confirmed using analytical 
gel filtration (supplemental Figure i). The elution profile shows a peak for the Triadi- 
Ubci3-Mms2 complex. The complex was not stochiometric, which is consistent with the 
fast off-rates as seen in the SPR data. It seems likely that it is the Ubci3 component of 
the E2 that interacts with a Triadi RING domain, analogous to the E2/E3 interaction 
observed in the crystal structure of the CHIP-Ubci3-UeviA complex(25) In contrast, UbcH7 
did not interact with Triadi in the SPR experiments, nor did it co-elute with Triadi in the 
analytical gelfiltration. These results indicate that the observed UbcH7-Triadi interactions 
as observed in cell line lysates (9) may need other factors or the presence of a substrate.
To test whether both ubiquitin conjugating enzymes interact with the same 
domain of Triadi, we tested various Triadi mutants for binding. Deletion constructs 
(Figure iA ) of Triadi were cloned in frame in the pGAD vector and co-transformed with 
UbcH7 or Ubci3 to analyze the interactions in yeast-two-hybrid assays. Both UbcH7 
and Ubci3 interacted with a Triadi mutant lacking the N-terminal acidic domain (acidic) 
(Figures iB  and C). The deletion of the complete TRIAD domain abolished the inter­
action with both UbcH7 and Ubci3, while both the coiled coil and DRIL domains were
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not necessary for E2 interaction. Earlier we proved that introduction of a point-mutation in 
RING1 abrogated binding to UbcH7(9). As expected, deletion of RING1 abrogated the inter­
action with UbcH7, while deletion of RING2 did not disturb the UbcH7 interaction. Conversely, 
yeast-two-hybrid analysis showed that the other RING finger (RING2) was essential for Ubci3 
interaction. To further study the Triadi and Ubc interaction, we transfected NIH3T3 cells with 
plasmids expressing Triadi-GFP and UbcH7 or Ubci3-flag(26). Similarly to Triadi, we found both 
UbcH7 and Ubci3 to be expressed in the nucleus and to a weaker extent in the cytoplasm
Figure 6A Figure 6 B
Figure 6, Triad1 catalyses the assembly of both K48 and K63 linked poly-ubiquitin chains
A, The effect of Triad1 on free ubiquitin chain formation by the Ubc13-Mms2 complex is tested at 
different concentrations of Triad1 using an a-ubiquitin antibody. The results show a catalytic effect of 
Triad1 on poly-ubiquitin chain formation. Note that at concentrations higher than 150nM Triad1, Triad1 
has an auto-inhibitory effect on the reactions.
B, The conjugation of poly-ubiquitin chains in rabbit reticulocyte fraction IIA was tested using recom­
binant wild-type ubiquitin and ubiquitin containing only lysine 48 (K48-Ub), only lysine 63 (K63-Ub) or 
no lysines at all (K0-Ub). Ubiquitin was added to Fraction IIA in the presence of increasing amounts of 
purified His-Triad1 and incubated for 1 hour at 370C. Western blot analysis of the samples, using an 
antibody that recognizes only poly-ubiquitinated proteins, indicated that Triad1 promotes the assembly 
of different poly-ubiquitin chains linked via both lysine 48 and 63 of ubiquitin. The band seen in the left 
lanes of the two right hand side panels are likely caused by E2/E3 contaminants present in the K48-Ub 
and K63-Ub mixtures because they are generated independently of Triad1 and are not seen in the lanes 
in which wild type and K0-Ub are used (see left lanes of the two left hand side panels).
The same blot was restained with an a-Triad1 antibody and did not detect high molecular bands. This 
indicated that the detected poly-ubiquitinated proteins are not ubiquitinated forms of Triad1. Ponceau- 
red staining was used to check the loading of His-Triad1. Staining with an antibody recognizing single 
ubiquitin moieties showed the presence of equal amounts of the wild type and mutant ubiquitin.
(supplemental Figure 2). We conclude that Triadi binds two different ubiquitin conju­
gating enzymes. The N-terminal RING domain interacts with UbcH7. The C-terminal RING 
domain is essential for the interaction between Triadi and Ubci3.
Triad! catalyses both K48 and K63 linked poly-ubiquitination
To test the functionality of the interaction between Triadi and Ubci3-Mms2 we 
performed in vitro ubiquitination assays with purified Ubai (Ei), Ubci3-Mms2 (E2), Triadi 
(E3) and ubiquitin. As expected, the Ubci3-Mms2 complex is capable of forming ubiquitin 
chains without the presence of an E3 ubiquitin ligase(27). Four independent assays showed 
that Triadi is enhancing free poly-ubiquitin chain formation above background at i5omM 
(Figure 6A, representative assay), indicating that the Ubci3-Mms2-Triadi complex is a 
functionally active complex. Remarkably, at higher Triadi concentrations we observed 
auto-inhibition of the ubiquitination reactions.
In addition to the direct in vitro interaction with Ubci3-Mms2, Triadi interacts 
with both UbcH7 and Ubci3 in cell line lysates. UbcH7 has been implicated in K48 linked 
poly-ubiquitination and Ubci3 in K63 linked poly-ubiquitination. Using in vitro ubiqui- 
tination assays we tested whether both types of ubiquitin modifications are catalyzed 
by Triadi. Increasing amounts of purified His-Triadi were incubated with rabbit retic­
ulocyte fraction IIA (enriched in E i and E2 activity and devoid of ubiquitin and prote- 
asome activity (8)) in the presence of different recombinant ubiquitin mutants. Reaction 
mixtures were resolved by Western blotting and stained with an antibody that recognizes 
only poly-ubiquitinated proteins (Figure 6B). When incubated with wild-type ubiquitin, 
we observed a Triadi dependent increase in poly-ubiquitinated proteins. Restaining of 
the same blot with an a-Triadi antibody indicated that these poly-ubiquitinated proteins 
are not Triadi. As expected, no Triadi mediated poly-ubiquitination could be detected
Figure 7, RING1 and RING2 of Triad1 are essential 
for clonogenic inhibition of U937 cells
U937 cells were transduced with full length Triadi and 
indicated deletion constructs. The MACS sorted cells 
were seeded in semi-solid medium and the number 
of colonies were analyzed after 7 days. Clearly visible 
is that deletion of the RING1 or RING2 domains abol­
ishes the Triad1 induced inhibition of clonogenic 
growth. Deletion of the coiled coils or the DRIL domain 
had no effect on the clonogenic inhibition of Triadi.
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using Ko ubiquitin, which is devoid of lysine residues. To test whether Triadi can catalyze 
the formation of Ub chains linked through K48 or K63, we used recombinant ubiquitin 
carrying only one lysine residue at position 48 (K48-Ub) or at position 63 (K63-Ub). Our 
results show that Triadi can catalyze the formation of Ub chains linked through both K48 
and K63. Remarkably, the patterns of modification differ between wildtype, K48 and K63 
ubiquitin.
The RING fingers o f Triadi are essential for clonogenic inhibition while other domains 
are dispensable
Earlier we showed that Triadi inhibits hematopoietic cell growth. N-terminal 
RING finger point mutations in Triadi that abrogate the UbcH7 interaction did not inhibit 
cell growth. To further study the relevance of the conserved domain of Triadi with regard 
to its growth inhibitory function, we tested various deletion mutants (Figure iA ) in clono­
genic assays. U937 cells were transduced with viruses expressing the deletion mutants, 
subsequently MACS sorted and seeded in semi-solid medium. Five to seven days later 
colonies were counted (Figure 7). As expected, wild type Triadi inhibited U937 colony 
formation by over 50% compared to GFP and empty vector transduced cells. The deletion 
of one or both coiled coil domains had no effect on the Triadi-induced inhibition of clono­
genic growth. Also the Triadi mutant lacking the conserved DRIL domain inhibited the 
clonogenic growth equally well as the wild type Triadi. Deletion of the N-terminal RING 
finger completely abrogated the growth inhibitory effect of Triadi in these colony assays. 
This was not unanticipated because earlier experiments showed that an intact N-terminal 
RING finger is required for the growth inhibition of Triadi(9). Deletion of the Ubci3 inter­
acting RING2 domain also completely abolished the observed clonogenic inhibition of 
Triadi. The latter finding is in line with data from earlier competitive liquid growth studies 
in which the RING2 deletion mutant was used(i9). Together, these data show that both 
RING fingers of Triadi are important for its function in the control of myeloid cell prolif­
eration while other domains are not required. Because the C-terminal RING finger is 
required to inhibit proliferation, interacts with Ubci3 and because Triadi functions as a 
dual ubiquitin ligase (see Figure 6) these data strongly suggest that non-canonical ubiqui- 
tination is important for the role of Triadi in myelopoiesis.
Discussion
Proteins can be modified in various ways with poly-ubiquitin chains. The type of 
chain determines the fate of the marked protein. Proteins that are conjugated with poly- 
ubiquitin chains linked through lysine 48 of ubiquitin are marked for rapid proteasomal 
degradation. In contrast, poly-ubiquitin chains linked through lysine 63 of ubiquitin do 
not mark proteins for degradation. Instead, they are often used to recruit other proteins 
to activate biological processes like for instance signal transduction pathways(2). Hema- 
topoiesis is controlled by both lysine 48 and lysine 63-linked poly-ubiquitination. Altera­
tions in both forms of ubiquitination disturb hematopoiesis and have been implicated 
in malignant transformation. Triadi is an E3 ubiquitin ligase that controls the prolifer­
ation of myeloid cells(9). Triadi is the first identified member of an unique set of ubiquitin 
ligases that contain two RING finger domains(28, 29). RING domains are known to mediate 
E2 ubiquitin conjugating enzyme interactions. We show here that the N-terminal RING 
finger (RINGi) of Triadi binds UbcH7 and that the C-terminal RING finger (RING2) binds 
Ubci3 (Figures iB  and C). In conjunction with E3 ligases, UbcH7 is known to catalyze the 
formation of lysine 48-linked poly-ubiquitin chains and Ubci3 can catalyze non-canonical 
lysine 63 poly-ubiquitin chains. In line with the interactions, Triadi was found to catalyze 
the formation of both types of poly-ubiquitin chains in in vitro ubiquitination experi­
ments (Figure 6B). Our finding that different ubiquitin mutants result in distinct patterns 
of poly-ubiquitination, may suggest that Triadi marks different substrates with different 
ubiquitin chains. The N-terminal RING finger domain in TRIAD proteins shows struc­
tural similarity with the classical RING domain as found in other, single RING ubiquitin 
ligases(30). For many TRIAD proteins RINGi has been shown to interact with UbcH7(9, 
3i-33). The C-terminal RING finger (RING2) that binds Ubci3 has a different topology as 
compared to the classical RING finger(3<0 34). RING2 is exclusively found in TRIAD proteins 
and the different topologies of the two RINGs may explain the differential binding to the 
E2 conjugating enzymes. Earlier we showed that the growth inhibitory function of Triadi 
could be partially restored by proteasome inhibition. This suggests that Triadi functions 
in part by marking proteins for proteasomal degradation. The functional interaction with 
Ubci3 (Figure 5 and 6A) suggests that Triadi may also mark proteins with ubiquitin in a 
non-proteolytic manner. Recent studies showed that the C-terminal RING domain of the 
TRIAD protein Parkin also binds Ubci3. In addition, Parkin can mark cellular proteins with 
lysine 63-linked ubiquitin chains that trigger their intracellular transport but not protea­
somal degradation(24, 37-38). Although lysine 63-linked ubiquitination of cellular proteins
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catalyzed by Triadi needs to be identified, the U bci3 interacting domain is crucial for the 
growth inhibitory function of Triadi. This is an interesting observation as U bci3 is known 
to play very important roles in immune receptor signaling and inflammatory responses. 
The function of U bci3 in these processes mainly occurs in the cytoplasm. Yet, U bci3 plays 
also important roles in nuclear processes including DNA repair. In hematopoietic cells 
Triadi is a predominantly nuclear protein (Figure 2B)(9). We show here that UbcH7 and 
U bci3 co-localize with Triadi in the nucleus (supplemental Figure 2). Thus, Triadi may 
mark nuclear proteins with ubiquitin to control blood cell proliferation. Unlike the RING 
fingers, other conserved domains in Triadi like the DRIL and the coiled coil domains were 
not necessary to inhibit proliferation. This was somewhat unanticipated because we 
expected the coiled coils to be involved in recruiting substrates to be ubiquitinated by 
the RING domains of Triadi. Apparently, the coiled coil domains are dispensable for the 
function of Triadi in myeloid cells. These data underscore the importance of the RING 
domains and suggest that the RINGs may recruit substrates themselves in addition to 
binding ubiquitin conjugating enzymes. Together with studies on Parkin(24, 37, 39, 40), our data 
suggest that members of the TRIAD family of ubiquitin E3 ligases may have the ability to 
catalyze multiple types of ubiquitin chains by interacting with different E2 conjugating 
enzymes. The fact that the TRIAD domain is heavily conserved and that RING2 is only 
found together with the other RING domain suggests that these modules act together 
and are required for an integrated function. Future studies should clarify whether the 
different ligase functions of Triadi are used to differentially ubiquitinate substrates with 
different types of ubiquitin chains, whether one and the same substrate is modified with 
different types of ubiquitin chains, or whether they are used to mediate the conjugation 
of mixed ubiquitin chains(i6, i7, 4i).
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Summary
Hematopoiesis is a tightly regulated process of proliferation and differenti­
ation that provides the body with sufficient numbers of functional blood cells. A combi­
nation of extrinsic (e.g. growth factors) and intrinsic (transcription factors) signals 
control the development of the hematopoietic stem cell (HSC) towards mature blood 
cells. Growth factor independence 1 (Gfii) is a transcriptional repressor that plays a 
crucial role throughout hematopoiesis. The Gfii protein controls HSC proliferation but 
is also involved in differentiation of cells of both the myeloid and lymphoid lineage. 
Furthermore, the Gfii protein is implicated in activation of B and T lymphocytes. Because 
G fii plays such an important role in hematopoiesis, proper expression and function of 
G fii is crucial for the normal development of blood cells. Indeed, patients that carry a 
mutation in the coding region of the G fii gene suffer from severe neutropenia.
While the biological role and molecular mechanism of Gfii function have been 
studied extensively, the factors that control cellular Gfii levels have received far less 
attention. Few, but important transcription factors have been identified that control 
G fii mRNA expression (e.g. P53 and Pu.i). Furthermore, Gfii expression is regulated by 
various cytokines, including IL-7 and G-CSF, although the molecular mechanism that 
underlies this regulation is often not fully understood. Cellular protein levels are not only 
controlled by the level of mRNA expression but are the result of the balance between 
production and degradation. The post-translational process of protein ubiquitination is 
critically involved in the regulation of protein stability.
Ubiquitination, the covalent attachment of one or more ubiquitin peptides 
on a substrate protein, was originally identified as a degradation signal that targets 
the substrate for proteasomal degradation. Nowadays, ubiquitination is regarded as a 
more general signaling molecule that, depending on the type of modification, can lead 
to degradation but may also affect the substrates function or localization. Through the 
subsequent action of ubiquitin activating (Ei), conjugating (E2) and ligase (E3) enzymes 
a substrate protein can be marked with one ubiquitin (mono), single ubiquitin peptides 
on multiple positions (multi-mono) or one or more ubiquitin chains (poly). Mono-ubiqui- 
tination is generally regarded as a functional modification, providing an interaction site 
for other proteins that can affect the function or localization of the substrate. Although 
cystein residues can be used, ubiquitin is usually coupled to lysine residues of the 
substrate. Similarly, one of the seven lysine residues within the ubiquitin protein can be 
used to couple a subsequent ubiquitin. In this way poly-ubiquitin chains can be formed.
Poly-ubiquitination may result in different outcome, depending on the lysine residue 
within ubiquitin that is used for poly-ubiquitination. Most of the ubiquitin chain types are 
recognized by the proteasome and thus serve as a degradation signal. Some chain types 
serve as an interaction site for other proteins, similar to mono-ubiquitin modifications.
Although many studies have focused on the G fii protein and its role in the 
various subsets of hematopoiesis, the control of Gfii expression levels is not fully under­
stood. Here a novel regulatory mechanism is presented that controls G fii protein levels. 
In chapter 2 G fii is identified as a substrate for protein ubiquitination. The protein ubiqui- 
tination that is described, controls the half-life of the Gfii protein. Interestingly, differ­
ential turn-over rates are used to control Gfii protein levels during myelopoiesis. In 
immature myeloid progenitors, Gfii protein levels are below detection limits, despite high 
mRNA levels. Experiments using proteasome inhibitors showed that the G fii protein is 
synthesized but rapidly degraded in these immature cells. Upon differentiation towards 
monocytes, the Gfii degradation is diminished resulting in an increase in protein levels. 
As G fii is known to repress its own promoter, this accumulation of protein is accompanied 
by a decrease of Gfii mRNA. Chromatin immunoprecipitation experiments showed that 
Gfii is present on the promoter of granulocyte specific genes. The binding of transcrip­
tional repressor G fii is correlated with a low expression of these genes in monocytes as 
compared to granulocytes. Thus, apart from identifying protein ubiquitination as a regu­
latory mechanism that controls Gfii protein levels during myeloid differentiation, this 
study defines a previously unidentified role for G fii in monocytes.
As protein ubiquitination plays such a crucial role in regulating Gfii protein levels, 
further understanding of the molecular mechanism that facilitates G fii ubiquitination 
is essential. In chapter 3 the minimal domain that is required for Gfii ubiquitination is 
defined. The G fii protein consists of a N-terminal repressor domain and six C-terminal 
Zinc (Zn) finger domains. An intermediate domain separates the repressor domain from 
the Zn fingers. A large number of Gfii mutants were tested in a combination of in vitro 
and cell based assays to identify the most C-terminal Zn finger domain as essential for 
ubiquitination and degradation of the Gfii protein. Deletion of this domain did not affect 
its DNA binding nor its repressive function but almost completely abolished Gfii protein 
ubiquitination. As a result, loss of the C-terminal Zn finger domain yielded a highly stable 
protein in both in vitro degradation assays and in transfection experiments. This is in 
sharp contrast to the wildtype G fii protein and other mutants, that are rapidly degraded 
in these assays. Although the C-terminal Zn finger is essential for G fii ubiquitination and
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degradation, it is not sufficient to target other proteins for degradation. Furthermore, 
mutation of the two lysine residues that discriminate the most C-terminal Zn finger 
domain from the others did not yield a stable protein. Together, this study identifies the 
most C-terminal Zn finger domain as a context dependent degradation signal that is 
required for proper G fii protein turn-over.
Although the previous chapters clearly define an important role for the ubiquitin- 
proteasome route in the regulation of G fii protein levels, the components that contribute 
to this regulation are not known. Protein ubiquitination requires subsequent action of Ei, 
E2 and E3 enzymes. The E3 ubiquitin ligase provides specificity to the pathway as it serves 
as a scaffold that joins the E2-ubiquitin complex and the substrate protein. Triadi is an 
ubiquitin ligase that is induced during myeloid differentiation. The experiments discussed 
in chapter 4 identify Triadi as a regulator of Gfii ubiquitination. Both yeast-two-hybrid 
and co-immunoprecipitation experiments identify Triadi as a Gfii interacting protein. 
The initial hypothesis that Triadi serves as the ubiquitin ligase that facilitates Gfii ubiqui­
tination was rejected as a result of the finding that co-expression of Triadi inhibits Gfii 
ubiquitination. As a result of this inhibition, Gfii protein levels increase upon expression 
of Triadi. Forced expression of Triadi slowed cell proliferation to a similar extent as 
expression of Gfii itself. While mutation of the Gfii interacting domain of the Triadi 
protein abolished the observed inhibition of ubiquitination, the inhibition did not depend 
on the E3 ligase activity of Triadi nor on proteasome function. These data suggest that 
Triadi competes for Gfii binding with an unknown ubiquitin ligase and thereby controls 
Gfii ubiquitination and degradation.
Although the ubiquitin ligase function of Triadi is not required to inhibit Gfii 
degradation, this enzyme has the unique intriguing property of containing two distinct 
ubiquitin ligase domains, called RING domains. Many proteins contain a RING domain 
that is homologous to the N-terminal RING in Triadi and most of these proteins exhibit 
ubiquitin ligase activity. The second, C-terminal RING domain of Triadi has a different 
structure as compared to the first RING domain. Although the C-terminal RING structure 
can be found in other proteins, it is only found in conjunction with the classical RING 
domain, separated by a conserved cystein-histidine rich domain termed DRIL/IBR. 
Chapter 5 describes a set of experiments that suggest that each RING domain in the 
Triadi protein serves a different function. The N-terminal RING specifically binds the E2 
conjugating enzyme UbcH7, while the C-terminal RING binds the E2 Ubci3. Interestingly, 
these E2 enzymes are known to serve different functions. UbcH7 catalyzes the formation
of lysine (K) 48 linked poly-ubiquitin chains that serve as a degradation signal. Ubci3 is 
the only known E2 that catalyzes K63 linked ubiquitin chains. These K63 chains are not 
recognized by the proteasome but are regarded as a functional modification. In line with 
the interactions with the two E2 enzymes, Triadi is capable of catalyzing both types of 
poly-ubiquitin chains. Forced expression of Triadi in myeloid progenitor cells strongly 
reduces the proliferation rate of these cells. While other domains are dispensable, 
deletion of either one of the RING domains completely abolishes this effect. Together, 
these data suggest that Triadi functions as a ubiquitin ligase that is capable of catalyzing 
multiple types of poly-ubiquitin chains and that both the UbcH7 and Ubci3 mediated 
chain formation is required for proper Triadi function.
Concluding remarks and discussion
G fii is a nuclear protein that primarily functions as transcriptional repressor. 
Although many studies have provided insight in the broad role of G fii in hematopoiesis, 
including the molecular mechanism that underlies its function, little is known about 
the regulation Gfii itself. It is clear that expression of the G fii gene is controlled by a 
number transcription factors, including Gfii itself, and that transcription may be regu­
lated by growth factors and cytokines. Both the detection of Gfii mRNA and the use of a 
Gfii:GFP knockin model, where GFP is expressed under control of the G fii promoter, have 
played an important part in elucidating the role of G fii in specific cell lineages. Based on 
expression analysis and supported by other experimental evidence Gfii is now recog­
nized as a key player in the process of proliferation and differentiation throughout hema­
topoiesis. Loss of function mutations in Gfii are found in patients suffering from severe 
congenital neutropenia*. The finding that mice that lack a functional copy of the Gfii gene 
are also neutropenic2;3 puts Gfii in a central position in the process of myeloid differenti­
ation, in particular granulopoiesis.
A role for G fii in monocytes
Despite the fact that both monocyte derived DCs and macrophages are 
abnormal in Gfii knockout mice, there are no studies on Gfii function in monocytes 
reported. This lack of interest may in part caused by the finding that while Gfii mRNA 
levels increase upon granulocytic differentiation, the levels decrease strongly during 
monocytic development. This suggests that the G fii protein is not present in monocytes, 
and therefore cannot be of great importance. As can be concluded from the experiments
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described in chapter 2, the detection of mRNA is not sufficient to predict a role for the 
G fii protein, as G fii protein levels do not always correlate with mRNA expression levels. 
Despite the presence of high mRNA levels, the ubiquitination and rapid turnover of the 
G fii protein in immature myeloid cells strongly decrease the protein levels. In mature 
monocytes, G fii ubiquitination in halted and protein levels increase. It was found that 
mRNA levels decrease during the process of monocytic development, possibly as a result 
of autoregulation. The functional consequence of this regulation is not yet fully under­
stood. In mature monocytes, the G fii protein is present on the promoter of genes that 
are implicated in granulocytic differentiation, suggesting a role for Gfii in suppression of 
a granulocytic development program in monocytes. The observation that a population 
of cells with both monocytic and granulocytic markers accumulates in Gfii-null mice2;3 
may be, at least in part, explained by aberrant differentiation of monocytes due to loss 
of repression of the granulocytic program. Future studies that for example make use of 
RNAi to inhibit G fii expression during monocytic differentiation, are required to support 
this hypothesis.
Why this energy consuming regulatory mechanism of protein assembly and 
subsequent degradation has developed during evolution, is currently unknown. Perhaps 
the turnover of the Gfii protein by the strongly regulated process of ubiquitination 
provides an escape mechanism for rapid accumulation of G fii protein. A similar mech­
anism has been described for the tumor suppressor protein P53. This protein is rapidly 
cleared from the cell and only upon stress, the ubiquitination and degradation is halted, 
resulting in rapid accumulation of the P53 protein. This rapid induction of P53 protein 
provides the cell with adequate means to respond to potentially fatal stress conditions. 
Interestingly, preliminary results4 suggest that G fii protects against DNA damaged 
induced apoptosis. Together with the fact that Gfii is a direct transcriptional target of 
P53 in HSCs5, this suggests that P53 and G fii act in a common pathway and may together 
provide a tight balance between pro- and anti-apoptotic signals. Inhibition of degradation 
of Gfii will then provide the cell with a rapid response mechanism in order to restrain 
stress induced pro-apoptotic signals.
Regulation o f G fii ubiquitination
The studies described in this thesis define a role for ubiquitination in regulating 
G fii protein levels. The Zinc (Zn) finger region of Gfii, in particular the most C-terminal 
(6th) Zn finger is crucial for the ubiquitination and turn-over of the Gfii protein (chapters
2 and 3). Although this Zn finger domain is required, it is not sufficient for ubiquitination 
and degradation. This suggests that this domain serves as a binding site for an ubiquitin 
ligase that is responsible for the ubiquitination on lysine residues outside of this 6th Zn 
finger domain. The ubiquitin ligase that targets G fii for degradation is currently unknown. 
Several candidate ubiquitin ligases were selected based on interaction with G fii in yeast- 
two-hybrid studies6;7 and tested for their capability to catalyze Gfii ubiquitination but to 
date, none of the tested proteins was identified as the enzyme that targets G fii for degra­
dation (data not shown). Because ubiquitination plays such an important role in regu­
lating G fii protein levels during monocytic differentiation, the identification of the E3 
ligase remains a valid subject to study. Future studies may include additional yeast-two- 
hybrid experiments or the identification of proteins that are found in complex with Gfii 
using a mass-spectrometry approach.
The results presented in this thesis clearly implicate regulation of Gfii protein 
turnover in myeloid development. This automatically raises the question whether the 
ubiquitin-proteasome route is also involved in the control of G fii function in other hema­
topoietic lineages. G fii expression drives neutrophilic differentiation (chapter 1). In case 
of infection, a rapid increase in neutrophil numbers is essential. Rapid accumulation 
of Gfii protein by diminished degradation, possible induced by cytokine binding, may 
provide a fast mechanism of increasing neutrophil counts. Furthermore, as increased 
Gfii expression has been implicated in lymphoma development, diminished degradation 
of Gfii may contribute to malignant transformation. This suggests that the E3 ubiquitin 
ligase that targets G fii for degradation may function as a tumor suppressor. The data 
described in this thesis therefore warrant further study on the role of G fii turnover in 
other lineages.
Triadi inhibits Gfii ubiquitination
Triadi inhibits G fii ubiquitination and subsequent degradation. Based on the 
experiments described in chapter 4 we hypothesized that Triadi competes for Gfii 
binding with an unknown ubiquitin ligase. Triadi binds to the Zn finger region of Gfii. 
Although the interacting domain has not been mapped in greater detail, it is tempting to 
speculate that the binding region for Triadi (partly) overlaps the putative binding site in 
the most C-terminal Zn finger (chapter 3), resulting in mutually exclusive binding of Triadi 
and the unknown E3 ligase.
Triadi expression is induced during myeloid differentiation (8 and chapter 5). In
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monocytes, this induction coincides with an inhibition of G fii degradation (chapter 2). 
Based on these experiments described in chapter 4, it can be hypothesized that Triadi 
is responsible for the observed inhibition. The finding that forced expression of Triadi 
in myeloid cells results in increased Gfi1 protein levels further supports this hypothesis. 
Future experiments may clarify whether Triadi is indeed necessary and sufficient for 
the observed inhibition of Gfii degradation during monocytic differentiation. Triadi 
expression is also induced during granulocytic differentiation8. Here this induction is not 
followed by stabilization of the G fii protein. In contrast to in monocytes, the Gfii protein 
is rapidly degraded mature granulocytes. A possible explanation for the rapid turn-over 
of Gfii, despite the presence of the Triadi protein, may be that the proteins reside in a 
different nuclear compartment. Triadi localizes in the DAPI dull region of the nucleus 
in granulocytes8. Although it is not known where G fii localizes in granulocytes, its close 
homologue Gfiib localizes in the heterochromatin9, a region that is brightly stained with 
DAPI. If the localization of G fii is similar to that of GfiiB, Triadi and Gfii may not be able 
to interact due to spatial separation.
Another explanation why Triadi is not capable of inhibiting G fii degradation 
in granulocytes may be the absence of an essential cofactor. As discussed in chapter 1, 
protein ubiquitination is a complex process that often requires the formation of multi­
protein complexes and may involve other post-translational modifications. The regulation 
of G fii degradation by Triadi may also require additional modifications of Gfii. Mass- 
spectrometry analysis of ubiquitinated Gfii revealed the phosphorylation of two serine 
residues (unpublished observation). As phosphorylation can provide a signal to induce 
ubiquitinationi0, these two types of modifications may cooperate in inducing Gfii degra­
dation and expand the regulatory network that controls Gfii protein stability.
The biological function of Triadi
Triadi controls Gfii stability during monocytic differentiation. This control 
relies on a direct interaction between Triadi and G fii but is not dependent on prote- 
asome function. However, the inhibitory effect of Triadi on the proliferation of murine 
progenitor cells can, at least in part, be overcome by the addition of proteasome 
inhibitor8. This suggests that Triadi targets substrates for degradation. In chapter 5 is 
described that Triadi is capable of catalyzing multiple types of poly-ubiquitin chains. 
The lysine-48 linked chains target the substrate for degradation, while the K63-linked 
chains are known to serve non-proteolytic functions. It will be of great interest to identify
proteins that are marked with ubiquitin by Triadi. Identification of the substrates may 
provide insight into how Triadi regulates proliferation. In addition, further studies on 
the biological and biochemical functions of Triadi requires the use of substrate proteins. 
The characteristic TRIAD domain, comprised of the two (different) RING domains, sepa­
rated by the conserved DRIL/IBR domain can be found in a number of other proteins, 
including the well studied protein Parkinii;i2. Analogous to the findings reported in 
chapter 5 for Triadi, it has been described that the two RING domains in Parkin differ­
entially interact with multiple ubiquitin conjugating enzymesi3'i5. Although many binding 
partners of Parkin have been identified, including substrates for its ubiquitin ligase 
function, it remains unclear why Parkin or the other TRIAD family members contain two 
RING domains. Further studies are required to elucidate whether TRIAD proteins target 
the same substrate with different poly-ubiquitin chains or use their capacity to catalyze 
different chains on different substrates and how this is regulated.
The use of the different RING mutants described in this thesis may provide useful 
tools to address these questions. The two RING domains do not only differentially interact 
with ubiquitin conjugating enzymes but are also required to bind different substrates. The 
C-terminal RING domain required for the interaction with Gfii. Interestingly, preliminary 
data indicate that tumor suppressor protein P53 interacts with Triadi via the N-terminal 
RING domain (unpublished observations). As suggested above, Gfii and P53 may collab­
orate in control of stress induced apoptosis. It will therefore be of great interest to test 
whether Triadi can bind both G fii and P53 simultaneously or whether these interactions 
are mutually exclusive.
Overall conclusion and final remarks
Together, the data described in this thesis provide more insight into the regu­
lation of Gfii protein stability. Although many additional questions should be addressed 
for the complete understanding of regulation of Gfii turn-over, the data described here 
show that the ubiquitin-proteasome mediated degradation plays an important role in 
regulating Gfii protein levels during monocytic differentiation.
As G fii plays such an important role during hematopoiesis and deregulated 
G fii function may contribute to leukemia and lymphoma development, insight in the 
regulation of G fii protein levels is of great value. The ubiquitin-proteasome route has 
gained interest over the last decade as a potential drug targeti6. Inhibition of the prote- 
asome by chemical compounds has proven to be an effective strategy in the treatment
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of multiple myeloma. Although proteasome inhibition is associated with surprisingly mild 
side-effects a more delicate approach is preferred. As the substrate specificity of ubiqui- 
tination is introduced by the E3-substrate interaction, targeting this level of the pathway 
may be an obvious choice. Indeed, ongoing clinical trials evaluate the effect of P53 stabili­
zation on tumor cell proliferation and survival and using chemical compounds that disrupt 
the binding between P53 and the ubiquitin ligase MDM2i7'i9. This approach more specific 
and associated with less side-effects, this strategy may also target the non-proteolytic 
function of ubiquitination. Keeping in mind that ubiquitin modifications are involved in 
almost every crucial cellular process, this technology may expand the therapeutic options 
dramatically.
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0 15 30 60 Minutes incubation 
U937 lysate + DMSO
U937 lysate + proteasome inhibitor MG132
Figure S1: Gfi1 is rapidly degraded in U937 lysates in a proteasome dependent manner.
An in vitro degradation assay using 35S-labeled in vitro-translated Gfil incubated with U937 lysates 
at 37°C in the presence of vehicle, or the proteasome inhibitor MG132. At the indicated time points, 
samples were inactivated in loading buffer and resolved by SDSPAGE.
35S Gfil degradation assay
0 15 30 60
Minutes incubation
Figure S2: Deletion of the 6th Zn finger domain doubles Gfi1 half-life.
Three independent in vitro degradation assays were quantified using a phospho-imager. On average, 
Gfil half-life was doubled in these experiments
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FigureS3: The6thZn finger domain of Gfi1 is not required for transcriptional repression
Transient transfection assays in Hep3B cells testing repression by the indicated mGfil mutants on a 
GL4 luciferase reporter fused to dimerized Gfi1 consensus binding site. Data shown are the mean ± 
standard error of two experiments.
378 FGCDLCGKGFQRKVDLRRHRETQHGLK 4 23 Gf i1
FQKLL Huntingtin
FQNLF Androgen eeceptor
AQRAA Mutated Gfi1 sequence
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Figure S4: Identification of a putative degron in Gfi1.
Sequence alignment comparing the 6th Zn finger domain and degrons in Huntingtin and the Androgen 
receptor. The bottom line shows the mutations that were introduced to test the involvement of this 
putative degron in Gfi1 stability
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Znfingerl YKCIKCSKVFSTPHGLEVHVRRSH
Znfinger2 FACEMCGKTFGHAVSLEQHKAV-H
Znfinger3 FDCKICGKSFKRSSTLSTHLLI-H
Znfinger4 YPCQYCGKRFHQKSDMKKHTFI-H
Znfinger5 HKCQVCGKAFSQSSNLITHSRK-H
Znfinger6 FGCDLCGKGFQRKVDLRRHRETQHGLK
Figure S5: Sequence alignment of the Gfi1 Zn finger domains
The sequences of the indivi dual Zn finger domains of Gfi1 were aligned using ClustalW software. The 
non-conserved lysine residues in Zn finger 6 are indicated in red.
GFP GFP-Zn2 GFP-Zn4 GFP-Zn6
Figure S6: In vivo stability test of GFP-Zn fusions
A. Individual Zn finger domains were cloned in frame with GFP. A SV40 NLS was introduced at the 
N-terminal part of GFP to ensure nuclear expression. Hep3B cells were transfected with plasmids 
encoding the GFP-Zn finger showed a predominant nuclear staining.
B. HL60 cells were transfected and 40 hours later treated with 100|jg/ml cycloheximide (CHX). At indi­
cated timepoints cells were fixed by adding paraformaldehyde (2% final concentration) and GFP 
expression was measured by flowcytometry.
C. HL60 cells were transfected and 40 hours later treated with 100jg/ml cycloheximide 
(CHX) for the indicated times. Samples were resolved by SDS-PAGE and stained for GFP
Table 
S1: Sequence 
of 
prim
ers 
used 
to 
generate 
Gfi1 
m
utants
Primer forward Reverse Sequence (5'- 3') Location Used for mutant #
FW Gfi1 start * AAAAGCTTGCCACCATGCCGCGCTCATTCCTG At start of coding sequence 2, 4-8, 14, 15
Gfi 1 Ddegron *
T CATTT GAGTCCATGCT GAGT CTCTCGGTGCCTCCT 
GGCATCGGCGGCCCTCTGGGCGCCCTTCCCACAC At the C-terminus 14
Gfi 1 DZn6 * TTAGGGCTTGAAGCCTGTGTGC before Zn finger 6 8, 16
Gfi 1 Zn finger only * AAAAG CTTGCCACCATGT AC AAAT G C AT C AAAT G C At start of Zn finger 1 3
Gfi 1 Zn2 * CTCGAGTTTGCGTGCGAGATGTGC At start of Zn finger 2 15
Gfi 1 Zn4 * CTCGAGTATCCCTGTCAGTACT G At start of Zn finger 4 16
Gfi 1 Zn6 * CTCGAGTTTGGCTGTGACCT GT G At start of Zn finger 6 19
Gfi1-2KR *
T CATCGGAGTCCATGCT GAGT CT CTCGGTGCCTCCT 
GAGATCCACCCGCCTCTGGAAGCCCT At the C-terminus 15
GFP * GGAT CCAACT CGAGCTTGTACAGCTCGTCCAT G
At end of GFP deleting the 
stop codon 17-19
GFP-stop * GGATCCTTACTTGTACAGCTCGTCCATG At end of GFP 16
NLS-GFP *
AAGCTTGCCACCATGCCAAAGAAGAAACGAAAGGTG
AGCAAGGGCGAGGAG
At start of GFP introducing a 
nuclear localization signal 16-19
Rev DZn * AAGGATCCTCAGGAGCCGCCGCCCAGCAGCAGAC Before start of Zn finger 1 2
Rev Zn only * AAGGAT CCT CATTT GAGTCCATGCT GAGTC At end of coding sequence 3, 19
Rev Zn1 * AAGGATCCTCAGGGTCTTGTGCCGCTGTG Before Zn finger 2 4
Rev Zn1-2 * AAGGATCCTCAGCTGCGTTCCTGGGAG Before Zn finger 3 5, 17
Rev Zn1-3 * AAGGATCCTCAGGGCCGGGTGTCCGAGTG Before Zn finger 4 6
Rev Zn1-4 * AAGGAT CCT CAGGGCTT CT CACCTGTGT G Before Zn finger 5 7, 18
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NTA bead pull down 
WB a-Flag
P
Gfi1-(Ub)n
Gfi1-Ub
Flag-Gfi1 - + 
His-Ub + - 
Triad1 - -
+ +
+ +
- +
Figure S1: Triadl inhibits G fil ubiquitination.
Cells were transfected as indicated. Triadl inhibits 
poly-ubiquitination of Gfi1. Under these circum­
stances, the mono-ubiquitination of Gfil (arrowhead) 
was less affected by Triadl, indicating that Triadl 
predominantly inhibits the poly-ubiquitination of Gfil. 
(*) Marks non-specific interaction of Flag-Gfi1 with the 
beads.
120%
100%
80%
60%
40%
20%
0%
Figure S2: Triadl siRNAI and -2  downmodulate 
Triadl in HEK293 cells.
HEK293 cells were transfected with combinations of 
GFP-Triad1 with indicated siRNA constructs. 48 hours 
after transfection the mean fluorescence intensity 
(MFI) was measured by flow cytometer. The MFI of 
GFP-Triad1 transfected cells was set at 100%. Trans­
fection with siRNA developed against Triad1 or GFP 
resulted in downregulated GFP-Triad1 protein levels, 
while the control siRNA showed no significant effect 
on GFP-Triad1 levels.
*
W b u -Triad l
Triadi Triad1dR2
+  -  Triadi 
.  +  Triad1-dR2
Figure S3: Triadl and Triad1dR2 expression after 
retroviral transduction.
NIH3T3 cells were retrovirally transduced (trans­
duction efficiency >95% based on NGFR expression 
measured by flowcytometer) with Triad1 and 
Triad1dR2 encoding viruses. Two days after trans­
duction 400,000 cells were lysed and used in 
Western blotting and stained with an Triad1 antibody 
to demonstrate Triad1 and Triad1dR2 expression 
(samples were run on one and the same gel, the blot 
was scanned as a whole and non-relevant lanes were 
deleted)
178
Wb a-GfM (N20)
Gfi1
- Gfi1
+ Vector
Figure S4: Gfil expression after viral transduction 
to U937 cells.
U937 cells were retrovirally transduced with Gfil or 
control vector encoding viruses. 6 days after trans­
duction when a total of 15% of cells were Gfil positive 
as based on GFP positivity, 100,000 cells were lysed 
and used in Western blot to confirm Gfil expression 
(samples were run on one and the same gel, the blot 
was scanned as a whole and non-relevant lanes were 
deleted).
+
Figure S5: Atx-1 shows higher expression in granulocytes compared to monocytes.
Relative Atx-1 mRNA expression in primary monocytes and granulocytes. Atx-1 is 4-fold higher 
expressed in granulocytes compared to monocytes. Atx-1 expression was measured using a pre­
designed taqman gene expression assay and was GAPDH normalised. 3 paired samples of healthy 
volunteers were measured.
Name Sequence 5'-3'
ÂTRÏÂdFÂCÂTCCCÂTCCCCCTCÂCCÂCCTÂGGÂGÂTTGGÂÂGÂCTCÂTGGCÂGT
Atriadr atgagtcttccaatct c c t a g g t g g t g a g g g g g a t g g g a t g t g g g a a c 
Aringif acatcccatccc c c t c a c c a c c c a c t c c g t a c a c c a g a g g a c t t t g t g 
Aringir g t c c t c t g g t g t a c g g a g t g g g tggtgagggggatgggatgtg ggaac 
Ad rilf agtcattaccag c t c c a g c t g g c c a c a a t c c g g a a a t g g c t c a c g a a g 
Ad rilr g a g c c a t t t c c g g a t t g t g g c c agctggagctggtaatgactc tccac 
Ar i n g2f attagtgctcacactaaagac c t a g g a g a t t g g a a g a c t c a t g g c a g t 
Ar i n g2r atgagtcttccaatctcctag g t c t t t a g t g t g a g c a c t a a t g t a g t t 
Ac c i+2r tcgcgaattcttagatgtc a g g a t t c t c c t t g t a a c g
Table S1: Primer sequences to generate Triadi deletion mutants in sexual PCR.
Primer CC1+2R was used in regular PCR to introduce a stopcodon coding for Triadi lacking the two 
C-terminal coiled coil domains.
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Figure S1: Analytical gel filtration chromatogram shows that Triadl interacts with Ubc13-Mms2. Single 
protein runs are compared with the complex. Each run contained 40|jM Triadl and 40|jM Ubc13-Mms2 
and followed by coommassie staining. Twelve consecutive fractions ranging in elution volume from 0.85 
to 1.4 mL are loaded on gel (inset).
Figure S2: Localization of with GFP-Triad1 and UbcH7 
or FLAG-Ubch13 in co-transfected NIH3T3 cells. Triad1 
is present in the same cellular compartments as UbcH7 
and FLAG-Ubc13. DAPI staining was used to stain the 
Nucleus.
UbcH7 Ubc13
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Nederlandse samenvatting
Het bloed is cruciaal voor het leven van mensen en de meeste diersoorten. Dit 
gespecialiseerde "vloeibare" orgaan verzorgt het transport van voedings- en afval­
stoffen en is bij de meer ontwikkelde diersoorten betrokken bij wondheling en de afweer 
tegen ziekteverwekkers. Bij zoogdieren bevat het bloed verschillende types cellen: 
naast de rode bloedcellen (die voornamelijk betrokken zijn bij het zuurstoftransport) 
en de bloedplaatjes (die een cruciale rol spelen bij de bloedstolling) maakt het lichaam 
een groot aantal verschillende types witte bloedcellen, elk met hun eigen specifieke 
rol bij de afweer. Omdat de levensduur van bloedcellen betrekkelijk kort is, vereist ons 
lichaam voor correct functioneren een constante aanmaak van nieuwe bloedcellen. Deze 
aanmaak, hematopoiese genaamd, vindt plaats in het beenmerg waar door een proces 
van celvermeerdering (proliferatie) en specialisatie (differentiatie) een zeer onrijpe 
stamcel uitgroeit tot de enorme hoeveelheden zeer gespecialiseerde bloedcellen die ons 
lichaam nodig heeft (figuur 1, hoofdstuk 1).
Fouten tijdens de hematopoiese, meestal veroorzaakt door een beschadiging 
van het erfelijk materiaal, het DNA, kunnen leiden tot een tekort aan functionele bloed­
cellen, maar ook tot de vorming van afwijkende cellen. Dit is het geval bij leukemie, 
bloedkanker. Bij patiënten die lijden aan leukemie is het proces van differentiatie en 
proliferatie verstoord. Door een blokkade in de differentiatie kan een cel niet volledig 
uitrijpen tot een functionele bloedcel. Omdat in het geval van leukemie deze cel niet snel 
afsterft of wordt opgeruimd, leidt dit tot een ophoping van onrijpe cellen, eerst in het 
beenmerg, maar later ook in het bloed. De onrijpe cellen verdringen de normale cellen 
uit het beenmerg waardoor de patiënt niet alleen een ophoping krijgt van het afwij­
kende celtype, maar ook een gebrek aan de andere bloedcellen. Dit kan zich uiten in 
vermoeidheid (veroorzaakt door een gebrek aan rode bloedcellen), infecties (als gevolg 
van een tekort aan witte bloedcellen) en stollingsproblemen (vanwege een gebrek aan 
bloedplaatjes in combinatie met de totaal afwijkende bloedsamenstelling).
U begrijpt, het is essentieel dat hematopoiese een strak gereguleerd en gecon­
troleerd proces is. Cruciaal hierin is, dat de cel weet welk deel van haar erfelijk materiaal 
zij moet gebruiken. Het DNA van iedere cel in ons lichaam is gelijk, en het feit dat een 
bloedcel anders is dan een zenuwcel of huidcel, ligt in het gebruik van een ander deel 
van het DNA, het gebruik van andere genen. Deze genen vormen de blauwdruk voor 
de productie van eiwitten, belangrijke bouwstoffen voor de cel. De activatie en inacti- 
vatie van genen wordt voor een belangrijk deel bepaald door de zogenaamde transcrip-
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tiefactoren. Deze moleculen, een van de vele soorten eiwitten, kunnen door binding 
op bepaalde posities op het DNA het gebruik van een gen promoten of juist blokkeren. 
Hiermee bepalen de transcriptiefactoren voor een belangrijk deel de samenstelling van 
de bouwstoffen en daarmee het uiterlijk en de functie van een cel. Inmiddels is van een 
groot aantal weefsels bekend welke transcriptiefactoren een rol spelen bij de vorming of 
het functioneren van de cel of het orgaan. Zo ook bij de bloedcelvorming.
Een eiwit genaamd "Growth factor independence 1" (Gfii) is een transcrip- 
tiefactor die essentieel is voor de vorming en functie van een uitzonderlijk groot aantal 
verschillende witte bloedcellen. Deze stelling wordt onderbouwd door het grote aantal 
afwijkingen dat is gevonden in dieren die na manipulatie in het laboratorium geen func­
tioneel G fii kunnen maken. Daarnaast wordt ook bij de mens het ontstaan van bepaalde 
bloedafwijkingen toegeschreven aan een defect G fii (dit is uitgebreid beschreven in 
hoofdstuk 1).
In dit proefschrift is beschreven hoe de aanwezigheid van Gfi1 is gereguleerd. De 
hoeveelheid van een bepaald eiwit in de cel wordt bepaald door verhouding van aanmaak 
en afbraak van dat eiwit. De focus van het onderzoek beschreven in dit proefschrift, ligt 
op de afbraak. Dit lijkt misschien verrassend, maar in de cel wordt niet alleen de aanmaak 
van eiwit gereguleerd, ook de afbraak is een gecontroleerd proces. Een complexe machi­
nerie is in de cel aanwezig die via een opeenvolging van stappen (figuur 5, hoofdstuk 1) 
de eiwitten markeert met een label, ubiquitine genaamd, zodat het kan worden herkend 
door het recycling station van de cel, het proteasoom. Het proteasoom breekt het gela­
belde eiwit af in kleine stukken, die vervolgens weer kunnen worden hergebruikt. Deze 
samenstelling van componenten die deze labelling, ubiquitinering, verzorgen, is uniek 
voor bijna ieder eiwit. Hiermee kan onderscheid gemaakt worden tussen eiwitten en kan 
eiwit A in de cel al binnen enkele minuten worden afgebroken, terwijl eiwit B in dezelfde 
cel een levensduur van enkele uren tot dagen kan hebben. Deze gecontroleerde afbraak 
stelt de cel in staat om op een hele korte termijn alle eiwitten van een bepaald proces op 
te ruimen om daarmee zich snel aan te passen aan een veranderde omgeving of vraag 
in activiteit. In hoofdstuk 2 is beschreven dat de regulatie van de afbraak van Gfi1 een 
belangrijke rol speelt bij de keuze tussen uitrijping tot monocyt of granulocyt, twee 
verschillende types witte bloedcellen. In de onrijpe voorlopercel wordt het Gfi1 eiwit wel 
gemaakt, maar direct weer afgebroken, waardoor de totale hoeveelheid Gfi1 eiwit in de 
cel bijna niet is aan te tonen met de beschikbare methodes. Ook bij de uitrijping naar 
granulocyt blijft de afbraak de aanmaak overheersen. Echter, wanneer de voorloper
cellen gedwongen worden tot monocyt te differentiëren, stijgt de hoeveelheid Gfi1 in de 
cel. Dit is echter niet het gevolg van een versterkte aanmaak, maar juist een sterk vermin­
derde afbraak zorgt ervoor dat de totale hoeveelheid Gfi1 stijgt. De cel gebruikt dus met 
name de afbraaksnelheid om het niveau van eiwitten, in dit geval Gfi1, te reguleren.
De grote vraag is nu natuurlijk: hoe doet de cel dit? In hoofdstuk 3 wordt bekeken 
of er iets bijzonders te vinden is aan het eiwit Gfi1 dat zorgt voor de snelle afbraak. 
Hoewel Gfi1, net als veel andere eiwitten, is opgebouwd uit een lange aaneengesloten 
rij bouwstenen (aminozuren), zijn binnen de keten toch verschillende delen te onder­
scheiden die een eigen functie hebben. Zo zijn bij Gfi1 delen (domeinen) aan te wijzen die 
verantwoordelijk zijn voor de interactie met het DNA en is er een domein dat voor een 
belangrijk deel bepaalt hoe Gfi1 zijn sturende functie uitoefent (figuur 2, hoofdstuk 1). 
Door steeds fragmentjes uit het eiwit weg te laten en vervolgens te kijken of het eiwit nog 
steeds wordt afgebroken of meer stabiel is geworden, is geprobeerd dat deel te vinden 
dat verantwoordelijk is voor de afbraak van Gfi1. Wij hebben ontdekt dat een klein deel 
van het eiwit, waarvan de functie nog niet bekend was, essentieel is voor de afbraak. 
Met andere woorden: als dat deel mist, wordt het eiwit niet meer afgebroken. De resul­
taten van de proeven wijzen erop, dat dit deel hoogstwaarschijnlijk fungeert als herken­
ningspunt voor eiwitten die de ubiquitinering en daarmee de afbraak van het Gfi1 eiwit 
aansturen. Welke eiwitten verantwoordelijk zijn voor de ubiquitinering van Gfi1, was 
echter niet bekend. Het in ons laboratorium voor het eerst beschreven eiwit Triad1 bleek 
een interessante kandidaat. Triad1 is een zogenaamde ubiquitine ligase, een eiwit dat 
ubiquitine kan koppelen aan het doel-eiwit en het zo kan markeren voor afbraak. Triad1, 
waarvan bekend is dat het een belangrijke rol speelt bij de uitrijping van granulocyten en 
monocyten, kan een interactie aangaan met Gfi1. In hoofdstuk 4 wordt beschreven dat 
in tegenstelling tot wat verwacht was, deze interactie van Triad1 met Gfi1 juist zorgt voor 
een verminderde ubiquitinering van Gfi1, en daarmee de afbraak remt. Door gebruik te 
maken van een defect eiwit, dat nog wel kan binden aan Gfi1, maar niet meer in staat is 
om eiwitten te ubiquitineren, hebben we laten zien dat slechts binding voldoende is voor 
deze bescherming. Hieruit volgt de theorie dat Triad1 andere eiwitten, die verantwoor­
delijk zijn voor de ubiquitinering van Gfi1, verdringt, en zo Gfi1 beschermd voor afbraak.
Hoewel het proces van ubiquitinering vooral bekend is vanwege de rol bij de 
afbraak van eiwitten, wordt er steeds meer bekend over een alternatieve functie van 
het ubiquitine label. De afbraak van eiwitten, waaronder Gfi1, wordt gestuurd door het 
markeren van het eiwit met een keten van ubiquitine. Wanneer deze keten de juiste
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lengte en samenstelling heeft, wordt ze herkend door het proteasoom, en wordt het 
gelabelde eiwit afgebroken. Het labellen van eiwitten met slechts 1 ubiquitine, of met 
een korte keten of een keten met een afwijkende samenstelling leidt echter niet tot 
afbraak. Deze vorm van ubiquitinering heeft in de recente jaren bijzonder veel aandacht 
gekregen. Zo is bekend geworden dat belangrijke processen in de cel, zoals bijvoorbeeld 
de reparatie van beschadigd DNA, worden gecontroleerd door deze alternatieve vorm 
van ubiquitinering. Bij deze vorm van ubiquitinering zijn dan ook weer andere eiwitten 
betrokken dan bij de labelling voor afbraak. Triad1 en eiwitten die sterk op Triad1 lijken, 
de TRIAD familie, vormen echter een uitzondering. Een aantal van de TRIAD familieleden 
is in staat meerdere types, vaak afwijkende ubiquitine ketens te vormen. In hoofdstuk 5 
wordt beschreven dat Triad1 in staat is om meerdere soorten ubiquitine ketens te maken. 
Triad1 maakt zowel ketens die betrokken zijn bij afbraak, als ketens die niet worden 
herkend door de afbraak machinerie, maar kunnen zorgen voor bijvoorbeeld activatie of 
inactivatie van eiwitten. Door opnieuw gebruik te maken van partieel defecte vormen van 
Triad1, hebben we aanwijzingen dat de vorming van beide type ketens essentieel is voor 
een correcte functie van het Triad1 eiwit.
Samenvattend hebben we laten zien dat regulatie van de snelheid 
van afbraak van de belangrijke transcriptie factor Gfi1 voor de cel een belang­
rijke manier is om de functie van dit eiwit te controleren. De aanwezigheid van de 
ubiquitine ligase Triad1 is een belangrijke factor voor de regulatie van de afbraak van Gfi1. 
Omdat Triad1 betrokken is bij ubiquitinering die kan leiden tot zowel afbraak als veran­
dering van functie, is het nog niet precies duidelijk op welke manier Triad1 is betrokken 
bij de regulatie van Gfi1 afbraak en daarmee de functie. Het is waarschijnlijk dat Triad1 
betrokken is bij de regulatie van andere eiwitten, naast Gfi1. Wat de exacte functie is van 
Triad1 en waarom, en in welke gevallen Triad1 de verschillende vormen van ubiquitinering 
gebruikt, is onduidelijk. Onbekend is welk eiwit wel verantwoordelijk is voor ubiquiti­
nering en afbraak van Gfi1. Onderzoek dat op dit moment wordt uitgevoerd in het labora­
torium hematologie van het Radboud ziekenhuis hoopt antwoorden te vinden op deze en 
andere vragen.
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Dankwoord
Het cliché "promoveren doe je niet alleen" is niet waar. Alleen de promovendus 
zal bij een geslaagde afronding een nieuwe titel krijen. Alle anderen die hebben bijge­
dragen aan het onderzoek waarop de kandidaat promoveert zullen genoegen moeten 
nemen met plaatsvervangende trots bij de promotie en met de vermelding in het dank­
woord van het proefschrift. Niet voor niets is dit deel daarmee een van de belangrijkste 
onderdelen van het proefschrift, en zeker het meest gelezen.
Ook bij mijn onderzoek zijn heel veel mensen in meer of mindere mate 
betrokken geweest. Velen hebben direct meegeholpen door proeven te doen, mee te 
denken of te discussieren. Anderen zijn meer op de achtergrond van belang geweest. 
Dit kan op wetenschappelijk gebied zijn of, maar zeker zo belangrijk, op persoonlijk 
vlak. Wegens plaatsgebrek zal ik hieronder slechts een klein aantal mensen met name 
noemen. Door het maken van deze kleine selectie te maken, worden er een heleboel 
mensen niet genoemd. Toch moeten die mensen wel worden bedankt. Daarom wil ik 
daarmee beginnen: Wat je ook hebt bijgedragen, het is waardevol geweest. Hiervoor mijn 
grootste dank.
Beste Bert, als directe begeleider ben je altijd dichtbij geweest. Jouw kamer 
was op slechts enkele stappen van het lab verwijderd en, minstens zo belangrijk, de deur 
stond altijd open. Daarmee was er voor je AIOs altijd gelegenheid om gebruik te maken 
van jouw oneindige enthousiasme. Ook als de proeven wat minder resultaat opleveren, 
zag je altijd weer andere routes en zijweggetjes. Hoewel je niet hebt kunnen voorkomen 
dat op de nieuwe locatie jouw kamer wat verder van het lab is verwijderd, ga ik er vanuit 
dat het concept "even bij Bert binnen lopen" slechts in fysieke afstand wat is veranderd. 
Van het begin tot aan de laatste letter van het proefschrift heb jij een goede invulling 
gegeven aan de taak van "begeleider".
Beste Jurgen, jij hebt het Triad-Gfi1 onderzoek opgezet en mij laten meerijden 
met deze "rijdende trein" (hoewel we soms niet wisten welke kant de trein op reed). Door 
onze dakpanconstructie heb ik nog lang geprofiteerd van jouw aanwezigheid op het lab. 
Je hebt me veel geleerd op pratisch, maar zeker ook persoonlijk vlak. We hebben samen 
proeven gedaan, gediscussieerd, gebaald, gedronken, gelachen en ook gefietst. Hoewel 
je nu in Rotterdam je eigen groepje hebt, vind ik dat je mij kunt beschouwen als je "eerste 
AIO". Jouw Rotterdamse AIOs moeten zich gelukkig prijzen met zo'n begeleider!
Beste Joop, samen met Bert run jij "de moleculaire". Je volgt het onderzoek van 
de "ubiquitinologen" vanaf een korte afstand en stuurt bij waar nodig. Je kritische opmer-
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kingen bij de werkbespreking zorgde ervoor dat er niet in circeltjes werd gedacht. Ook 
het aandringen op het nemen van beslissingen over links of rechtsom heeft er mede voor 
gezorgd dat dit boekje nu af is. Deze kwaliteiten worden nu ook door anderen, buiten 
de moleculaire, benut. Je nieuwe functie heeft een overvolle agenda tot gevolg. Toch 
hoop ik dat de andere AIOs ruim gebruik kunnen blijven maken van jouw waardevolle 
helicopter-view.
Beste Theo, als promoter vervul je een belangrijke rol bij mijn promotieon­
derzoek. Hoewel je niet direct betrokken bent geweest bij het dagelijkse werk op het lab, 
ben jij wel diegene die ons erop wijst waarvoor we dit onderzoek doen. Ik denk dat jouw 
streven naar een goede samenwerking tussen lab en kliniek erg waardevol is voor het 
onderzoek.
Beste Sylvie, jij bent een echte "homo universalis": slim, muzikaal en sportief. 
Jij hebt het Triad eiwit geadopteerd nadat ik het een beetje had laten vallen. Als schei­
kundige vind je het vast jammer dat de biologie wat minder voorspelbaar is, en zeker niet 
altijd meewerkt bij onze proeven. Toch weet ik zeker dat je er achter komt dat dit eiwit 
(waar dan ook) een cruciale rol speelt. Overigens zal dat een eitje zijn in vergelijking met 
wat je al hebt bereikt op het lab: je hebt mij de klassieke muziek leren waarderen.
Jimmy en Davide, in mijn laatste maanden op het lab zijn jullie gestart in het 
groepje van Bert. Het muzikaal talent is met jouw komst, Jimmy, weer uitgebreid (en 
gelijk weer teniet gedaan door de komst van die "crazy italian"). Doordat jullie nu met z'n 
drieën zijn, is het makkelijk om de krachten te verdelen en zo het onderzoek naar de rol 
van ubiquitinering bij de bloedcelvorming van meerdere kanten te benaderen. Ik vond het 
leuk om (helaas maar kort) in dit groepje aan hetzelfde onderwerp te werken!
Er zijn er natuurlijk nog meer die direct betrokken zijn geweest bij het ubiquitine 
onderzoek. Liesbeth, je hebt samen met Jurgen de fundering gelegd voor mijn promotie­
onderzoek. Hoewel ik de indruk kreeg dat je me wilde ontlopen (zowel door een zwanger- 
schapverlof als door het veranderen van baan), vind ik het achteraf een goed idee dat je 
bent weggegaan. Je hebt opnieuw een fundering voor mijn onderzoek gelegd, al hoop ik 
dat je deze keer wel blijft! Ook Saskia B. wil ik bedanken voor haar input, of liever gezegd: 
output in het ubiquitine onderzoek.
Tijdens mijn promotie periode heb ik een aantal hele goeie studenten mogen 
begeleiden: Wouter, Alsya, Marleen, Tianna en Thessa. Doordat jullie allemaal een talent 
voor labonderzoek bezitten, is nooit echt getest of ik kan kwalificeren als goed docent! 
Ik hoop dat ik jullie wat heb kunnen bijbrengen over het onderzoek, maar, minstens zo
belangrijk, ik hoop dat jullie je net zo goed hebben vermaakt als ik!
"De moleculaire" bestaat uit meer dan alleen ubiquitinologen. De AIOs Sake, 
Jeannet en Elke werden in de periode dat ik onderdeel uitmaakte van de groep lang­
zaamaan opgevolgd door Saskia L., LeiLei, Maaike, Mariam en Gorica. Ruth, Gorica 
(he, alweer?) en Willemijn en zorgden samen met de al eerder genoemde Saskia B. en 
Liesbeth en nu ook Thessa voor een vaste bron van kennis er ervaring in de groep, waar 
ook de postdocs Aswin en Aneta graag uit putten. Zonder er personen of gebeurtenissen 
uit te lichten, heeft een ieder van jullie ervoor gezorgd dat ik met plezier naar het werk 
ging. Ook de overige collega's van het CHL wil ik bedanken voor hun bijdrage (RT-PCR, 
FACS, kleuringen etc.) maar vooral voor hun gezelligheid!
Niet alleen in Nijmegen heeft dit onderzoek mensen bezig gehouden. In 
Amsterdam, bij het Nederlands Kanker Instituut proberen ook Judith Smit en Titia Sixma 
te begrijpen wat dat Triadi eiwit nu eigenlijk doet. Hun input is van groot belang geweest 
bij de afronding van de publicatie die in dit proefschrift is opgenomen als hoofdstuk vijf.
Hoewel het leven van een AIO zich vooral in en rond het lab afspeelt, zijn er daar­
buiten ook mensen die een belangrijke rol hebben gespeeld bij het voltooien van het 
promotie onderzoek. Voor de broodnodige afleiding of (inspannende) ontspanning wil ik 
een aantal mensen specifiek noemen:
Femke, jij hebt een tijd lang voor een thuis gezorgd. We zijn samen aan een 
avontuur Nijmegen begonnen, en hoewel jij eerst je werk en vervolgens ook je thuis naar 
buiten Nijmegen hebt verplaatst, wil ik je bedanken voor je steun. Ook Bregje heeft een 
tijd deel uitgemaakt van "thuis". 's Ochtends ging ik met veel plezier naar mijn werk, maar 
ging ik 's avonds met minstens net zoveel plezier weer terug naar thuis. Voor de brood­
nodige ontspanning hebben onder meer de collega's van de Bever (van wie velen het 
niveau van collega zijn ontstegen tot vrienden) en de mensen met wie ik tot grote hoogte 
ben gestegen aan de klimwand of in de rots gezorgd. Het fiets-, klim-, kampeer-, can­
yoning-, speleo- en BBQ-avontuur van de "hot summer of 2003" (maar ook die daarna 
kwamen) heeft voor een permanente goede herinnering gezorgd die ik kan oproepen 
wanneer er een dringende behoefte is aan stress-onderdrukking. Ook het "lotgenoten­
contact" met collega AIOs hebben frustraties doen afnemen. Onder het genot van een 
spelletje Catan of Carcassonne werd gedeelde smart halve smart (het kan altijd erger).
Tijdens mijn studie heb meer dan alleen boekenwijsheid opgedaan, maar 
ook veel andere inzichten gekregen. Hoewel al bij TNO een motiverend woordje werd 
gesproken voor het toekomstperspectief van de biologie-student ("ach, iedere lul kan
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promoveren"), werd mijn interesse voor het onderzoek pas echt gewekt door het werken 
bij Prof. Gerats. Beste Tom, ik wil jou bedanken voor het overbrengen van jouw enthou­
siasme voor de wetenschap. De kloof tussen de planten-wereld en de mensen-wereld is in 
de praktijk nog breder dan alleen de Heyendaalseweg. Toch denk ik dat ik bij jou en Janny 
heel veel heb geleerd dat ik nu direct kan toepassen.
In het huidige systeem van projectfinanciering ben je als wetenschapper 
gedwongen om te jobhoppen. In een steeds veranderende omgeving leer je weer nieuwe 
mensen kennen, maar verlies je anderen weer uit het oog. De laatste woorden van dit 
dankwoord gaan echter naar de mensen die je nooit uit het oog wilt en mag verliezen:
Maarten en Jasper, ik vind het een eer dat wij met z'n drieën in zo'n pinguinpak 
mijn promotie gaan doen. Ook Marlieke en Jocelyn kunnen daar vast van genieten. Ik vind 
het jammer dat die ïookm een net te grote afstand blijkt om vaak samen leuke dingen te 
doen. Wellicht maar een keertje op vakantie dan?
Lieve Pap en Mam, ik kan niet opnoemen waar ik jullie allemaal voor wil 
bedanken. Om er toch maar wat uit te lichten: jullie onvoorwaardelijke steun is onge­
lofelijk waardevol. Mijn feestje is nu nog net wat eerder dan dat van jou, Pap, maar in 
tegenstelling tot bij mij, zullen jullie na je feestje wel meer tijd voor elkaar hebben!
Tenslotte zijn de allerlaatste woorden voor jou, Sas. Als ik ze tenminste kon 
vinden. Ik kan niet omschrijven wat jij voor mij betekent! Misschien is er toch één 
woord dat in de buurt komt: ALLES!
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Curriculum Vitae
Laurens Theodoor van der Meer werd op 3 oktober 1979 geboren te Sliedrecht. 
Na de middelbare school in Dordrecht te hebben doorlopen, startte hij in 1997 met de 
opleiding Biologie en Medisch Laboratorium Onderzoek aan het Hogere Laboratorium 
Onderwijs te Etten-Leur (tegenwoordig onderdeel van Avans en gevestigd in Breda). Als 
afstudeeropdracht werd gedurende negen maanden onderzoek verricht bij TNO, afdeling 
Preventie en Gezondheid te Leiden. Onder begeleiding van Dr. Jos Seegers werden de 
mogelijkheden van het gebruik van melkzuurbacterien als manier voor het toedienen van 
antivirale vaccins bestudeerd.
In 2001 startte hij met de studie Biologie aan de Radboud Universiteit 
te Nijmegen. Ter afronding van deze studie werd op twee verschillende afde­
lingen stage gelopen. In de eerste periode werd onder begeleiding van Prof. Dr. Tom 
Gerats en Dr. Janny Peters bij de afdeling Plantengenetica van de Radboud Univer­
siteit onderzoek gedaan naar recombinatie van het DNA tijdens de celdeling, 
een proces dat deels ten grondslag ligt aan genetische variatie tussen individuen. 
In de tweede periode werd bij geneesmiddelenfabrikant Organon onder begeleiding van 
Dr. Koen Dechering en Ing. Cindy van de Ven meegewerkt aan de identificatie van nieuwe 
aangrijpingspunten voor de ontwikkeling van medicijnen tegen osteoporose.
In 2004 werd gestart met het promotie onderzoek bij het Centraal Hematolo- 
gisch Laboratorium (tegenwoordig Laboratorium Hematologie van de afdeling Labo- 
ratoriumgeneeskunde) van het Universitair Medisch Centrum St. Radboud in Nijmegen. 
Onder leiding van Dr. Bert van der Reijden werden de experimenten verricht waarvan een 
groot deel van de resultaten staan beschreven in dit proefschrift.
De experimenten van het promotie onderzoek werden afgerond in het voorjaar 
van 2009. Sinds die tijd is de focus van de hematologie bij volwassenen verlegd naar de 
kinderhematologie. Onder leiding van Dr. Frank van Leeuwen wordt er in het Labora­
torium Kinderoncologie van de afdeling Kindergeneeskunde van het UMC St Radboud 
onderzoek gedaan naar het moleculaire mechanisme van therapie resistentie bij kinderen 
met acute lymfatische leukemie.
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